The present invention relates to novel ophthalmic devices comprising polymerized compounds comprising a photoactive unit, said polymerized compounds, and special monomer compounds being particularly suitable for compositions and ophthalmic devices. Background of the Invention

Cataract is a general term for an affection of the eye that leads to a loss of vision and in the extreme to blindness by clouding of the normally clear lens of the eye. It is the major cause of blindness in the world, affecting more than 100 million people. Due to the fact that its major cause is age and the population’s average age is increasing, it is expected that the number of cataracts will continue to increase substantially in the future. Effective treatment of cataract is only possible by surgical intervention, whereby the natural lens of the eye is removed through an incision in the cornea and replaced with an artificial lens, often also referred to as “intraocular lens". In preparation of surgery current state-of-the-art surgical methods employ eye mapping so as to approximate the refractive power best suited to the respective patient. Even though cataract surgery is one of the most widely used and safest surgical procedures it is not without specific post-surgery problems. It frequently happens that the refractive power of the implanted intraocular lens (IOL) is insufficient for restoring good vision. Such problems may, for example, be caused by changes in eye geometry as consequence of the surgery as well as irregular wound healing and positioning errors that result in the artificial lens not having the optimal optical properties. As a result the patient will still require corrective vision aids, e.g. glasses, to be able to see correctly. In some cases the resulting refractive power of the implanted artificial lens is so far removed from the required refractive power that further surgery will be required. Particularly for aged persons this is not desirable because the body’s capability for healing is reduced with increasing age. Furthermore, there is the risk of attracting endophthalmitis, an inflammation of the eye, which can even lead to a complete loss of vision or worse, loss of the eye. There is therefore a need in the health sector for optically active ophthalmic devices, and particularly for artificial intraocular lenses, that would allow for non-invasive adjustment of refractive power after implantation of the lens, thereby preferably further reducing the need for post-surgery vision aids. Some developments in this sense have already been made, as for example evidenced by WO 2007/033831, WO 2009/074520, US 2010/0324165, WO 2017/032442, WO 2017/032443, WO 2017/032444, WO 2018/149850, WO 2018/149852, WO 2018/149853, WO 2018/149855, WO 2018/149856 or WO 2018/149857.

M. Schraub et al, European Polymer Journal 51 (2014) 21-27 describes the photochemistry of 3-phenyl-coumarin containing polymethacrylates. The photochemistry of 3-phenyl-1,2-dihydronaphthalenes is subject of the articles of F. Keijzer et al, Journal of Photochemistry and Photobiology, A: Chemistry, 1990, 50, 401-406, J.J.M Lamberts et al, Recueil, Journal of the Royal Netherlands Chemical Society, 1984, 103/4,131-135 and H. Behm et al, Journal of Crystallographic and Spectroscopic Research 1988, 18(4), 471-475. JP3417969 describes 5,6-difluoro-1H-indene derivatives and liquid crystal compositions comprising the same. WO200059861 describes selective retinoic acid analogs useful in various dermatological diseases, in the treatment of malignant tumors and as agents for the minimization or prevention of post-surgical adhesion formation and pharmaceutical compositions comprising said compounds. JP2003238459 describes indene compounds useful as a component of a liquid crystal composition and liquid crystal electrooptic elements

comprising these. EP 1342770 describes polymerizable liquid crystal compounds bearing two polymerizable end groups, their polymers, liquid crystal compositions, an optical retardation film, an optically anisotropic element, a nonlinear optical device and an electro-optical device comprising the liquid crystal polymers. US20070087289 describes dipole-like polymer brushes which may consist of poly[styrene-co-2-(4-vinylphenyl)indene]/P2VP polymer systems to be used within rewritable and erasable printing forms. WO2008043567 describes phenyl-substituted 3H-indenes for use in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity and pharmaceutical compositions comprising said compounds. WO2009047343 describes benzocycloheptene derivatives as estrogens having selective activity and pharmaceutical compositions comprising said compounds. M. Silverman et al, Journal of Organic Chemistry, 1946, 11,34-49 describe the synthesis of 1-ethyl-3,4-dihydro-6-(2-propen-1-yloxy)-2-[4-(2-propen-1- yloxy)phenyl]naphthalene. T. Kametani et al, J. Chem. Soc. (C), 1971, (6), 1032-43 describe the synthesis of 3-(2-ethenyl-4,5-dimethoxyphenyl)-4,5,6-trimethoxy-1H-indene . S. Kano et al, Chem. Pharm. Bull.1975, 23(5), 1171-1172 describe the synthesis of 2-(2-ethenyl-4,5-dimethoxyphenyl)-5,6-dimethoxy-1H-indene. A. Padwa et al, J. Am. Chem. Soc.1983, 105, 4446-4456 describe the synthesis of 1,2-diphenyl-3-methyl-4-vinylindene, 1,2-diphenyl-1-vinyl-3- methylindene and 2-methyl-1-phenyl-3-(o-vinyl-phenyl)indene. S.C. Diehl et al, Israel Journal of Chemistry, 2003, Volume Date 2002, 42(4), 393-401describe polystyrene-supported 2-arylindenyl zirconocene catalysts for propylene polymerization.2-[4-(2-propen-1-yl)phenyl]-1H- indene is described therein. R. Schinner, T. Wolff, Colloid Polym. Sci.2001, 279, 1225-1230 describe cross-linking in solution of polystyrene containing phenylindene units.

Styrene and 2-(4'-styryl)indene are used for copolymerization. J.N. D'Amour et al, Proceedings of SPIE– The international Society for Optical Engineering, 2003, 5039 (Pt.2, Advances in resist Technology and Processing XX) describe photocrosslinkable polystyrene films show a linear decrease in glass transition temperature with decreasing film thickness.2- (4’-Styryl)-indene is used to synthesize said photocrosslinkable polystyrene. Frank Hoffmann et al, Journal of Colloid and Interface Science, 2008, 322, 434-447 describe polymer brushes grafted on silica wafers. Said polymer brushes are made up from poly-4-vinylpyridine, polymethacrylic acid and polystyrene copolymerized with 2-(4’-styryl)-indene. They are reported to be switchable polymer brushes that can be fixed in one state via photo-cross- linking via photodimerization of two phenylindene moieties.2- Trimethylsilyloxy-2-(4-vinylphenyl)-indane is used within the monomer solutions. Frank Hoffmann et al, Polymeric Materials: Science & Engineering 2004, 90, 374 describe photochemical structuring of binary polymer brush layers via photodimerization by using a photosensitive styrene/2-(4-styryl)-indene copolymer.2-Trimethylsilyloxy-2-(4-vinylphenyl)-indane is used within the monomer solutions. Xinfei Ji et al, ACS Omega, 2018, 3, 10099-10106 describe the facile synthesis of 3-arylindenes by HMPA-promoted direct arylation of indenes with aryl fluorides. Moon Gon Jeong et al, Macromolecules, 2017, 50(1), 223-234 report the cross-linking of hydrophobic compartments of complex self-assembled structures of amphiphilic block copolymers by the [2 p+2 p]-cycloaddition of an indene moiety such as 2-(4-vinylphenyl)indene present in a hydrophobic block based on polystryrene. They further demonstrate that the micellar structures and complex inverse bicontinuous bilayers could be covalently cross-linked in aqueous solutions upon irradiation with long-wavelength UV light ( l = 365 nm). However, there is still a need to provide alternative or improved ophthalmic devices to be implanted by state of the art cataract surgical methods and there is still a need to provide special compounds for the manufacture of intraocular lenses to be implanted by state of the art cataract surgical methods, particularly by state of the art micro-incision cataract surgical methods. Consequently, it is an objective of the present application to provide for alternative or improved ophthalmic devices and suitable compounds for the manufacture of such ophthalmic devices. It is also an objective of the present application to provide for compounds, the optical properties of which may be changed, preferably by non-invasive techniques. It is a further objective of the present application to provide alternative compounds or compounds having advantages over currently known compounds, preferably in combination with being suitable for ophthalmic devices. An advantage for the monomers of formula (I) to be used for the

preparation of the ophthalmic device according to the invention is the better handling through low melting points by using them in compositions and or polymers/copolymers. A further advantage is that the liquid to low melting monomers of formula (I) to be used for the preparation of the ophthalmic device according to the invention enable a higher flexibility in the choice of initiators for a thermally activated polymerization. Advantages for polymers or copolymers comprising polymerized monomers of formula (I) according to the invention are better flexibilities and low glass transition temperatures. The polymers or copolymers according to the invention preferably show a shift of 20 to 50 nm of the absorption maximum compared to coumarin containing polymers or copolymers and 5 to 25 nm of the absorption maximum compared to benzofuran containing polymers or copolymers. This results in a wider non-absorption range of the polymer and enables a higher flexibility in adjusting the absorption edge of an ophthalmic material by e.g. choice of UV absorber. Summary of the Invention

The present inventors have now found that the above objects may be attained either individually or in any combination by ophthalmic devices and the compounds of the present application. The invention relates to an ophthalmic device or a precursor article for an ophthalmic device comprising at least one polymerized compound of formula (I),

, wherein

A is the same or different at each instance and is CH ₂ , CHR0 or

C(R ₀ ) ₂ ;

m is 0, 1, 2 or 3;

Y is independently of each other O, S, SO ₂ , or a bond;

n is 0 or 1;

m1 is 0 or 1;

n+m1 is 1;

n1 is 0, 1, 2, 3 or 4;

R ₀ is at each occurrence independently selected from the group consisting of F, a linear or branched alkyl group having 1 to 4 C atoms and a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms;

R' is at each occurrence independently selected from the group consisting of F, a linear or branched, non-halogenated, partially or completely halogenated alkyl group having 1 to 20 C atoms, a non-halogenated, partially or completely halogenated cycloalkyl group having 3 to 6 C atoms, a linear or branched, non- halogenated, partially or completely halogenated alkoxy group having 1 to 20 C atoms and a linear or branched, non- halogenated, partially or completely halogenated thioalkyl group having 1 to 20 C atoms; R ₁ is a trialkoxysilyl group or a dialkoxyalkylsilyl group where the alkyl and/or alkoxy groups are each independently linear or branched having 1 to 6 C atoms, or a silyl group of formula (1), (2) or (3) or a polymerizable group of formula (4),

, where alkyl means at each occurrence independently of each other a linear or branched alkyl group having 1 to 6 C atoms and the asterisk“*” denotes at each occurrence independently of each other a linkage to the linker [-R2-Y]n or [Y-R2-]m1; and wherein

X ₁₁ is selected from the group consisting of O, S, O-SO ₂ , SO ₂ -O, C(=O), OC(=O), C(=O)O, S(C=O) and (C=O)S , R10, R11, R12 are at each occurrence independently of each other selected from the group consisting of H, F, a linear or branched, non-fluorinated, partially or completely fluorinated alkyl group having 1 to 20 C atoms and aryl with 6 to 14 C atoms and

c is 0 or 1;

-R ₂ - is–(C(R) ₂ ) _o –, or–(C(R) ₂ ) _p –X8–(C(R) ₂ ) _q –(X9) _s –(C(R) ₂ ) _r –(X10) _t - (C(R) ₂ ) _u -;

R is at each occurrence independently selected from the group consisting of H, F, a linear or branched alkyl group having 1 to 4 C atoms or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms; o is selected from the group consisting of 0 to 20,

X8, X9, X10 are at each occurrence independently O, S, SO ₂ , or NR0,

s, t is 0 or 1,

p, q are at each occurrence independently selected from the group consisting of 1 to 10,

r, u are at each occurrence independently selected from the group consisting of 0 to 10, wherein the overall number of atoms for–(C(R) ₂ )p–X8–(C(R) ₂ )q–(X9)s–(C(R) ₂ )r–(X10)t- (C(R) ₂ )u- is up to 20 atoms,

R ₃ , R ₄ , R _5, R ₆ , R ₇ , R ₈ are at each occurrence independently selected from the group consisting of H, F, Cl, Br, CN, SO ₂ CF ₃ , a linear or branched, non-halogenated, partially or completely halogenated alkyl group having 1 to 20 C atoms, a non-halogenated, partially or completely halogenated cycloalkyl group having 3 to 6 C atoms, a linear or branched, non-halogenated, partially or completely halogenated alkoxy group having 1 to 20 C atoms and a linear or branched, non-halogenated and partially or completely halogenated thioalkyl group having 1 to 20 C atoms;

R9 is H or R' in case m1 is 0 and

R9 is R1 in case m1 is 1. The invention relates further to a process of forming an ophthalmic device or a precursor article for an ophthalmic device as described before or preferably described below, said process comprising the steps of

- providing a composition comprising at least one compound of formulae (I) as described before or preferably described below and/or an oligomer or polymer derived from a compound of formula (I) as described below or preferably described below but having at least one reactive group left for polymerization and optionally further monomers different from compounds of formula (I) and/or crosslinking agents and/or UV absorbers and/or radical initiators;

- subsequently forming the ophthalmic device or precursor article of said composition. The invention relates further to a process of changing the optical properties of an ophthalmic device or a precursor article for an ophthalmic device as described before or preferably described below said process comprising the steps of

- providing an ophthalmic device or a precursor article with the process as described before or preferably described below, and

- subsequently exposing said ophthalmic device or precursor article to irradiation having a wavelength of at least 200 nm and at most 1500 nm. The invention relates further to oligomers, polymers or copolymer comprising at least one polymerized compound of formula (I) as described before where oligomers, polymers and copolymers of 2-(4- vinylphenyl)indene and 2-[4-(2-propen-1-yl)phenyl-1H-indene are excluded. The invention relates further to compositions for polymerization comprising at least one compound of formulae (I) as described before or preferably described below and/or an oligomer or polymer derived from compounds of formula (I) as described before or preferably described below but having at least one reactive group left for polymerization excluding 2- (vinylphenyl)indene, 2-[4-(2-propen-1-yl)phenyl-1H-indene and any oligomer, polymer or copolymer derived from 2-(vinylphenyl)indene and 2- [4-(2-propen-1-yl)phenyl-1H-indene and/or a crosslinking agent and/or a UV absorber and/or a radical initiator and optionally further monomers different from compounds of formula (I). The invention relates further to compounds of formula (I),

, wherein

A is the same or different at each instance and is CH ₂ , CHR ₀ or

C(R ₀ ) ₂ ;

m is 0, 1, 2 or 3;

Y is independently of each other O, S, SO ₂ , or a bond;

n is 0 or 1;

m1 is 0 or 1;

n+m1 is 1;

n1 is 0, 1, 2, 3 or 4;

R ₀ is at each occurrence independently selected from the group consisting of F, a linear or branched alkyl group having 1 to 4 C atoms and a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms;

R' is at each occurrence independently selected from the group consisting of F, a linear or branched, non-halogenated, partially or completely halogenated alkyl group having 1 to 20 C atoms, a non-halogenated, partially or completely halogenated cycloalkyl group having 3 to 6 C atoms, a linear or branched, non- halogenated, partially or completely halogenated alkoxy group having 1 to 20 C atoms and a linear or branched, non- halogenated, partially or completely halogenated thioalkyl group having 1 to 20 C atoms;

R ₁ is a trialkoxysilyl group or a dialkoxyalkylsilyl group where the alkyl and/or alkoxy groups are each independently linear or branched having 1 to 6 C atoms, or a silyl group of formula (1), (2) or (3) or a polymerizable group of formula (4),

, ,

, , where alkyl means at each occurrence independently of each other a linear or branched alkyl group having 1 to 6 C atoms and the asterisk“*” denotes at each occurrence independently of each other a linkage to the linker [-R2-Y]n or [Y-R2-]m1; and wherein

X11 is selected from the group consisting of O, S, O-SO ₂ , SO ₂ -O, C(=O), OC(=O), C(=O)O, S(C=O) and (C=O)S , R ₁₀ , R ₁₁ , R ₁₂ are at each occurrence independently of each other selected from the group consisting of H, F, a linear or branched, non-fluorinated, partially or completely fluorinated alkyl group having 1 to 20 C atoms and aryl with 6 to 14 C atoms and

c is 0 or 1;

-R ₂ - is–(C(R) ₂ ) _o –, or–(C(R) ₂ ) _p –X ₈ –(C(R) ₂ ) _q –(X ₉ ) _s –(C(R) ₂ ) _r –(X ₁₀ ) _t - (C(R) ₂ ) _u -;

R is at each occurrence independently selected from the group consisting of H, F, a linear or branched alkyl group having 1 to 4 C atoms or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms;

o is selected from the group consisting of 0 to 20, X ₈ , X _9, X ₁₀ are at each occurrence independently O, S, SO ₂ , or NR0,

s, t is 0 or 1,

p, q are at each occurrence independently selected from the group consisting of 1 to 10,

r, u are at each occurrence independently selected from the group consisting of 0 to 10, wherein the overall number of atoms for–(C(R) ₂ ) _p –X ₈ –(C(R) ₂ ) _q –(X ₉ ) _s –(C(R) ₂ ) _r –(X ₁₀ ) _t - (C(R) ₂ )u- is up to 20 atoms,

R3, R4, R5, R6, R7, R8 are at each occurrence independently selected from the group consisting of H, F, Cl, Br, CN, SO ₂ CF ₃ , a linear or branched, non-halogenated, partially or completely halogenated alkyl group having 1 to 20 C atoms, a non-halogenated, partially or completely halogenated cycloalkyl group having 3 to 6 C atoms, a linear or branched, non-halogenated, partially or completely halogenated alkoxy group having 1 to 20 C atoms and a linear or branched, non-halogenated and partially or completely halogenated thioalkyl group having 1 to 20 C atoms;

R ₉ is H or R' in case m1 is 0 and

R9 is R1 in case m1 is 1,

provided that in case of m is 0, m1 is 1 and Y is a bond, o is selected from the group consisting of 3 to 20; and

provided that in case of m is 0 and m1 is 1, two substituents from the group of R3, R4 and R8 are not simultaneously F; and

provided that in case of m is 0, m1 is 1 and Y is a bond or O, R' is on each occurrence not F; and

provided that in case of m is 0, R6 and R7 are on each occurrence not a non-halogenated, partially or completely halogenated cycloalkyl group having 3 to 6 C atoms; and provided that in case of m is 1, n is 1 and Y is a bond, o is selected from 1 to 20; and

provided that in case of m is 2, m1 is 1 and Y is a bond, o is selected from the group consisting of 3 to 20; and

provided that in case of m is 2, m1 is 1 and Y is O, o is selected from the group consisting of 1 to 20; and

provided that in case of m is 2, n is 1 and Y is a bond, o is selected from the group consisting of 3 to 20; and

provided that in case of m is 2, n is 1 and Y is O, o is selected from the group consisting of 1 to 20. Detailed Description of the Invention Compounds of formula (I) as described before or preferably described below can be preferably used as monomers for the preparation of a precursor article such as a blank which may be transformed to an ophthalmic device such as an eye-implant or specifically an intraocular lens or can be preferably used for the preparation of the ophthalmic device as such as described before or preferably described below. The compounds of formula (I) and all preferred embodiments of compounds of formula (I) including any monomeric units according to the present invention include all stereoisomers or racemic mixtures. The compounds of formula (I) provide several advantages over prior art materials for the preparation of ophthalmic devices or precursor articles for an ophthalmic device

- the number of C atoms of the linker -R ₂ - is reduced compared to the 1- benzopyran-2-one, 1-benzopyran-2-thione, thiochromene-2-one,

thiochromene-2-thione, quinolin-2-one or quinolin-2-thione ring systems of the state of the art but still their melting points or glass transition

temperatures allow for foldable or bendable ophthalmic devices or precursor articles for an ophthalmic device comprising polymerized compounds of formula (I),

- due to the low melting points and/or liquid monomers of formula (I) at room temperature, the handling of the materials is much easier and their use enable a higher flexibility in the choice of initiators for a thermally activated polymerization within the process of manufacturing the ophthalmic device or precursor article for an ophthalmic device according to the invention. Polymers that are foldable at room temperature generally exhibit glass transition temperatures (T _g ) lower than room temperature (ca.21 °C). They are easily deformable at this temperature without causing physical damage to the polymer, for example by inducing creep, stress or fissures. For polymers in intraocular lenses, T _g s of less than or equal to 15 °C are preferred. Polymers used in ophthalmic device manufacturing, preferably in

intraocular lens manufacturing, have preferably relatively high refractive indices, which enable the fabrication of thinner ophthalmic devices such as intraocular lenses. Preferably, the polymer used in an ophthalmic device, preferably an intraocular lens, will have a refractive index greater than about 1.5 and presently most preferably greater than about 1.55. In case an asterisk ("*") is used within the description of the present invention, it denotes a linkage to an adjacent unit or group or, in case of a polymer, to an adjacent repeating unit or any other group whenever it is not specifically defined. A linear or branched alkyl group having 1 to 10 C atoms denotes an alkyl group having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms, for example methyl, ethyl, iso-propyl, n-propyl, iso-butyl, n-butyl, tert-butyl, n-pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, n- heptyl, n-octyl, ethylhexyl, n-nonyl or n-decyl. A linear or branched alkyl group having 1 to 20 C atoms include all examples for a linear or branched alkyl group having 1 to 10 C atoms including any alkyl group having 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20 C atoms such as n-undecyl, n-dodecyl, n- tridecyl, n-tetradecyl, n-pentadecyl, n-hexadecyl, n-heptadecyl, n-octadecyl, n-nonadecyl and n-eicosyl. The term partially halogenated alkyl group denotes that at least one H atom of the alkyl group is replaced by F, Cl, Br or I. Preferably, the alkyl group is partially fluorinated meaning that at least one H atom of the alkyl group is replaced by F. A preferred partially halogenated alkyl group is CH ₂ CF ₃ . The term completely halogenated alkyl group denotes that all H atoms of the alkyl group are replaced by F, Cl, Br and/or I. Preferably, the alkyl group is completely fluorinated meaning that all H atoms of the alkyl group are replaced by F. A preferred completely fluorinated alkyl group is

trifluoromethyl or pentafluoroethyl. The term halogenated or preferably fluorinated corresponds additionally to other groups such as a halogenated cycloalkyl group, a halogenated alkoxy group or a halogenated thioalkyl group. A cycloalkyl group having 3 to 6 C atoms includes cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl which may be partially or completely

halogenated or fluorinated as explained before. Preferably, the cycloalkyl group is cyclopropyl. A linear or branched alkoxy group having 1 to 20 C atoms denotes an O-alkyl group having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 C atoms, for example methoxy, ethoxy, iso-propoxy, n- propoxy, iso-butoxy, n-butoxy, tert-butoxy, n-pentyloxy, 1-, 2- or

3-methylbutyloxy, 1,1-, 1,2- or 2,2-dimethylpropoxy, 1-ethylpropoxy, n- hexyloxy, n-heptyloxy, n-octyloxy, ethylhexyloxy, n-nonyloxy, n-decyloxy, n- undecyloxy, n-dodecyloxy, n-tridecyloxy, n-tetradecyloxy, n-pentadecyloxy, n-hexadecyloxy, n-heptadecyloxy, n-octadecyloxy, n-nonadecyloxy and n- eicosyloxy which may be partially or completely halogenated or preferably may be partially or completely fluorinated. A preferred completely fluorinated alkoxy group is trifluoromethoxy. A linear or branched thioalkyl group having 1 to 20 C atoms denotes a S-alkyl group having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 C atoms, for example thiomethyl, 1-thioethyl, 1-thio-iso-propyl, 1-thio-n-propoyl, 1-thio-iso-butyl, 1-thio-n-butyl, 1-thio-tert-butyl, 1-thio-n- pentyl, 1-thio-1-, -2- or -3-methylbutyl, 1-thio-1,1-, -1,2- or -2,2- dimethylpropyl, 1-thio-1-ethylpropyl, 1-thio-n-hexyl, 1-thio-n-heptyl, 1-thio-n- octyl, 1-thio-ethylhexyl, 1-thio-n-nonyl, 1-thio-n-decyl, 1-thio-n-undecyl, 1- thio-n-dodecyl, 1-thio-n-tridecyl, 1-thio-n-tetradecyl, 1-thio-n-pentadecyl, 1- thio-n-hexadecyl, 1-thio-n-heptadecyl, 1-thio-n-octadecyl, 1-thio-n- nonadecyl and 1-thio-n-eicosyl which may be partially or completely halogenated or preferably may be partially or completely fluorinated. A preferred completely fluorinated thioether group is trifluoromethyl thioether. Preferred alkyl and alkoxy radicals have 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms. An aryl group in the context of this invention contains 6 to 40 ring atoms and a heteroaryl group in the context of this invention contains 5 to 40 ring atoms comprising at least one heteroatom. The heteroatoms are preferably selected from N, O and/or S. An aryl group or heteroaryl group is

understood here to mean either a simple aromatic cycle, i.e. phenyl, or a simple heteroaromatic cycle, for example pyridinyl, pyrimidinyl, thiophenyl, etc., or a fused (annelated) aryl or heteroaryl group, for example naphthyl, anthracenyl, phenanthrenyl, quinolinyl or isoquinolinyl. An aryl group or heteroaryl group is preferably derived from benzene, naphthalene, anthracene, phenanthrene, pyrene, benzanthracene, chrysene, perylene, fluoranthene, naphthacene, pentacene, benzopyrene, biphenyl, biphenylene, terphenyl, triphenylene, fluorene, spirobifluorene, dihydrophenanthrene, dihydropyrene, tetrahydropyrene, cis- or trans- indenofluorene, cis- or trans-indenocarbazole, cis- or trans-indolocarbazole, truxene, isotruxene, spirotruxene, spiroisotruxene, furan, benzofuran, isobenzofuran, dibenzofuran, thiophene, benzothiophene,

isobenzothiophene, dibenzothiophene, pyrrole, indole, isoindole, carbazole, pyridine, quinoline, isoquinoline, acridine, phenanthridine, benzo-5,6- quinoline, benzo-6,7-quinoline, benzo-7,8-quinoline, phenothiazine, phenoxazine, pyrazole, indazole, imidazole, benzimidazole,

naphthimidazole, phenanthrimidazole, pyridimidazole, pyrazinimidazole, quinoxalinimidazole, oxazole, benzoxazole, naphthoxazole, anthroxazole, phenanthroxazole, isoxazole, 1,2-thiazole, 1,3-thiazole, benzothiazole, pyridazine, hexaazatriphenylene, benzopyridazine, pyrimidine,

benzopyrimidine, quinoxaline, 1,5-diazaanthracene, 2,7-diazapyrene, 2,3- diazapyrene, 1,6-diazapyrene, 1,8-diazapyrene, 4,5-diazapyrene, 4,5,9,10- tetraazaperylene, pyrazine, phenazine, phenoxazine, phenothiazine, fluorubine, naphthyridine, azacarbazole, benzocarboline, phenanthroline, 1,2,3-triazole, 1,2,4-triazole, benzotriazole, 1,2,3-oxadiazole, 1,2,4- oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, 1,2,3-thiadiazole, 1,2,4- thiadiazole, 1,2,5-thiadiazole, 1,3,4-thiadiazole, 1,3,5-triazine, 1,2,4-triazine, 1,2,3-triazine, tetrazole, 1,2,4,5-tetrazine, 1,2,3,4-tetrazine, 1,2,3,5- tetrazine, purine, pteridine, indolizine and benzothiadiazole. A polymerizable group is a group which can be subject to or can undergo polymerization thus forming an oligomer or a polymer. Polymerization is the process of taking individual monomers and chaining them together to make longer units. These longer units are called polymers. The compounds of formula (I) as described before and preferably described below are suitable monomers for the preparation of an ophthalmic device or a precursor article for an ophthalmic device. Within the gist of the invention, the polymerizable group R1 once

oligomerized or polymerized thus forms or is part of the backbone of the oligomer, polymer or copolymer comprising polymerized compounds of formula (I). Suitable polymerizable groups are defined to be

a trialkoxysilyl group or a dialkoxyalkylsilyl group where the alkyl and/or alkoxy groups are each independently linear or branched having 1 to 6 C atoms, or a silyl group of formula (1), (2) or (3) or a polymerizable group of formula (4),

, , where alkyl means at each occurrence independently of each other a linear or branched alkyl group having 1 to 6 C atoms and the asterisk“*” denotes at each occurrence independently of each other a linkage to the linker [-R ₂ - Y]n or [Y-R2-]m1;

and wherein

X ₁₁ is selected from the group consisting of O, S, O-SO ₂ , SO ₂ -O, C(=O), OC(=O), C(=O)O, S(C=O) and (C=O)S,

R10, R11, R12 are at each occurrence independently of each other selected from the group consisting of H, F, a linear or branched, non-fluorinated, partially or completely fluorinated alkyl group having 1 to 20 C atoms and aryl with 6 to 14 C atoms and

c is 0 or 1. Particularly preferred polymerizable groups are described below.

Particularly preferred polymerized groups are described below. Aryl with 6 to 14 C atoms is an aryl group preferably selected from the group consisting of phenyl, naphthyl or anthryl, particularly preferably phenyl. In one preferred embodiment, the compounds of formula (I) acting as monomers for the preparation of the ophthalmic device or precursor article of the ophthalmic device as described before or for the preparation of an oligomer, polymer or copolymer according to the invention or as compound according to the invention contain the polymerizable group R1 attached via - R ₂ - and Y to the photoactive ring system. This is the case for compounds of formula (I) in which n is 1 and m1 is 0 which can be described accordingly in formula (I'). The invention is therefore additionally directed to an ophthalmic device or a precursor article for an ophthalmic device comprising at least one

polymerized compound of formula (I'),

,

wherein R1, -R2-, Y, R3, R4, R5, R6, R7, R8, A, m, R', and n1 have a meaning as described before or preferably described before or below and R ⁹ is H or R' as described before or preferably described before. The invention is therefore additionally directed to compounds of formula (I) wherein n is 1 and m1 is 0 which can preferably be described according to formula (I'),

,

wherein R1, -R2-, Y, R3, R4, R5, R6, R7, R8, A, m, R', and n1 have a meaning as described before or preferably described before or below and R ⁹ is H or R' as described before or preferably described before,

provided that in case of m is 0, R6 and R7 are on each occurrence not a non-halogenated, partially or completely halogenated cycloalkyl group having 3 to 6 C atoms; and

provided that in case of m is 1, n is 1 and Y is a bond, o is selected from 1 to 20; and

provided that in case of m is 2, n is 1 and Y is a bond, o is selected from the group consisting of 3 to 20; and

provided that in case of m is 2, n is 1 and Y is O, o is selected from the group consisting of 1 to 20. The position of substituent R1-R2-Y in formulae (I) or (I’) is not limited. In compounds of formula (I'-a), the substituent R1-R2-Y is in position 8 of the annellated aromatic ring.

In compounds of formula (I'-b), the substituent R1-R2-Y is in position 7 of the annellated aromatic ring.

In compounds of formula (I'-c), the substituent R ₁ -R ₂ -Y is in position 6 of the annellated aromatic ring.

In compounds of formula (I'-d), the substituent R1-R2-Y is in position 5 of the annellated aromatic ring. The invention is therefore additionally directed to an ophthalmic device or a precursor article for an ophthalmic device comprising at least one polymerized compound of formula (I) wherein n is 1 and m1 is 0 which can preferably be described according to formulae (I'-a), (I'-b), (I'-c) and (I'-d),

,

,

, wherein R ₁ , -R ₂ -, Y, R ₃ , R ₄ , R ₅ , R ₆ , R ₇ , R ₈ , R ₉ , A, m, R', and n1 have a meaning as described before or preferably described before or below. The invention is therefore additionally directed to compounds of formula (I) wherein n is 1 and m1 is 0 which can preferably be described according to formulae (I'-a), (I'-b), (I'-c) and (I'-d),

,

,

,

wherein R1, -R2-, Y, R3, R4, R5, R6, R7, R8, R9, A, m, R', and n1 have a meaning as described before or preferably described before or below, provided that in case of m is 0, R ₆ and R ₇ are on each occurrence not a non-halogenated, partially or completely halogenated cycloalkyl group having 3 to 6 C atoms; and

provided that in case of m is 1, n is 1 and Y is a bond, o is selected from 1 to 20; and

provided that in case of m is 2, n is 1 and Y is a bond, o is selected from the group consisting of 3 to 20; and

provided that in case of m is 2, n is 1 and Y is O, o is selected from the group consisting of 1 to 20. Preferred positions of R1-R2-X are position 8 and/or 7 of the annellated aromatic ring as e.g. visualized in formulae (I'-a) and (I'-b). In another preferred embodiment of the invention, the compounds of formula (I) acting as monomers for the preparation of the ophthalmic device or precursor article of the ophthalmic device as described before or for the preparation of an oligomer, polymer or copolymer according to the invention or as compound according to the invention as described before contain the polymerizable group R1 attached via -R2- and Y to the phenyl substituent of the photoactive ring system. This is the case for compounds of formula (I) in which n is 0 and m1 is 1 which can be described accordingly in formula (I''). The invention is therefore additionally directed to an ophthalmic device or a precursor article for an ophthalmic device comprising at least one polymerized compound of formula (I''),

, wherein R1, -R2-, Y, R3, R4, R5, R6, R7, R8, A, m, R', and n1 have a meaning as described before or preferably described before or below. The invention is therefore additionally directed to compounds of formula (I) wherein n is 0 and m1 is 1 which can preferably be described according to formula (I''),

, wherein R1, -R2-, Y, R3, R4, R5, R6, R7, R8, R9, A, m, R', and n1 have a meaning as described before or preferably described before or below, provided that in case of m is 0, m1 is 1 and Y is a bond, o is selected from the group consisting of 3 to 20; and

provided that in case of m is 0 and m1 is 1, two substituents from the group of R3, R4 and R8 are not simultaneously F; and

provided that in case of m is 0, m1 is 1 and Y is a bond or O, R' is on each occurrence not F; and provided that in case of m is 0, R ₆ and R ₇ are on each occurrence not a non-halogenated, partially or completely halogenated cycloalkyl group having 3 to 6 C atoms; and

provided that in case of m is 2, m1 is 1 and Y is a bond, o is selected from the group consisting of 3 to 20; and

provided that in case of m is 2, m1 is 1 and Y is O, o is selected from the group consisting of 1 to 20. As described before within the ophthalmic device, precursor article, compounds of formula (I), (I'), (I'') and any oligomers, polymers or copolymers derived therefrom according to the invention, the substituents R ₃ , R ₄ , R ₅ , R ₆ , R ₇ and R ₈ are at each occurrence independently selected from the group consisting of H, F, Cl, Br, CN, SO ₂ CF3, a linear or branched, non-halogenated, partially or completely halogenated alkyl group having 1 to 20 C atoms, a non-halogenated, partially or completely halogenated cycloalkyl group having 3 to 6 C atoms, a linear or branched, non- halogenated, partially or completely halogenated alkoxy group having 1 to 20 C atoms and a linear or branched, non-halogenated and partially or completely halogenated thioalkyl group having 1 to 20 C atoms.

R3, R4 and R8 are preferably H, F, a straight-chain alkyl group with 1 to 4 C atoms or a straight-chain alkoxy group with 1 to 4 C atoms. R ₃ , R ₄ and R ₈ are particularly preferably H.

R5 is preferably H, F, CN, SO ₂ CF3, CF3, CF2CF3, or CH ₂ CF3. R5 is particularly preferably H, F, CF3. R5 is very particularly preferably H or F. R5 is very particularly preferably H.

R6 and R7 are preferably independently of each other H, F, a linear or branched alkyl group having 1 to 4 C atoms or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms. R ₆ is preferably H and R7 has a meaning as described or preferably described before or below. R6 and R7 are independently of each other particularly preferably H or F. R6 and R ₇ are preferably identical. R ₆ and R ₇ are very particularly preferably H. With regards to the compounds according to the invention, the described disclaimers have to be considered for the definition and preferred embodiments of R3, R4, R5, R6, R7 and R8. Compounds of formula (I), (I') or (I'') wherein m is 0 are based on an indene ring system and can be described as compounds of formulae (I-1), (I'-1) or (I''-1)

,

,

wherein R1, -R2-, Y, n, R3, R4, R5, R6, R7, R8, R9, m1, n1 and R' have a meaning as described before or preferably described before or below and act preferably as monomers for the preparation of the ophthalmic device or precursor article of the ophthalmic device as described before or for the preparation of an oligomer, polymer or copolymer according to the invention. Compounds of formula (I), (I') or (I'') wherein m is 1 are based on a 1,2- dihydronaphthalene ring system and can be described as compounds of formula (I-2), (I'-2) or (I''-2)

,

,

wherein A, R1, -R2-, Y, n, R3, R4, R5, R6, R7, R8, R9, m1, n1 and R' have a meaning as described before or preferably described before or below and act preferably as monomers for the preparation of the ophthalmic device or precursor article of the ophthalmic device as described before or for the preparation of an oligomer, polymer or copolymer according to the invention. A is the same or different at each instance and is CH ₂ , CHR0 or C(R0) ₂ and R0 has a meaning as described before or preferably described below.

Preferably, A is the same or different at each instance and is CH ₂ or CHR0 and R ₀ has a meaning as described before or preferably described below. Particularly preferably, A is at each instance CH ₂ . Compounds of formula (I-2), (I'-2) and (I''-2) wherein A is CH ₂ correspond to formulae (I-2-H), (I'-2-H) and (I''-2-H),

,

,

wherein R1, -R2-, Y, n, R3, R4, R5, R6, R7, R8, R9, m1, n1 and R' have a meaning as described before or preferably described before or below and act preferably as monomers of formulae (I), (I') and (I'') for the preparation of the ophthalmic device or precursor article of the ophthalmic device as described before or for the preparation of an oligomer, polymer or copolymer according to the invention. Compounds of formula (I), (I') or (I'') wherein m is 2 are based on a 6,7- dihydro-5H-benzo[7]annulene ring system and can be described as compounds of formula (I-3), (I'-3) or (I''-3)

,

,

wherein A, R ₁ , -R ₂ -, Y, n, R ₃ , R ₄ , R ₅ , R ₆ , R ₇ , R ₈ , R ₉ , m1, n1 and R' have a meaning as described before or preferably described before or below and act preferably as monomers for the preparation of the ophthalmic device or precursor article of the ophthalmic device as described before or for the preparation of an oligomer, polymer or copolymer according to the invention. A is the same or different at each instance and is CH ₂ , CHR0 or C(R0) ₂ and R ₀ has a meaning as described before or preferably described below. Preferably, A is the same or different at each instance and is CH ₂ or CHR0 and R0 has a meaning as described before or preferably described below Particularly preferably, A is at each instance CH ₂ . Compounds of formula (I-3), (I'-3) and (I''-3) wherein each A is CH ₂ correspond to formulae (I-3-H), (I'-3-H) and (I''-3-H),

,

, wherein R ₁ , -R ₂ -, Y, n, R ₃ , R ₄ , R ₅ , R ₆ , R ₇ , R ₈ , R ₉ , m1, n1 and R' have a meaning as described before or preferably described before or below and act preferably as monomers of formulae (I), (I') and (I'') for the preparation of the ophthalmic device or precursor article of the ophthalmic device as described before or for the preparation of an oligomer, polymer or copolymer according to the invention. Compounds of formula (I), (I') or (I'') wherein m is 2 are based on a (Z)- 5,6,7,8-tetrahydrobenzo[8]annulene ring system and can be described as compounds of formula (I-4), (I'-4) or (I''-4)

,

,

wherein A, R1, -R2-, Y, n, R3, R4, R5, R6, R7, R8, R9, m1, n1 and R' have a meaning as described before or preferably described before or below as monomers for the preparation of the ophthalmic device or precursor article of the ophthalmic device as described before or for the preparation of an oligomer, polymer or copolymer according to the invention. A is the same or different at each instance and is CH ₂ , CHR0 or C(R0) ₂ and R0 has a meaning as described before or preferably described below. Preferably, A is the same or different at each instance and is CH ₂ or CHR ₀ and R0 has a meaning as described before or preferably described below Particularly preferably, A is at each instance CH ₂ . Compounds of formula (I-4), (I'-4) and (I''-4) wherein each A is CH ₂ correspond to formulae (I-4-H), (I'-4-H) and (I''-4-H),

,

,

,

wherein R ₁ , -R ₂ -, Y, n, R ₃ , R ₄ , R ₅ , R ₆ , R ₇ , R ₈ , R ₉ , m1, n1 and R' have a meaning as described before or preferably described before or below and act preferably as monomers of formulae (I), (I') and (I'') for the preparation of the ophthalmic device or precursor article of the ophthalmic device as described before or for the preparation of an oligomer, polymer or copolymer according to the invention. As described before within the ophthalmic device, precursor article, compounds of formulae (I), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I'), (I'-a), (I'-b), (I'-c), (I'-d), (I'-1), (I'-2), (I'-2-H), (I'-3), (I'-3-H), (I'-4) and (I'-4-H) and any oligomers, polymers or copolymers derived therefrom according to the invention, R0 is at each occurrence independently selected from the group consisting of F, a linear or branched alkyl group having 1 to 4 C atoms and a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms. R0 is independently at each occurrence and preferably F, Methyl, Ethyl or Trifluoromethyl. R0 is independently at each occurrence particularly preferably Methyl. R ₀ is independently at each occurrence particularly preferably F. The invention furthermore relates to an ophthalmic device or a precursor article for an ophthalmic device comprising at least one polymerized compound of formulae (I), (I'), (I'-a), (I'-b), (I'-c), (I'-d) or (I'') as described before or preferably described before wherein A is independently at each occurrence CH ₂ and m is 1, 2 or 3.

The invention therefore relates to an ophthalmic device or a precursor article for an ophthalmic device comprising at least one polymerized compound of formulae (I), (I'), (I'-a), (I'-b), (I'-c), (I'-d) or (I'') as described before or preferably described before wherein A is independently at each occurrence CH ₂ and m is 1.

The invention therefore relates to an ophthalmic device or a precursor article for an ophthalmic device comprising at least one polymerized compound of formulae (I), (I'), (I'-a), (I'-b), (I'-c), (I'-d) or (I'') as described before or preferably described before wherein A is independently at each occurrence CH ₂ and m is 2.

The invention therefore relates to an ophthalmic device or a precursor article for an ophthalmic device comprising at least one polymerized compound of formulae (I), (I'), (I'-a), (I'-b), (I'-c), (I'-d) or (I'') as described before or preferably described before wherein A is independently at each occurrence CH ₂ and m is 3. The invention furthermore relates to compounds of formula (I), (I'), (I'-a), (I'- b), (I'-c), (I'-d) or (I'') as described before or preferably described before wherein A is independently at each occurrence CH ₂ and m is 1, 2 or 3. The invention therefore relates to compounds of formula (I), (I'), (I'-a), (I'-b), (I'-c), (I'-d) or (I'') as described before or preferably described before wherein A is independently at each occurrence CH ₂ and m is 1. The invention therefore relates to compounds of formula (I), (I'), (I'-a), (I'-b), (I'-c), (I'-d) or (I'') as described before or preferably described before wherein A is independently at each occurrence CH ₂ and m is 2.

The invention therefore relates to compounds of formula (I), (I'), (I'-a), (I'-b), (I'-c), (I'-d) or (I'') as described before or preferably described before wherein A is independently at each occurrence CH ₂ and m is 3.

With regards to the compounds according to the invention, the described disclaimers have to be considered when m is 0, 1 and/or 2. As described before, the substituent R9 corresponds to H or R' in case m1 is 0 wherein R' has a meaning as described before or a preferred or particularly preferred meaning as described below. In one embodiment of the invention, R ₉ is preferably H in case m1 is 0. Therefore, the invention is furthermore directed to an ophthalmic device or a precursor article for an ophthalmic device comprising at least one polymerized compound of formulae (I), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I'), (I'-a), (I'-b), (I'-c), (I'-d), (I'-1), (I'-2), (I'-2-H), (I'-3), (I'-3-H), (I'-4) and (I'-4-H) where R9 is H in case m1 is 0 and n1 and R' have a meaning as described before or preferably described below.

Therefore, the invention is furthermore directed to compounds of formulae (I), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I'), (I'-a), (I'-b), (I'-c), (I'-d), (I'-1), (I'-2), (I'-2-H), (I'-3), (I'-3-H), (I'-4) and (I'-4-H) where R9 is H in case m1 is 0 and n1 and R' have a meaning as described before or preferably described below.

In this embodiment, it is preferred that n1 is 0.

Therefore, the invention is furthermore directed to an ophthalmic device or a precursor article for an ophthalmic device comprising at least one polymerized compound of formulae (I), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I'), (I'-a), (I'-b), (I'-c), (I'-d), (I'-1), (I'-2), (I'-2-H), (I'-3), (I'-3-H), (I'-4) and (I'-4-H) wherein R ₉ is H in case m1 is 0 and n1 is 0. Therefore, the invention is furthermore directed to compounds of formulae (I), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I'), (I'-a), (I'-b), (I'-c), (I'-d), (I'-1), (I'-2), (I'-2-H), (I'-3), (I'-3-H), (I'-4) and (I'-4-H) wherein R9 is H in case m1 is 0 and n1 is 0. In another embodiment of the invention, R9 is preferably R' in case m1 is 0. Therefore, the invention is furthermore directed to an ophthalmic device or a precursor article for an ophthalmic device comprising at least one polymerized compound of formulae (I), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I'), (I'-a), (I'-b), (I'-c), (I'-d), (I'-1), (I'-2), (I'-2-H), (I'-3), (I'-3-H), (I'-4) and (I'-4-H) wherein R ₉ is R' in case m1 is 0 and n1 and R' have a meaning as described before or preferably described below.

Therefore, the invention is furthermore directed to compounds of formulae (I), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I'), (I'-a), (I'-b), (I'-c), (I'-d), (I'-1), (I'-2), (I'-2-H), (I'-3), (I'-3-H), (I'-4) and (I'-4-H) wherein R9 is R' in case m1 is 0 and n1 and R' have a meaning as described before or preferably described below. In this embodiment, it is preferred that n1 is 0, 1 or 2, preferably 0 or 1. Therefore, the invention is furthermore directed to an ophthalmic device or a precursor article for an ophthalmic device comprising at least one polymerized compound of formulae (I), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I'), (I'-a), (I'-b), (I'-c), (I'-d), (I'-1), (I'-2), (I'-2-H), (I'-3), (I'-3-H), (I'-4) and (I'-4-H) wherein R9 is R' in case m1 is 0 and n1 is 0, 1 or 2 and R' has a meaning as described before or preferably described below.

Therefore, the invention is furthermore directed to an ophthalmic device or a precursor article for an ophthalmic device comprising at least one polymerized compound of formulae (I), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I'), (I'-a), (I'-b), (I'-c), (I'-d), (I'-1), (I'-2), (I'-2-H), (I'-3), (I'-3-H), (I'-4) and (I'-4-H) wherein R9 is R' in case m1 is 0 and n1 is 0 or 1 and R' has a meaning as described before or preferably described below. Therefore, the invention is furthermore directed to compounds of formulae (I), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I'), (I'-a), (I'-b), (I'-c), (I'-d), (I'-1), (I'-2), (I'-2-H), (I'-3), (I'-3-H), (I'-4) and (I'-4-H) wherein R9 is R' in case m1 is 0 and n1 is 0, 1 or 2 and R' has a meaning as described before or preferably described below.

Therefore, the invention is furthermore directed to compounds of formulae (I), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I'), (I'-a), (I'-b), (I'-c), (I'-d), (I'-1), (I'-2), (I'-2-H), (I'-3), (I'-3-H), (I'-4) and (I'-4-H) wherein R ₉ is R' in case m1 is 0 and n1 is 0 or 1 and R' has a meaning as described before or preferably described below. According to the invention, R' is independently of each other preferably selected from the group consisting of F, a linear or branched partially or fully fluorinated alkyl group having 1 to 10 C atoms, a linear or branched alkyl group having 1 to 10 C atoms, a linear or branched alkoxy group having 1 to 10 C atoms, a linear or branched partially or fully fluorinated alkoxy group having 1 to 10 C atoms and a linear or branched thioalkyl group having 1 to 10 C atoms.

R' is independently of each other particularly preferably selected from the group consisting of F, methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n- heptyl, n-octyl, trifluoromethyl, pentafluoroethyl, heptafluoropropyl, methoxy, ethoxy, propoxy, trifluoromethoxy, pentafluoroethoxy, thiomethyl and thioethyl.

R' is independently of each other particularly preferably selected from the group consisting of F, ethyl, n-pentyl, trifluoromethyl, methoxy and trifluoromethoxy.

With regards to the compounds according to the invention, the described disclaimers have to be considered for the definition of R'. In these embodiments of the invention when m1 is 0, R9 is H or R' and n1 is 0 or 1, the substitution pattern of the substituents R' is preferably selected from (S-1) to (S-12)

, , ,

, , ,

R' R'

, , (S-9) , ,

, ,

wherein R' has independently of each other a meaning as described before or preferably described below. Preferred substitution patterns are (S-1), (S- 7), (S-10), (S-11) and (S-12). Particularly preferred substitution patterns are (S-7) and/or (S-10) and/or (S-12). A very particularly preferred substitution pattern is (S-7). A very particularly preferred substitution pattern is (S-10). A very particularly preferred substitution pattern is (S-12). The invention therefore relates additionally to an ophthalmic device or precursor article for an ophthalmic device comprising polymerized compounds of formulae (I), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I'), (I'-a), (I'-b), (I'-c), (I'-d), (I'-1), (I'-2), (I'-2-H), (I'-3), (I'-3-H), (I'-4) and (I'-4-H) as described or preferably described before wherein the substitution pattern of the R' substituents is (S-7) or (S-10) or (S-12).

The invention therefore relates additionally to compounds of formulae (I), (I- 1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I'), (I'-a), (I'-b), (I'-c), (I'-d), (I'-1), (I'-2), (I'-2-H), (I'-3), (I'-3-H), (I'-4) and (I'-4-H) as described or preferably described before wherein the substitution pattern of the R' substituents is (S-7) or (S-10) or (S-12). As described before, the substituent R ₉ corresponds to R ₁ in case m1 is 1 wherein R' has a meaning as described before or a preferred or particularly preferred meaning as described below. Therefore, the invention is furthermore directed to an ophthalmic device or precursor article for an ophthalmic device comprising polymerized compounds of formulae (I), (I-1), (I-2), (I-2-H), (I-3), (I-3-H), (I-4), (I-4-H), (I''), (I''-1), (I''-2), (I''-2-H), (I''-3), (I''-3-H), (I''-4) and (I''-4-H) wherein R ₉ is R ₁ in case m1 is 1 and n1 and R' have a meaning as described before or preferably described below.

Therefore, the invention is furthermore directed to compounds of formulae (I), (I-1), (I-2), (I-2-H), (I-3), (I-3-H), (I-4), (I-4-H), (I''), (I''-1), (I''-2), (I''-2-H), (I''-3), (I''-3-H), (I''-4) and (I''-4-H) wherein R9 is R1 in case m1 is 1 and n1 and R' have a meaning as described before or preferably described below. In this embodiment of the invention, n1 is preferably 0 or 1 and R' has a meaning as described or preferably described before. In this embodiment where R9 is R1 and R1 is linked via -R2-Y- to the phenyl group, such R1-R2- Y-group is preferably in ortho, meta or para position to the bond of said phenyl group linked to the rest of formulae (I), (I-1), (I-2), (I-2-H), (I-3), (I-3-

In this embodiment where R9 is R1 and R1 is linked via -R2-Y- to the phenyl group, such R1-R2-Y-group is particularly preferably in ortho or para position to the bond of said phenyl group linked to the rest of formulae (I), (I-1), (I-2), (I-2-H), (I-3), (I-3-H), (I-4), (I-4-H), (I''), (I''-1), (I''-2), (I''-2-H), (I''-3), (I''-3-H), (I''-4) or (I''-4-H). In this embodiment where R9 is R1 and R1 is linked via -R2- Y- to the phenyl group, such R1-R2-Y-group is very particularly preferably in para position to the bond of said phenyl group linked to the rest of formulae (I), (I-1), (I-2), (I-2-H), (I-3), (I-3-H), (I-4), (I-4-H), (I''), (I''-1), (I''-2), (I''-2-H), (I''-3), (I''-3-H), (I''-4) or (I''-4-H). Therefore, the invention is furthermore directed to an ophthalmic device or precursor article for an ophthalmic device comprising polymerized compounds of formulae (I), (I-1), (I-2), (I-2-H), (I-3), (I-3-H), (I-4), (I-4-H), (I''), (I''-1), (I''-2), (I''-2-H), (I''-3), (I''-3-H), (I''-4) and (I''-4-H) wherein R9 is R1, n1 is 0 or 1 and R' has a meaning as described before or preferably described below and R1 is linked via -R2-Y- to the phenyl group and such R ₁ -R ₂ -Y-group is in ortho, meta or para position, preferably in meta or para position, particularly preferably in para position to the bond of said phenyl group linked to the rest of said formulae.

Therefore, the invention is furthermore directed to compounds of formulae (I), (I-1), (I-2), (I-2-H), (I-3), (I-3-H), (I-4), (I-4-H), (I''), (I''-1), (I''-2), (I''-2-H), (I''-3), (I''-3-H), (I''-4) and (I''-4-H) wherein R9 is R1, n1 is 0 or 1 and R' has a meaning as described before or preferably described below and R1 is linked via -R ₂ -Y- to the phenyl group and such R ₁ -R ₂ -Y-group is in ortho, meta or para position, preferably in meta or para position, particularly preferably in para position to the bond of said phenyl group linked to the rest of said formulae. In this embodiment, it is preferred that n1 is 0.

Therefore, the invention is furthermore directed to an ophthalmic device or precursor article for an ophthalmic device comprising polymerized compounds of formulae (I), (I-1), (I-2), (I-2-H), (I-3), (I-3-H), (I-4), (I-4-H), (I''), (I''-1), (I''-2), (I''-2-H), (I''-3), (I''-3-H), (I''-4) and (I''-4-H) wherein R9 is R1 in case m1 is 1 and n1 is 0.

Therefore, the invention is furthermore directed to compounds of formulae (I), (I-1), (I-2), (I-2-H), (I-3), (I-3-H), (I-4), (I-4-H), (I''), (I''-1), (I''-2), (I''-2-H), (I''-3), (I''-3-H), (I''-4) and (I''-4-H) wherein R9 is R1 in case m1 is 1 and n1 is 0. Therefore, the invention is furthermore directed to an ophthalmic device or precursor article for an ophthalmic device comprising polymerized compounds of formulae (I), (I-1), (I-2), (I-2-H), (I-3), (I-3-H), (I-4), (I-4-H), (I''), (I''-1), (I''-2), (I''-2-H), (I''-3), (I''-3-H), (I''-4) and (I''-4-H) wherein R ₉ is R ₁ in case m1 is 1 and n1 is 0 and R1 is linked via -R2-Y- to the phenyl group and such R ₁ -R ₂ -Y-group is in ortho, meta or para position, preferably in meta or para position, particularly preferably in para position to the bond of said phenyl group linked to the rest of said formulae.

Therefore, the invention is furthermore directed to an ophthalmic device or precursor article for an ophthalmic device comprising polymerized compounds of formulae (I), (I-1), (I-2), (I-2-H), (I-3), (I-3-H), (I-4), (I-4-H), (I''), (I''-1), (I''-2), (I''-2-H), (I''-3), (I''-3-H), (I''-4) and (I''-4-H) wherein R9 is R1 in case m1 is 1 and n1 is 0 and R ₁ is linked via -R ₂ -Y- to the phenyl group and such R1-R2-Y-group is in para position to the bond of said phenyl group linked to the rest of said formulae.

Therefore, the invention is furthermore directed to compounds of formulae (I), (I-1), (I-2), (I-2-H), (I-3), (I-3-H), (I-4), (I-4-H), (I''), (I''-1), (I''-2), (I''-2-H), (I''-3), (I''-3-H), (I''-4) and (I''-4-H) wherein R9 is R1 in case m1 is 1 and n1 is 0 and R ₁ is linked via -R ₂ -Y- to the phenyl group and such R ₁ -R ₂ -Y-group is in ortho, meta or para position, preferably in meta or para position, particularly preferably in para position to the bond of said phenyl group linked to the rest of said formulae.

Therefore, the invention is furthermore directed to compounds of formulae (I), (I-1), (I-2), (I-2-H), (I-3), (I-3-H), (I-4), (I-4-H), (I''), (I''-1), (I''-2), (I''-2-H), (I''-3), (I''-3-H), (I''-4) and (I''-4-H) wherein R ₉ is R ₁ in case m1 is 1 and n1 is 0 and R1 is linked via -R2-Y- to the phenyl group and such R1-R2-Y-group is in para position to the bond of said phenyl group linked to the rest of said formulae. An ophthalmic device or precursor article for an ophthalmic device comprising polymerized compounds of formula (I) with linkers and substituents as described before or preferably described before or below are preferred when m is 1 or 2.

Compounds of formula (I) with linkers and substituents as described before or preferably described before or below are preferred when m is 1 or 2. An ophthalmic device or precursor article for an ophthalmic device comprising polymerized compounds of formula (I) with linkers and substituents as described before or preferably described before or below are preferred when m is 2.

Compounds of formula (I) with linkers and substituents as described before or preferably described before or below are particularly preferred when m is 2. The preferred position of the phenyl group in all compounds of formulae (I), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I'), (I'-a), (I'-b), (I'-c), (I'-d), (I'- 1), (I'-2), (I'-2-H), (I'-3), (I'-3-H), (I'-4), (I'-4-H) (I''), (I''-1), (I''-2), (I''-2-H), (I''- 3), (I''-3-H), (I''-4) and (I''-4-H) is at the C atom of the isolated double bond which is adjacent to C(R ₆ )(R ₇ ). Correspondingly, the preferred position of R5 in all compounds of formulae (I), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I- 4-H), (I'), (I'-a), (I'-b), (I'-c), (I'-d), (I'-1), (I'-2), (I'-2-H), (I'-3), (I'-3-H), (I'-4), (I'- 4-H) (I''), (I''-1), (I''-2), (I''-2-H), (I''-3), (I''-3-H), (I''-4) and (I''-4-H) is at the C atom adjacent to the fused aromatic ring. The following formula summarizes the preferred positions of R ₅ and phenyl group for compounds of formula (I) reading formula (I#),

wherein R1, -R2-, Y, R3, R4, R5, R6, R7, R8, R9, A, m, R', and n1 have a meaning as described before or preferably described before or below. Such compounds according to formula (I#) act preferably as monomers of formulae (I) for the preparation of the ophthalmic device or precursor article of the ophthalmic device as described before or for the preparation of an oligomer, polymer or copolymer according to the invention. According to the invention, compounds of formulae (I), (I#), (I-1), (I-2), (I- 2H), (I-3), (I-3-H), (I-4), (I-4-H), (I'), (I'-a), (I'-b), (I'-c), (I'-d), (I'-1), (I'-2), (I'-2- H), (I'-3), (I'-3-H), (I'-4), (I'-4-H) (I''), (I''-1), (I''-2), (I''-2-H), (I''-3), (I''-3-H), (I''- 4) and (I''-4-H) with substituents as described before or preferably described before have a polymerizable group as described before or preferably described before or below and have at least one linking element Y-R2. According to the invention, Y is independently at each occurrence O, S, O=S=O or a bond.

According to the invention, the linking element -R2- is selected from the group consisting of–(C(R) ₂ ) _o –, or–(C(R) ₂ ) _p –X ₈ –(C(R) ₂ ) _q –(X ₉ ) _s –(C(R) ₂ ) _r – (X10)t-(C(R) ₂ )u-, R is at each occurrence independently selected from the group consisting of H, F, a linear or branched alkyl group having 1 to 4 C atoms or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms and o is selected from the group consisting of 1 to 20, X ₈ , X ₉ and X10 are at each occurrence O, S, SO ₂ , or NR0, s and t are at each occurrence independently 0 or 1, p and q are at each occurrence independently selected from the group consisting of 1 to 10, r and u are at each occurrence independently selected from the group consisting of 0 to 10, wherein the overall number of atoms for–(C(R) ₂ )p–X8–(C(R) ₂ )q–(X9)s– (C(R) ₂ )r–(X10)t-(C(R) ₂ )u-, is up to 20 C atoms. R0 in NR0 has a meaning as described before excluding F. According to the invention, R is at each occurrence independently selected from the group consisting of H, F, a linear or branched alkyl group having 1 to 8 C atoms or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms.

R is particularly preferably at each occurrence independently H, F, methyl or ethyl. R is very particularly preferably H. In another preferred embodiment of the invention, o is preferably selected from the group consisting of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 within the compounds of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I- 4-H), (I'), (I'-a), (I'-b), (I'-c), (I'-d), (I'-1), (I'-2), (I'-2-H), (I'-3), (I'-3-H), (I'-4), (I'- 4-H) (I''), (I''-1), (I''-2), (I''-2-H), (I''-3), (I''-3-H), (I''-4) and (I''-4-H) acting as monomers for the preparation of the ophthalmic device or precursor article of the ophthalmic device as described before or for the preparation of an oligomer, polymer or copolymer according to the invention or within the compounds according to the invention. Preferably, o is selected from the group consisting of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12. Particularly preferably, o is selected from the group consisting of 1, 2, 3, 4, 5, 6 and 7 where 1, 3, 5 and 7 or 2, 3, 4, 5 and 6 is especially preferred. Very particularly preferably, o is 5. With regards to the compounds according to the invention, the described disclaimers have to be considered for the definition of o. In another preferred embodiment of the invention, s, t, X8, X9, X10, p, q, r and u within the compounds of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I- 3-H), (I-4), (I-4-H), (I'), (I'-a), (I'-b), (I'-c), (I'-d), (I'-1), (I'-2), (I'-2-H), (I'-3), (I'- 3-H), (I'-4), (I'-4-H) (I''), (I''-1), (I''-2), (I''-2-H), (I''-3), (I''-3-H), (I''-4) and (I''-4- H) acting as monomers for the preparation of the ophthalmic device or precursor article of the ophthalmic device as described before or for the preparation of an oligomer, polymer or copolymer according to the invention or within the compounds according to the invention have the following preferred meaning:

Preferably, s is 1. Preferably, s is 0.

Preferably t is 0 or 1.

Preferably, s and t are 0. Preferably, X ₈ , X ₉ and X ₁₀ are O, S or SO ₂ . Particularly preferably, X ₈ , X ₉ and X ₁₀ are O. Particularly preferably, X ₈ , X ₉ and X ₁₀ are S. Particularly preferably, X8, X9 and X10 are SO ₂ . Preferably, p and q are each independently 1, 3, 3, 4, 5 or 6, particularly preferably 1 or 2, very particularly preferably 2

Preferably, r and u are each independently 0, 1, 2 or 3, particularly preferably 0, 1 or 2, very particularly preferably 0. In case o is 0, -R2- is a bond.

According to the invention, suitable examples for -R ₂ - are -(CH ₂ )-, -(CH ₂ ) ₂ -, -(CH ₂ )3-, -(CH ₂ )4-, -(CH ₂ )5-, -(CH ₂ )6-, -(CH ₂ )7-, -(CH ₂ )8-, -(CH ₂ )9-, -(CH ₂ )10-, - (CH ₂ )11-, -(CH ₂ )12-, -(CH ₂ )13-, -(CH ₂ )14-, -(CH ₂ )15-, -(CH ₂ )16-, -(CH ₂ )17-, - (CH ₂ )18-, -(CH ₂ )19-, -(CH ₂ ) ₂ 0-, -(CHCH ₃ )-, -(CHCH ₃ ) ₂ -, -(CHCH ₃ )3-, - (CHCH ₃ ) ₄ -, -(CHCH ₃ ) ₅ -, -(CHCH ₃ ) ₆ -, -(CHCH ₃ ) ₇ -, -(CHCH ₃ ) ₈ -, -(CHCH ₃ ) ₉ -, - (CHCH ₃ )10-, -(CHCH ₃ )11-, -(CHCH ₃ )12-, -(CHCH ₃ )13-, -(CHCH ₃ )14-, - (CHCH ₃ ) ₁₅ -, -(CHCH ₃ ) ₁₆ -, -(CHCH ₃ ) ₁₇ -, -(CHCH ₃ ) ₁₈ -, -(CHCH ₃ ) ₁₉ -, - (CHCH ₃ ) ₂₀ -, -(C(CH ₃ ) ₂ )-, -(C(CH ₃ ) ₂ ) ₂ -, -(C(CH ₃ ) ₂ ) ₃ -, -(C(CH ₃ ) ₂ ) ₄ -, - (C(CH ₃ ) ₂ )5-, -(C(CH ₃ ) ₂ )6-, -(C(CH ₃ ) ₂ )7-, -(C(CH ₃ ) ₂ )8-, -(C(CH ₃ ) ₂ )9-, - (C(CH ₃ ) ₂ )10-, -(C(CH ₃ ) ₂ )11-, -(C(CH ₃ ) ₂ )12-, -(C(CH ₃ ) ₂ )13-, -(C(CH ₃ ) ₂ )14-, - (C(CH ₃ ) ₂ ) ₁₅ -, -(C(CH ₃ ) ₂ ) ₁₆ -, -(C(CH ₃ ) ₂ ) ₁₇ -, -(C(CH ₃ ) ₂ ) ₁₈ -, -(C(CH ₃ ) ₂ ) ₁₉ -, - (C(CH ₃ ) ₂ ) ₂₀ -, -(CHC ₂ H ₅ )-, -(CHC ₂ H ₅ ) ₂ -, -(CHC ₂ H ₅ ) ₃ -, -(CHC ₂ H ₅ ) ₄ -, - (CHC ₂ H ₅ ) ₅ -, -(CHC ₂ H ₅ ) ₆ -, -(CHC ₂ H ₅ ) ₇ -, -(CHC ₂ H ₅ ) ₈ -, -(CHC ₂ H ₅ ) ₉ -, - (CHC2H5)10-, -(CHC2H5)11-, -(CHC2H5)12-, -(CHC2H5)13-, -(CHC2H5)14-, - (CHC2H5)15-, -(CHC2H5)16-, -(CHC2H5)17-, -(CHC2H5)18-, -(CHC2H5)19-, - (CHC2H5) ₂ 0-, -(CH ₂ )-(CHCH ₃ )-(CH ₂ )-, -(CH ₂ )-(CHCH ₃ )-(CH ₂ ) ₂ -, -(CH ₂ )- (CHCH ₃ )-(CH ₂ ) ₃ -, -(CH ₂ )-(CHCH ₃ )-(CH ₂ ) ₁₁ -, -(CH ₂ ) ₂ -(CHCH ₃ )-(CH ₂ )-, - (CH ₂ )3-(CHCH ₃ )-(CH ₂ )-, -(CH ₂ )11-(CHCH ₃ )-(CH ₂ )-, -(CH ₂ ) ₂ -O-(CH ₂ ) ₂ -, - (CH ₂ )3-O-(CH ₂ )3-, -(CH ₂ ) ₂ -O-(CH ₂ ) ₂ -O-(CH ₂ ) ₂ -, -(CH ₂ )3-O-(CH ₂ )3-O-(CH ₂ )3-, -(CH ₂ ) ₂ -O-(CH ₂ ) ₂ -O-(CH ₂ ) ₆ -, -(CH ₂ ) ₆ -O-(CH ₂ ) ₂ -O-(CH ₂ ) ₂ -, -(CH ₂ ) ₂ -O-(CH ₂ ) ₂ - O-(CH ₂ )8-, -(CH ₂ )8-O-(CH ₂ ) ₂ -O-(CH ₂ ) ₂ -, -(CH ₂ ) ₂ -S-(CH ₂ ) ₂ -, -(CH ₂ )3-S-(CH ₂ )3- , -(CH ₂ ) ₂ -S-(CH ₂ ) ₂ -S-(CH ₂ ) ₂ -, -(CH ₂ )3-S-(CH ₂ )3-S-(CH ₂ )3-, -(CH ₂ ) ₂ -S-(CH ₂ ) ₂ - S-(CH ₂ ) ₆ -, -(CH ₂ ) ₆ -S-(CH ₂ ) ₂ -S-(CH ₂ ) ₂ -, -(CH ₂ ) ₂ -S-(CH ₂ ) ₂ -S-(CH ₂ ) ₈ -, -(CH ₂ ) ₈ - S-(CH ₂ ) ₂ -S-(CH ₂ ) ₂ -, -(CH ₂ ) ₂ -SO ₂ -(CH ₂ ) ₂ -, -(CH ₂ ) ₃ -SO ₂ -(CH ₂ ) ₃ -, -(CH ₂ ) ₂ -SO ₂ - (CH ₂ ) ₂ -SO ₂ -(CH ₂ ) ₂ -, -(CH ₂ )3-SO ₂ -(CH ₂ )3-SO ₂ -(CH ₂ )3-, -(CH ₂ ) ₂ -SO ₂ -(CH ₂ ) ₂ - SO ₂ -(CH ₂ ) ₆ -, -(CH ₂ ) ₆ -SO ₂ -(CH ₂ ) ₂ -SO ₂ -(CH ₂ ) ₂ -, -(CH ₂ ) ₂ -SO ₂ -(CH ₂ ) ₂ -SO ₂ - (CH ₂ )8-, -(CH ₂ )8-SO ₂ -(CH ₂ ) ₂ -SO ₂ -(CH ₂ ) ₂ -, -(CH ₂ )-S-(CH ₂ ) ₂ -O-(CH ₂ )-, -(CH ₂ )- SO ₂ -(CH ₂ ) ₂ -O-(CH ₂ )-, -(CH ₂ )-SO ₂ -(CH ₂ ) ₂ -S-(CH ₂ )-, -(CH ₂ )-O-(CH ₂ ) ₂ -S- (CH ₂ ) ₂ -O-(CH ₂ )-, -(CH ₂ )-S-(CH ₂ ) ₂ -O-(CH ₂ ) ₂ -S-(CH ₂ )-, -(CH ₂ )-SO ₂ -(CH ₂ ) ₂ -O- (CH ₂ ) ₂ -SO ₂ -(CH ₂ )-, -(CH ₂ )-S-(CH ₂ ) ₂ -S-(CH ₂ ) ₂ -S-(CH ₂ )-, -(CH ₂ )-SO ₂ -(CH ₂ ) ₂ - SO ₂ -(CH ₂ ) ₂ -SO ₂ -(CH ₂ )-, -(CH ₂ )-O-(CH ₂ ) ₂ -SO ₂ -(CH ₂ ) ₂ -O-(CH ₂ )-, -(CH ₂ ) ₂ - (NCH ₃ )-(CH ₂ ) ₂ -, -(CH ₂ )3-(NCH ₃ )-(CH ₂ )3-, -(CH ₂ ) ₂ -(NCH ₃ )-(CH ₂ ) ₂ -(NCH ₃ )- (CH ₂ ) ₂ -, -(CH ₂ ) ₃ -(NCH ₃ )-(CH ₂ ) ₃ -(NCH ₃ )-(CH ₂ ) ₃ -, -(CH ₂ ) ₂ -(NCH ₃ )-(CH ₂ ) ₂ - (NCH ₃ )-(CH ₂ )6-, -(CH ₂ )6-(NCH ₃ )-(CH ₂ ) ₂ -(NCH ₃ )-(CH ₂ ) ₂ -, -(CH ₂ ) ₂ -(NCH ₃ )- (CH ₂ ) ₂ -(NCH ₃ )-(CH ₂ )8- and-(CH ₂ )8-(NCH ₃ )-(CH ₂ ) ₂ -(NCH ₃ )-(CH ₂ ) ₂ -;

-(CF2)-(CH ₂ )-, -(CH ₂ )-(CF2)-, -(CH ₂ )-(CF2)-(CH ₂ )-, -(CH ₂ )-(CF2)-(CH ₂ ) ₂ -, - (CH ₂ )-(CF ₂ )-(CH ₂ ) ₃ -, -(CH ₂ )-(CF ₂ )-(CH ₂ ) ₄ -, -(CH ₂ )-(CF ₂ )-(CH ₂ ) ₅ -, -(CH ₂ )- (CF2)-(CH ₂ )6-, -(CH ₂ )-(CF2)-(CH ₂ )7-, -(CH ₂ )-(CF2)-(CH ₂ )8-, -(CH ₂ )-(CF2)- (CH ₂ ) ₉ -, -(CH ₂ )-(CF ₂ )-(CH ₂ ) ₁₀ -, -(CH ₂ ) ₂ -(CF ₂ )-(CH ₂ )-, -(CH ₂ ) ₃ -(CF ₂ )-(CH ₂ )-, - (CH ₂ ) ₄ -(CF ₂ )-(CH ₂ )-, -(CH ₂ ) ₅ -(CF ₂ )-(CH ₂ )-, -(CH ₂ ) ₆ -(CF ₂ )-(CH ₂ )-, -(CH ₂ ) ₇ - (CF2)-(CH ₂ )-, -(CH ₂ )8-(CF2)-(CH ₂ )-, -(CH ₂ )9-(CF2)-(CH ₂ )-, -(CH ₂ )10-(CF2)- (CH ₂ )-, -(CH ₂ ) ₂ -(CF2)-(CH ₂ ) ₂ -, -(CH ₂ )3-(CF2)-(CH ₂ )3-, -(CH ₂ )4-(CF2)-(CH ₂ )4- , -(CH ₂ ) ₅ -(CF ₂ )-(CH ₂ ) ₅ -, -(CH ₂ ) ₂ -(CF ₂ )-(CH ₂ )-, -(CH ₂ ) ₂ -(CF ₂ )-(CH ₂ ) ₃ -, - (CH ₂ ) ₂ -(CF ₂ )-(CH ₂ ) ₄ -, -(CH ₂ ) ₂ -(CF ₂ )-(CH ₂ ) ₅ -, -(CH ₂ ) ₂ -(CF ₂ )-(CH ₂ ) ₆ -, -(CH ₂ ) ₂ - (CF ₂ )-(CH ₂ ) ₇ -, -(CH ₂ ) ₂ -(CF ₂ )-(CH ₂ ) ₈ -, -(CH ₂ ) ₂ -(CF ₂ )-(CH ₂ ) ₉ -, -(CH ₂ ) ₃ -(CF ₂ )- (CH ₂ )-, -(CH ₂ )3-(CF2)-(CH ₂ ) ₂ -, -(CH ₂ )3-(CF2)-(CH ₂ )4-, -(CH ₂ )3-(CF2)-(CH ₂ )5-, -(CH ₂ )3-(CF2)-(CH ₂ )6-, -(CH ₂ )3-(CF2)-(CH ₂ )7-, -(CH ₂ )3-(CF2)-(CH ₂ )8-, -(CH ₂ )4- (CF2)-(CH ₂ )-, -(CH ₂ )4-(CF2)-(CH ₂ ) ₂ -, -(CH ₂ )4-(CF2)-(CH ₂ )3-, -(CH ₂ )4-(CF2)- (CH ₂ ) ₅ -, -(CH ₂ ) ₄ -(CF ₂ )-(CH ₂ ) ₆ -, -(CH ₂ ) ₄ -(CF ₂ )-(CH ₂ ) ₇ -, -(CH ₂ ) ₅ -(CF ₂ )-(CH ₂ )-, -(CH ₂ )5-(CF2)-(CH ₂ ) ₂ -, -(CH ₂ )5-(CF2)-(CH ₂ )3-, -(CH ₂ )5-(CF2)-(CH ₂ )4-, -(CH ₂ )5- (CF2)-(CH ₂ )6-, -(CH ₂ )6-(CF2)-(CH ₂ )-, -(CH ₂ )6-(CF2)-(CH ₂ ) ₂ -, -(CH ₂ )6-(CF2)- (CH ₂ ) ₃ -, -(CH ₂ ) ₆ -(CF ₂ )-(CH ₂ ) ₄ -, -(CH ₂ ) ₆ -(CF ₂ )-(CH ₂ ) ₅ -,

-(CFH)-(CH ₂ )-, -(CH ₂ )-(CFH)-, -(CH ₂ )-(CFH)-(CH ₂ )-, -(CH ₂ )-(CFH)-(CH ₂ ) ₂ -, - (CH ₂ )-(CFH)-(CH ₂ )3-, -(CH ₂ )-(CFH)-(CH ₂ )4-, -(CH ₂ )-(CFH)-(CH ₂ )5-, -(CH ₂ )- (CFH)-(CH ₂ ) ₆ -, -(CH ₂ )-(CFH)-(CH ₂ ) ₇ -, -(CH ₂ )-(CFH)-(CH ₂ ) ₈ -, -(CH ₂ )-(CFH)- (CH ₂ ) ₉ -, -(CH ₂ )-(CFH)-(CH ₂ ) ₁₀ -, -(CH ₂ ) ₂ -(CFH)-(CH ₂ )-, -(CH ₂ ) ₃ -(CFH)-(CH ₂ )- , -(CH ₂ )4-(CFH)-(CH ₂ )-, -(CH ₂ )5-(CFH)-(CH ₂ )-, -(CH ₂ )6-(CFH)-(CH ₂ )-, - (CH ₂ ) ₇ -(CFH)-(CH ₂ )-, -(CH ₂ ) ₈ -(CFH)-(CH ₂ )-, -(CH ₂ ) ₉ -(CFH)-(CH ₂ )-, -(CH ₂ ) ₁₀ - (CFH)-(CH ₂ )-, -(CH ₂ ) ₂ -(CFH)-(CH ₂ ) ₂ -, -(CH ₂ )3-(CFH)-(CH ₂ )3-, -(CH ₂ )4- (CFH)-(CH ₂ )4-, -(CH ₂ )5-(CFH)-(CH ₂ )5-, -(CH ₂ ) ₂ -(CFH)-(CH ₂ )-, -(CH ₂ ) ₂ - (CFH)-(CH ₂ )3-, -(CH ₂ ) ₂ -(CFH)-(CH ₂ )4-, -(CH ₂ ) ₂ -(CFH)-(CH ₂ )5-, -(CH ₂ ) ₂ - (CFH)-(CH ₂ ) ₆ -, -(CH ₂ ) ₂ -(CFH)-(CH ₂ ) ₇ -, -(CH ₂ ) ₂ -(CFH)-(CH ₂ ) ₈ -, -(CH ₂ ) ₂ - (CFH)-(CH ₂ )9-, -(CH ₂ )3-(CFH)-(CH ₂ )-, -(CH ₂ )3-(CFH)-(CH ₂ ) ₂ -, -(CH ₂ )3- (CFH)-(CH ₂ )4-, -(CH ₂ )3-(CFH)-(CH ₂ )5-, -(CH ₂ )3-(CFH)-(CH ₂ )6-, -(CH ₂ )3- (CFH)-(CH ₂ ) ₇ -, -(CH ₂ ) ₃ -(CFH)-(CH ₂ ) ₈ -, -(CH ₂ ) ₄ -(CFH)-(CH ₂ )-, -(CH ₂ ) ₄ - (CFH)-(CH ₂ ) ₂ -, -(CH ₂ )4-(CFH)-(CH ₂ )3-, -(CH ₂ )4-(CFH)-(CH ₂ )5-, -(CH ₂ )4- (CFH)-(CH ₂ )6-, -(CH ₂ )4-(CFH)-(CH ₂ )7-, -(CH ₂ )5-(CFH)-(CH ₂ )-, -(CH ₂ )5- (CFH)-(CH ₂ ) ₂ -, -(CH ₂ )5-(CFH)-(CH ₂ )3-, -(CH ₂ )5-(CFH)-(CH ₂ )4-, -(CH ₂ )5- (CFH)-(CH ₂ ) ₆ -, -(CH ₂ ) ₆ -(CFH)-(CH ₂ )-, -(CH ₂ ) ₆ -(CFH)-(CH ₂ ) ₂ -, -(CH ₂ ) ₆ - (CFH)-(CH ₂ )3-, -(CH ₂ )6-(CFH)-(CH ₂ )4-, -(CH ₂ )6-(CFH)-(CH ₂ )5-,

-(CF ₂ ) ₂ -(CH ₂ )-, -(CH ₂ )-(CF ₂ ) ₂ -, -(CH ₂ )-(CF ₂ ) ₂ -(CH ₂ )-, -(CH ₂ )-(CF ₂ ) ₂ -(CH ₂ ) ₂ -, - (CH ₂ )-(CF ₂ ) ₂ -(CH ₂ ) ₃ -, -(CH ₂ )-(CF ₂ ) ₂ -(CH ₂ ) ₄ -, -(CH ₂ )-(CF ₂ ) ₂ -(CH ₂ ) ₅ -, -(CH ₂ )- (CF2) ₂ -(CH ₂ )6-, -(CH ₂ )-(CF2) ₂ -(CH ₂ )7-, -(CH ₂ )-(CF2) ₂ -(CH ₂ )8-, -(CH ₂ )-(CF2) ₂ - (CH ₂ )9-, -(CH ₂ ) ₂ -(CF2) ₂ -(CH ₂ )-, -(CH ₂ )3-(CF2) ₂ -(CH ₂ )-, -(CH ₂ )4-(CF2) ₂ -(CH ₂ )-, -(CH ₂ ) ₅ -(CF ₂ ) ₂ -(CH ₂ )-, -(CH ₂ ) ₆ -(CF ₂ ) ₂ -(CH ₂ )-, -(CH ₂ ) ₇ -(CF ₂ ) ₂ -(CH ₂ )-, -(CH ₂ ) ₈ - (CF ₂ ) ₂ -(CH ₂ )-, -(CH ₂ ) ₉ -(CF ₂ ) ₂ -(CH ₂ )-, -(CH ₂ ) ₂ -(CF ₂ ) ₂ -(CH ₂ ) ₂ -, -(CH ₂ ) ₃ -(CF ₂ ) ₂ - (CH ₂ ) ₃ -, -(CH ₂ ) ₄ -(CF ₂ ) ₂ -(CH ₂ ) ₄ -, -(CH ₂ ) ₅ -(CF ₂ ) ₂ -(CH ₂ ) ₅ -, -(CH ₂ ) ₂ -(CF ₂ ) ₂ - (CH ₂ )-,-(CH ₂ ) ₂ -(CF2) ₂ -(CH ₂ )3-, -(CH ₂ ) ₂ -(CF2) ₂ -(CH ₂ )4-, -(CH ₂ ) ₂ -(CF2) ₂ -(CH ₂ )5- , -(CH ₂ ) ₂ -(CF2) ₂ -(CH ₂ )6-, -(CH ₂ ) ₂ -(CF2) ₂ -(CH ₂ )7-, -(CH ₂ ) ₂ -(CF2) ₂ -(CH ₂ )8-, - (CH ₂ )3-(CF2) ₂ -(CH ₂ )-, -(CH ₂ )3-(CF2) ₂ -(CH ₂ ) ₂ -, -(CH ₂ )3-(CF2) ₂ -(CH ₂ )4-, - (CH ₂ ) ₃ -(CF ₂ ) ₂ -(CH ₂ ) ₅ -, -(CH ₂ ) ₃ -(CF ₂ ) ₂ -(CH ₂ ) ₆ -, -(CH ₂ ) ₃ -(CF ₂ ) ₂ -(CH ₂ ) ₇ -, - (CH ₂ )4-(CF2) ₂ -(CH ₂ )-, -(CH ₂ )4-(CF2) ₂ -(CH ₂ ) ₂ -, -(CH ₂ )4-(CF2) ₂ -(CH ₂ )3-, - (CH ₂ )4-(CF2) ₂ -(CH ₂ )5-, -(CH ₂ )4-(CF2) ₂ -(CH ₂ )6-, -(CH ₂ )5-(CF2) ₂ -(CH ₂ )-, - (CH ₂ ) ₅ -(CF ₂ ) ₂ -(CH ₂ ) ₂ -, -(CH ₂ ) ₅ -(CF ₂ ) ₂ -(CH ₂ ) ₃ -, -(CH ₂ ) ₅ -(CF ₂ ) ₂ -(CH ₂ ) ₄ -, - (CH ₂ )6-(CF2) ₂ -(CH ₂ )-, -(CH ₂ )6-(CF2) ₂ -(CH ₂ ) ₂ -, -(CH ₂ )6-(CF2) ₂ -(CH ₂ )3-, - (CH ₂ )6-(CF2) ₂ -(CH ₂ )4-,

-(CFH) ₂ -(CH ₂ )-, -(CH ₂ )-(CFH) ₂ -, -(CH ₂ )-(CFH) ₂ -(CH ₂ )-, -(CH ₂ )-(CFH) ₂ - (CH ₂ ) ₂ -, -(CH ₂ )-(CFH) ₂ -(CH ₂ ) ₃ -, -(CH ₂ )-(CFH) ₂ -(CH ₂ ) ₄ -, -(CH ₂ )-(CFH) ₂ - (CH ₂ )5-, -(CH ₂ )-(CFH) ₂ -(CH ₂ )6-, -(CH ₂ )-(CFH) ₂ -(CH ₂ )7-, -(CH ₂ )-(CFH) ₂ - (CH ₂ ) ₈ -, -(CH ₂ )-(CFH) ₂ -(CH ₂ ) ₉ -, -(CH ₂ ) ₂ -(CFH) ₂ -(CH ₂ )-, -(CH ₂ ) ₃ -(CFH) ₂ - (CH ₂ )-, -(CH ₂ )4-(CFH) ₂ -(CH ₂ )-, -(CH ₂ )5-(CFH) ₂ -(CH ₂ )-, -(CH ₂ )6-(CFH) ₂ - (CH ₂ )-, -(CH ₂ )7-(CFH) ₂ -(CH ₂ )-, -(CH ₂ )8-(CFH) ₂ -(CH ₂ )-, -(CH ₂ )9-(CFH) ₂ - (CH ₂ )-, -(CH ₂ ) ₂ -(CFH) ₂ -(CH ₂ ) ₂ -, -(CH ₂ )3-(CFH) ₂ -(CH ₂ )3-, -(CH ₂ )4-(CFH) ₂ - (CH ₂ ) ₄ -, -(CH ₂ ) ₅ -(CFH) ₂ -(CH ₂ ) ₅ -, -(CH ₂ ) ₂ -(CFH) ₂ -(CH ₂ )-,-(CH ₂ ) ₂ -(CFH) ₂ - (CH ₂ )3-, -(CH ₂ ) ₂ -(CFH) ₂ -(CH ₂ )4-, -(CH ₂ ) ₂ -(CFH) ₂ -(CH ₂ )5-, -(CH ₂ ) ₂ -(CFH) ₂ - (CH ₂ )6-, -(CH ₂ ) ₂ -(CFH) ₂ -(CH ₂ )7-, -(CH ₂ ) ₂ -(CFH) ₂ -(CH ₂ )8-, -(CH ₂ )3-(CFH) ₂ - (CH ₂ )-, -(CH ₂ ) ₃ -(CFH) ₂ -(CH ₂ ) ₂ -, -(CH ₂ ) ₃ -(CFH) ₂ -(CH ₂ ) ₄ -, -(CH ₂ ) ₃ -(CFH) ₂ - (CH ₂ )5-, -(CH ₂ )3-(CFH) ₂ -(CH ₂ )6-, -(CH ₂ )3-(CFH) ₂ -(CH ₂ )7-, -(CH ₂ )4-(CFH) ₂ - (CH ₂ )-, -(CH ₂ )4-(CFH) ₂ -(CH ₂ ) ₂ -, -(CH ₂ )4-(CFH) ₂ -(CH ₂ )3-, -(CH ₂ )4-(CFH) ₂ - (CH ₂ )5-, -(CH ₂ )4-(CFH) ₂ -(CH ₂ )6-, -(CH ₂ )5-(CFH) ₂ -(CH ₂ )-, -(CH ₂ )5-(CFH) ₂ - (CH ₂ ) ₂ -, -(CH ₂ ) ₅ -(CFH) ₂ -(CH ₂ ) ₃ -, -(CH ₂ ) ₅ -(CFH) ₂ -(CH ₂ ) ₄ -, -(CH ₂ ) ₆ -(CFH) ₂ - (CH ₂ )-, -(CH ₂ )6-(CFH) ₂ -(CH ₂ ) ₂ -, -(CH ₂ )6-(CFH) ₂ -(CH ₂ )3-, -(CH ₂ )6-(CFH) ₂ - (CH ₂ ) ₄ -,

-(CF ₂ ) ₃ -(CH ₂ )-, -(CH ₂ )-(CF ₂ ) ₃ -, -(CH ₂ )-(CF ₂ ) ₃ -(CH ₂ )-, -(CH ₂ )-(CF ₂ ) ₃ -(CH ₂ ) ₂ -, - (CH ₂ )-(CF2)3-(CH ₂ )3-, -(CH ₂ )-(CF2)3-(CH ₂ )4-, -(CH ₂ )-(CF2)3-(CH ₂ )5-, -(CH ₂ )- (CF2)3-(CH ₂ )6-, -(CH ₂ )-(CF2)3-(CH ₂ )7-, -(CH ₂ )-(CF2)3-(CH ₂ )8-, -(CH ₂ ) ₂ -(CF2)3- (CH ₂ )-, -(CH ₂ ) ₃ -(CF ₂ ) ₃ -(CH ₂ )-, -(CH ₂ ) ₄ -(CF ₂ ) ₃ -(CH ₂ )-, -(CH ₂ ) ₅ -(CF ₂ ) ₃ -(CH ₂ )-, - (CH ₂ ) ₆ -(CF ₂ ) ₃ -(CH ₂ )-, -(CH ₂ ) ₇ -(CF ₂ ) ₃ -(CH ₂ )-, -(CH ₂ ) ₈ -(CF ₂ ) ₃ -(CH ₂ )-, -(CH ₂ ) ₂ - (CF ₂ ) ₃ -(CH ₂ ) ₂ -, -(CH ₂ ) ₃ -(CF ₂ ) ₃ -(CH ₂ ) ₃ -, -(CH ₂ ) ₄ -(CF ₂ ) ₃ -(CH ₂ ) ₄ -, -(CH ₂ ) ₂ -(CF ₂ ) ₃ - (CH ₂ )-,-(CH ₂ ) ₂ -(CF2)3-(CH ₂ )3-, -(CH ₂ ) ₂ -(CF2)3-(CH ₂ )4-, -(CH ₂ ) ₂ -(CF2)3-(CH ₂ )5-, -(CH ₂ ) ₂ -(CF2)3-(CH ₂ )6-, -(CH ₂ ) ₂ -(CF2)3-(CH ₂ )7-, -(CH ₂ )3-(CF2)3-(CH ₂ )-, -(CH ₂ )3- (CF2)3-(CH ₂ ) ₂ -, -(CH ₂ )3-(CF2)3-(CH ₂ )4-, -(CH ₂ )3-(CF2)3-(CH ₂ )5-, -(CH ₂ )3-(CF2)3- (CH ₂ ) ₆ -, -(CH ₂ ) ₄ -(CF ₂ ) ₃ -(CH ₂ )-, -(CH ₂ ) ₄ -(CF ₂ ) ₃ -(CH ₂ ) ₂ -, -(CH ₂ ) ₄ -(CF ₂ ) ₃ -(CH ₂ ) ₃ -, -(CH ₂ )4-(CF2)3-(CH ₂ )5-, -(CH ₂ )5-(CF2)3-(CH ₂ )-, -(CH ₂ )5-(CF2)3-(CH ₂ ) ₂ -, -(CH ₂ )5- (CF2)3-(CH ₂ )3-, -(CH ₂ )5-(CF2)3-(CH ₂ )4-, (CH ₂ )6-(CF2)3-(CH ₂ )-, -(CH ₂ )6-(CF2)3- (CH ₂ ) ₂ -, -(CH ₂ ) ₆ -(CF ₂ ) ₃ -(CH ₂ ) ₃ -,

-(CF2)4-(CH ₂ )-, -(CH ₂ )-(CF2)4-, -(CH ₂ )-(CF2)4-(CH ₂ )-, -(CH ₂ )-(CF2)4-(CH ₂ ) ₂ -, - (CH ₂ )-(CF2)4-(CH ₂ )3-, -(CH ₂ )-(CF2)4-(CH ₂ )4-, -(CH ₂ )-(CF2)4-(CH ₂ )5-, -(CH ₂ )- (CF ₂ ) ₄ -(CH ₂ ) ₆ -, -(CH ₂ )-(CF ₂ ) ₄ -(CH ₂ ) ₇ -, -(CH ₂ )-(CF ₂ ) ₄ -(CH ₂ ) ₈ -, -(CH ₂ )-(CF ₂ ) ₄ - (CH ₂ ) ₉ -, -(CH ₂ )-(CF ₂ ) ₄ -(CH ₂ ) ₁₀ -, -(CH ₂ ) ₂ -(CF ₂ ) ₄ -(CH ₂ )-, -(CH ₂ ) ₃ -(CF ₂ ) ₄ -(CH ₂ )- , -(CH ₂ )4-(CF2)4-(CH ₂ )-, -(CH ₂ )5-(CF2)4-(CH ₂ )-, -(CH ₂ )6-(CF2)4-(CH ₂ )-, - (CH ₂ ) ₇ -(CF ₂ ) ₄ -(CH ₂ )-, -(CH ₂ ) ₂ -(CF ₂ ) ₄ -(CH ₂ ) ₂ -, -(CH ₂ ) ₃ -(CF ₂ ) ₄ -(CH ₂ ) ₃ -, - (CH ₂ )4-(CF2)4-(CH ₂ )4-, -(CH ₂ )5-(CF2)4-(CH ₂ )5-, -(CH ₂ ) ₂ -(CF2)4-(CH ₂ )3-, - (CH ₂ ) ₂ -(CF2)4-(CH ₂ )4-, -(CH ₂ ) ₂ -(CF2)4-(CH ₂ )5-, -(CH ₂ ) ₂ -(CF2)4-(CH ₂ )6-, - (CH ₂ )3-(CF2)4-(CH ₂ ) ₂ -, -(CH ₂ )3-(CF2)4-(CH ₂ )4-, -(CH ₂ )4-(CF2)4-(CH ₂ ) ₂ -, - (CH ₂ ) ₄ -(CF ₂ ) ₄ -(CH ₂ ) ₃ -, -(CH ₂ ) ₅ -(CF ₂ ) ₄ -(CH ₂ ) ₂ -, -(CH ₂ ) ₅ -(CF ₂ ) ₄ -(CH ₂ ) ₃ -, - (CH ₂ )6-(CF2)4-(CH ₂ ) ₂ -,

-(CF2)5-(CH ₂ )-, -(CH ₂ )-(CF2)5-, -(CH ₂ )-(CF2)5-(CH ₂ )-, -(CH ₂ )-(CF2)5-(CH ₂ ) ₂ -, - (CH ₂ )-(CF ₂ ) ₅ -(CH ₂ ) ₃ -, -(CH ₂ )-(CF ₂ ) ₅ -(CH ₂ ) ₄ -, -(CH ₂ )-(CF ₂ ) ₅ -(CH ₂ ) ₅ -, -(CH ₂ )- (CF2)5-(CH ₂ )6-, -(CH ₂ ) ₂ -(CF2)5-(CH ₂ )-, -(CH ₂ )3-(CF2)5-(CH ₂ )-, -(CH ₂ )4-(CF2)5- (CH ₂ )-, -(CH ₂ )5-(CF2)5-(CH ₂ )-, -(CH ₂ )6-(CF2)5-(CH ₂ )-, -(CH ₂ ) ₂ -(CF2)5-(CH ₂ ) ₂ -, -(CH ₂ )3-(CF2)5-(CH ₂ )3-, -(CH ₂ )4-(CF2)5-(CH ₂ )4-, -(CH ₂ ) ₂ -(CF2)5-(CH ₂ )3-, - (CH ₂ ) ₂ -(CF ₂ ) ₅ -(CH ₂ ) ₄ -, -(CH ₂ ) ₂ -(CF ₂ ) ₅ -(CH ₂ ) ₅ -, -(CH ₂ ) ₂ -(CF ₂ ) ₅ -(CH ₂ ) ₆ -, - (CH ₂ )3-(CF2)5-(CH ₂ ) ₂ -, -(CH ₂ )3-(CF2)5-(CH ₂ )4-, -(CH ₂ )4-(CF2)5-(CH ₂ ) ₂ -, - (CH ₂ ) ₄ -(CF ₂ ) ₅ -(CH ₂ ) ₃ -, -(CH ₂ ) ₅ -(CF ₂ ) ₅ -(CH ₂ ) ₂ -,

-(CHCF ₃ )-(CH ₂ )-, -(CH ₂ )-(CHCF ₃ )-, -(CH ₂ )-(CHCF ₃ )-(CH ₂ )-, -(CH ₂ )- (CHCF3)-(CH ₂ ) ₂ -, -(CH ₂ )-(CHCF3)-(CH ₂ )3-, -(CH ₂ )-(CHCF3)-(CH ₂ )4-, -(CH ₂ )- (CHCF3)-(CH ₂ )5-, -(CH ₂ )-(CHCF3)-(CH ₂ )6-, -(CH ₂ )-(CHCF3)-(CH ₂ )7-, -(CH ₂ )- (CHCF ₃ )-(CH ₂ ) ₈ -, -(CH ₂ )-(CHCF ₃ )-(CH ₂ ) ₉ -, -(CH ₂ )-(CHCF ₃ )-(CH ₂ ) ₁₀ -, - (CH ₂ ) ₂ -(CHCF ₃ )-(CH ₂ )-, -(CH ₂ ) ₃ -(CHCF ₃ )-(CH ₂ )-, -(CH ₂ ) ₄ -(CHCF ₃ )-(CH ₂ )-, - (CH ₂ ) ₅ -(CHCF ₃ )-(CH ₂ )-, -(CH ₂ ) ₆ -(CHCF ₃ )-(CH ₂ )-, -(CH ₂ ) ₇ -(CHCF ₃ )-(CH ₂ )-, - (CH ₂ )8-(CHCF3)-(CH ₂ )-, -(CH ₂ )9-(CHCF3)-(CH ₂ )-, -(CH ₂ )10-(CHCF3)-(CH ₂ )-, - (CH ₂ ) ₂ -(CHCF3)-(CH ₂ ) ₂ -, -(CH ₂ )3-(CHCF3)-(CH ₂ )3-, -(CH ₂ )4-(CHCF3)-(CH ₂ )4- , -(CH ₂ )5-(CHCF3)-(CH ₂ )5-, -(CH ₂ ) ₂ -(CHCF3)-(CH ₂ )3-, -(CH ₂ ) ₂ -(CHCF3)- (CH ₂ ) ₄ -, -(CH ₂ ) ₂ -(CHCF ₃ )-(CH ₂ ) ₅ -, -(CH ₂ ) ₂ -(CHCF ₃ )-(CH ₂ ) ₆ -, -(CH ₂ ) ₂ - (CHCF3)-(CH ₂ )7-, -(CH ₂ ) ₂ -(CHCF3)-(CH ₂ )8-, -(CH ₂ ) ₂ -(CHCF3)-(CH ₂ )9-, - (CH ₂ )3-(CHCF3)-(CH ₂ ) ₂ -, -(CH ₂ )3-(CHCF3)-(CH ₂ )4-, -(CH ₂ )3-(CHCF3)-(CH ₂ )5- , -(CH ₂ ) ₃ -(CHCF ₃ )-(CH ₂ ) ₆ -, -(CH ₂ ) ₃ -(CHCF ₃ )-(CH ₂ ) ₇ -, -(CH ₂ ) ₃ -(CHCF ₃ )- (CH ₂ )8-, -(CH ₂ )4-(CHCF3)-(CH ₂ ) ₂ -, -(CH ₂ )4-(CHCF3)-(CH ₂ )3-, -(CH ₂ )4- (CHCF3)-(CH ₂ )5-, -(CH ₂ )4-(CHCF3)-(CH ₂ )6-, -(CH ₂ )4-(CHCF3)-(CH ₂ )7-, - (CH ₂ ) ₅ -(CHCF ₃ )-(CH ₂ ) ₂ -, -(CH ₂ ) ₅ -(CHCF ₃ )-(CH ₂ ) ₃ -, -(CH ₂ ) ₅ -(CHCF ₃ )-(CH ₂ ) ₄ - , -(CH ₂ ) ₅ -(CHCF ₃ )-(CH ₂ ) ₆ -, -(CH ₂ ) ₆ -(CHCF ₃ )-(CH ₂ ) ₂ -, -(CH ₂ ) ₆ -(CHCF ₃ )- (CH ₂ )3-, -(CH ₂ )6-(CHCF3)-(CH ₂ )4-, -(CH ₂ )6-(CHCF3)-(CH ₂ )5-,

-(CHCF ₃ ) ₂ -(CH ₂ )-, -(CH ₂ )-(CHCF ₃ ) ₂ -, -(CH ₂ )-(CHCF ₃ ) ₂ -(CH ₂ )-, -(CH ₂ )- (CHCF3) ₂ -(CH ₂ ) ₂ -, -(CH ₂ )-(CHCF3) ₂ -(CH ₂ )3-, -(CH ₂ )-(CHCF3) ₂ -(CH ₂ )4-, - (CH ₂ )-(CHCF3) ₂ -(CH ₂ )5-, -(CH ₂ )-(CHCF3) ₂ -(CH ₂ )6-, -(CH ₂ )-(CHCF3) ₂ -(CH ₂ )7- , -(CH ₂ )-(CHCF3) ₂ -(CH ₂ )8-, -(CH ₂ )-(CHCF3) ₂ -(CH ₂ )9-, -(CH ₂ ) ₂ -(CHCF3) ₂ - (CH ₂ )-, -(CH ₂ ) ₃ -(CHCF ₃ ) ₂ -(CH ₂ )-, -(CH ₂ ) ₄ -(CHCF ₃ ) ₂ -(CH ₂ )-, -(CH ₂ ) ₅ - (CHCF3) ₂ -(CH ₂ )-, -(CH ₂ )6-(CHCF3) ₂ -(CH ₂ )-, -(CH ₂ )7-(CHCF3) ₂ -(CH ₂ )-, - (CH ₂ )8-(CHCF3) ₂ -(CH ₂ )-, -(CH ₂ )9-(CHCF3) ₂ -(CH ₂ )-, -(CH ₂ ) ₂ -(CHCF3) ₂ - (CH ₂ ) ₂ -, -(CH ₂ ) ₃ -(CHCF ₃ ) ₂ -(CH ₂ ) ₃ -, -(CH ₂ ) ₄ -(CHCF ₃ ) ₂ -(CH ₂ ) ₄ -, -(CH ₂ ) ₅ - (CHCF3) ₂ -(CH ₂ )5-, -(CH ₂ ) ₂ -(CHCF3) ₂ -(CH ₂ )3-, -(CH ₂ ) ₂ -(CHCF3) ₂ -(CH ₂ )4-, - (CH ₂ ) ₂ -(CHCF3) ₂ -(CH ₂ )5-, -(CH ₂ ) ₂ -(CHCF3) ₂ -(CH ₂ )6-, -(CH ₂ ) ₂ -(CHCF3) ₂ - (CH ₂ )7-, -(CH ₂ ) ₂ -(CHCF3) ₂ -(CH ₂ )8-, -(CH ₂ )3-(CHCF3) ₂ -(CH ₂ ) ₂ -, -(CH ₂ )3- (CHCF ₃ ) ₂ -(CH ₂ ) ₄ -, -(CH ₂ ) ₃ -(CHCF ₃ ) ₂ -(CH ₂ ) ₅ -, -(CH ₂ ) ₃ -(CHCF ₃ ) ₂ -(CH ₂ ) ₆ -, - (CH ₂ )3-(CHCF3) ₂ -(CH ₂ )7-, -(CH ₂ )4-(CHCF3) ₂ -(CH ₂ ) ₂ -, -(CH ₂ )4-(CHCF3) ₂ - (CH ₂ ) ₃ -, -(CH ₂ ) ₄ -(CHCF ₃ ) ₂ -(CH ₂ ) ₅ -, -(CH ₂ ) ₄ -(CHCF ₃ ) ₂ -(CH ₂ ) ₆ -, -(CH ₂ ) ₅ - (CHCF ₃ ) ₂ -(CH ₂ ) ₂ -, -(CH ₂ ) ₅ -(CHCF ₃ ) ₂ -(CH ₂ ) ₃ -, -(CH ₂ ) ₅ -(CHCF ₃ ) ₂ -(CH ₂ ) ₄ -, - (CH ₂ )6-(CHCF3) ₂ -(CH ₂ ) ₂ -, -(CH ₂ )6-(CHCF3) ₂ -(CH ₂ )3-, -(CH ₂ )6-(CHCF3) ₂ - (CH ₂ )4-,

-(CHCF ₃ ) ₃ -(CH ₂ )-, -(CH ₂ )-(CHCF ₃ ) ₃ -, -(CH ₂ )-(CHCF ₃ ) ₃ -(CH ₂ )-, -(CH ₂ )- (CHCF ₃ ) ₃ -(CH ₂ ) ₂ -, -(CH ₂ )-(CHCF ₃ ) ₃ -(CH ₂ ) ₃ -, -(CH ₂ )-(CHCF ₃ ) ₃ -(CH ₂ ) ₄ -, - (CH ₂ )-(CHCF ₃ ) ₃ -(CH ₂ ) ₅ -, -(CH ₂ )-(CHCF ₃ ) ₃ -(CH ₂ ) ₆ -, -(CH ₂ )-(CHCF ₃ ) ₃ -(CH ₂ ) ₇ - , -(CH ₂ )-(CHCF3)3-(CH ₂ )8-, -(CH ₂ ) ₂ -(CHCF3)3-(CH ₂ )-, -(CH ₂ )3-(CHCF3)3- (CH ₂ )-, -(CH ₂ )4-(CHCF3)3-(CH ₂ )-, -(CH ₂ )5-(CHCF3)3-(CH ₂ )-, -(CH ₂ )6- (CHCF3)3-(CH ₂ )-, -(CH ₂ )7-(CHCF3)3-(CH ₂ )-, -(CH ₂ )8-(CHCF3)3-(CH ₂ )-, - (CH ₂ ) ₂ -(CHCF ₃ ) ₃ -(CH ₂ ) ₂ -, -(CH ₂ ) ₃ -(CHCF ₃ ) ₃ -(CH ₂ ) ₃ -, -(CH ₂ ) ₄ -(CHCF ₃ ) ₃ - (CH ₂ )4-, -(CH ₂ ) ₂ -(CHCF3)3-(CH ₂ )3-, -(CH ₂ ) ₂ -(CHCF3)3-(CH ₂ )4-, -(CH ₂ ) ₂ - (CHCF3)3-(CH ₂ )5-, -(CH ₂ ) ₂ -(CHCF3)3-(CH ₂ )6-, -(CH ₂ ) ₂ -(CHCF3)3-(CH ₂ )7-, - (CH ₂ ) ₃ -(CHCF ₃ ) ₃ -(CH ₂ ) ₂ -, -(CH ₂ ) ₃ -(CHCF ₃ ) ₃ -(CH ₂ ) ₄ -, -(CH ₂ ) ₃ -(CHCF ₃ ) ₃ - (CH ₂ )5-, -(CH ₂ )3-(CHCF3)3-(CH ₂ )6-, -(CH ₂ )4-(CHCF3)3-(CH ₂ ) ₂ -, -(CH ₂ )4- (CHCF3)3-(CH ₂ )3-, -(CH ₂ )4-(CHCF3)3-(CH ₂ )5-, -(CH ₂ )5-(CHCF3)3-(CH ₂ ) ₂ -, - (CH ₂ ) ₅ -(CHCF ₃ ) ₃ -(CH ₂ ) ₃ -, -(CH ₂ ) ₅ -(CHCF ₃ ) ₃ -(CH ₂ ) ₄ -, -(CH ₂ ) ₆ -(CHCF ₃ ) ₃ - (CH ₂ ) ₂ -, -(CH ₂ ) ₆ -(CHCF ₃ ) ₃ -(CH ₂ ) ₃ -,

-(CHCF3)4-(CH ₂ )-, -(CH ₂ )-(CHCF3)4-, -(CH ₂ )-(CHCF3)4-(CH ₂ )-, -(CH ₂ )- (CHCF ₃ ) ₄ -(CH ₂ ) ₂ -, -(CH ₂ )-(CHCF ₃ ) ₄ -(CH ₂ ) ₃ -, -(CH ₂ )-(CHCF ₃ ) ₄ -(CH ₂ ) ₄ -, - (CH ₂ )-(CHCF3)4-(CH ₂ )5-, -(CH ₂ )-(CHCF3)4-(CH ₂ )6-, -(CH ₂ )-(CHCF3)4-(CH ₂ )7- , -(CH ₂ )-(CHCF3)4-(CH ₂ )8-, -(CH ₂ )-(CHCF3)4-(CH ₂ )9-, -(CH ₂ )-(CHCF3)4- (CH ₂ )10-, -(CH ₂ ) ₂ -(CHCF3)4-(CH ₂ )-, -(CH ₂ )3-(CHCF3)4-(CH ₂ )-, -(CH ₂ )4- (CHCF ₃ ) ₄ -(CH ₂ )-, -(CH ₂ ) ₅ -(CHCF ₃ ) ₄ -(CH ₂ )-, -(CH ₂ ) ₆ -(CHCF ₃ ) ₄ -(CH ₂ )-, - (CH ₂ )7-(CHCF3)4-(CH ₂ )-, -(CH ₂ ) ₂ -(CHCF3)4-(CH ₂ ) ₂ -, -(CH ₂ )3-(CHCF3)4- (CH ₂ )3-, -(CH ₂ )4-(CHCF3)4-(CH ₂ )4-, -(CH ₂ )5-(CHCF3)4-(CH ₂ )5-, -(CH ₂ ) ₂ - (CHCF ₃ ) ₄ -(CH ₂ ) ₃ -, -(CH ₂ ) ₂ -(CHCF ₃ ) ₄ -(CH ₂ ) ₄ -, -(CH ₂ ) ₂ -(CHCF ₃ ) ₄ -(CH ₂ ) ₅ -, - (CH ₂ ) ₂ -(CHCF3)4-(CH ₂ )6-, -(CH ₂ )3-(CHCF3)4-(CH ₂ ) ₂ -, -(CH ₂ )3-(CHCF3)4- (CH ₂ )4-, -(CH ₂ )4-(CHCF3)4-(CH ₂ ) ₂ -, -(CH ₂ )4-(CHCF3)4-(CH ₂ )3-, -(CH ₂ )5- (CHCF3)4-(CH ₂ ) ₂ -, -(CH ₂ )5-(CHCF3)4-(CH ₂ )3-, -(CH ₂ )6-(CHCF3)4-(CH ₂ ) ₂ -, -(CHCF ₃ ) ₅ -(CH ₂ )-, -(CH ₂ )-(CHCF ₃ ) ₅ -, -(CH ₂ )-(CHCF ₃ ) ₅ -(CH ₂ )-, -(CH ₂ )- (CHCF3)5-(CH ₂ ) ₂ -, -(CH ₂ )-(CHCF3)5-(CH ₂ )3-, -(CH ₂ )-(CHCF3)5-(CH ₂ )4-, - (CH ₂ )-(CHCF ₃ ) ₅ -(CH ₂ ) ₅ -, -(CH ₂ )-(CHCF ₃ ) ₅ -(CH ₂ ) ₆ -, -(CH ₂ ) ₂ -(CHCF ₃ ) ₅ -(CH ₂ )- , -(CH ₂ ) ₃ -(CHCF ₃ ) ₅ -(CH ₂ )-, -(CH ₂ ) ₄ -(CHCF ₃ ) ₅ -(CH ₂ )-, -(CH ₂ ) ₅ -(CHCF ₃ ) ₅ - (CH ₂ )-, -(CH ₂ )6-(CHCF3)5-(CH ₂ )-, -(CH ₂ ) ₂ -(CHCF3)5-(CH ₂ ) ₂ -, -(CH ₂ )3- (CHCF3)5-(CH ₂ )3-, -(CH ₂ )4-(CHCF3)5-(CH ₂ )4-, -(CH ₂ ) ₂ -(CHCF3)5-(CH ₂ )3-, - (CH ₂ ) ₂ -(CHCF ₃ ) ₅ -(CH ₂ ) ₄ -, -(CH ₂ ) ₂ -(CHCF ₃ ) ₅ -(CH ₂ ) ₅ -, -(CH ₂ ) ₂ -(CHCF ₃ ) ₅ - (CH ₂ ) ₆ -, -(CH ₂ ) ₃ -(CHCF ₃ ) ₅ -(CH ₂ ) ₂ -, -(CH ₂ ) ₃ -(CHCF ₃ ) ₅ -(CH ₂ ) ₄ -, -(CH ₂ ) ₄ - (CHCF3)5-(CH ₂ ) ₂ -, -(CH ₂ )4-(CHCF3)5-(CH ₂ )3-, -(CH ₂ )5-(CHCF3)5-(CH ₂ ) ₂ -, -[C(CH ₃ )CF3]-(CH ₂ )-, -(CH ₂ )-[C(CH ₃ )CF3]-, -(CH ₂ )-[C(CH ₃ )CF3]-(CH ₂ )-, - (CH ₂ )-[C(CH ₃ )CF3]-(CH ₂ ) ₂ -, -(CH ₂ )-[C(CH ₃ )CF3]-(CH ₂ )3-, -(CH ₂ )- [C(CH ₃ )CF ₃ ]-(CH ₂ ) ₄ -, -(CH ₂ )-[C(CH ₃ )CF ₃ ]-(CH ₂ ) ₅ -, -(CH ₂ )-[C(CH ₃ )CF ₃ ]- (CH ₂ )6-, -(CH ₂ )-[C(CH ₃ )CF3]-(CH ₂ )7-, -(CH ₂ )-[C(CH ₃ )CF3]-(CH ₂ )8-, -(CH ₂ )- [C(CH ₃ )CF3]-(CH ₂ )9-, -(CH ₂ )-[C(CH ₃ )CF3]-(CH ₂ )10-, -(CH ₂ ) ₂ -[C(CH ₃ )CF3]- (CH ₂ )-, -(CH ₂ ) ₃ -[C(CH ₃ )CF ₃ ]-(CH ₂ )-, -(CH ₂ ) ₄ -[C(CH ₃ )CF ₃ ]-(CH ₂ )-, -(CH ₂ ) ₅ - [C(CH ₃ )CF3]-(CH ₂ )-, -(CH ₂ )6-[C(CH ₃ )CF3]-(CH ₂ )-, -(CH ₂ )7-[C(CH ₃ )CF3]- (CH ₂ )-, -(CH ₂ )8-[C(CH ₃ )CF3]-(CH ₂ )-, -(CH ₂ )9-[C(CH ₃ )CF3]-(CH ₂ )-, -(CH ₂ )10- [C(CH ₃ )CF ₃ ]-(CH ₂ )-, -(CH ₂ ) ₂ -[C(CH ₃ )CF ₃ ]-(CH ₂ ) ₂ -, -(CH ₂ ) ₃ -[C(CH ₃ )CF ₃ ]- (CH ₂ ) ₃ -, -(CH ₂ ) ₄ -[C(CH ₃ )CF ₃ ]-(CH ₂ ) ₄ -, -(CH ₂ ) ₅ -[C(CH ₃ )CF ₃ ]-(CH ₂ ) ₅ -, -(CH ₂ ) ₂ - [C(CH ₃ )CF3]-(CH ₂ )3-, -(CH ₂ ) ₂ -[C(CH ₃ )CF3]-(CH ₂ )4-, -(CH ₂ ) ₂ -[C(CH ₃ )CF3]- (CH ₂ ) ₅ -, -(CH ₂ ) ₂ -[C(CH ₃ )CF ₃ ]-(CH ₂ ) ₆ -, -(CH ₂ ) ₂ -[C(CH ₃ )CF ₃ ]-(CH ₂ ) ₇ -, -(CH ₂ ) ₂ - [C(CH ₃ )CF3]-(CH ₂ )8-, -(CH ₂ ) ₂ -[C(CH ₃ )CF3]-(CH ₂ )9-, -(CH ₂ )3-[C(CH ₃ )CF3]- (CH ₂ ) ₂ -, -(CH ₂ )3-[C(CH ₃ )CF3]-(CH ₂ )4-, -(CH ₂ )3-[C(CH ₃ )CF3]-(CH ₂ )5-, -(CH ₂ )3- [C(CH ₃ )CF3]-(CH ₂ )6-, -(CH ₂ )3-[C(CH ₃ )CF3]-(CH ₂ )7-, -(CH ₂ )3-[C(CH ₃ )CF3]- (CH ₂ ) ₈ -, -(CH ₂ ) ₄ -[C(CH ₃ )CF ₃ ]-(CH ₂ ) ₂ -, -(CH ₂ ) ₄ -[C(CH ₃ )CF ₃ ]-(CH ₂ ) ₃ -, -(CH ₂ ) ₄ - [C(CH ₃ )CF3]-(CH ₂ )5-, -(CH ₂ )4-[C(CH ₃ )CF3]-(CH ₂ )6-, -(CH ₂ )4-[C(CH ₃ )CF3]- (CH ₂ )7-, -(CH ₂ )5-[C(CH ₃ )CF3]-(CH ₂ ) ₂ -, -(CH ₂ )5-[C(CH ₃ )CF3]-(CH ₂ )3-, -(CH ₂ )5- [C(CH ₃ )CF ₃ ]-(CH ₂ ) ₄ -, -(CH ₂ ) ₅ -[C(CH ₃ )CF ₃ ]-(CH ₂ ) ₆ -, -(CH ₂ ) ₆ -[C(CH ₃ )CF ₃ ]- (CH ₂ ) ₂ -, -(CH ₂ )6-[C(CH ₃ )CF3]-(CH ₂ )3-, -(CH ₂ )6-[C(CH ₃ )CF3]-(CH ₂ )4-, -(CH ₂ )6- [C(CH ₃ )CF3]-(CH ₂ )5-,

-[C(CH ₃ )CF3]2-(CH ₂ )-, -(CH ₂ )-[C(CH ₃ )CF3]2-, -(CH ₂ )-[C(CH ₃ )CF3]2-(CH ₂ )-, - (CH ₂ )-[C(CH ₃ )CF ₃ ] ₂ -(CH ₂ ) ₂ -, -(CH ₂ )-[C(CH ₃ )CF ₃ ] ₂ -(CH ₂ ) ₃ -, -(CH ₂ )- [C(CH ₃ )CF3]2-(CH ₂ )4-, -(CH ₂ )-[C(CH ₃ )CF3]2-(CH ₂ )5-, -(CH ₂ )-[C(CH ₃ )CF3]2- (CH ₂ ) ₆ -, -(CH ₂ )-[C(CH ₃ )CF ₃ ] ₂ -(CH ₂ ) ₇ -, -(CH ₂ )-[C(CH ₃ )CF ₃ ] ₂ -(CH ₂ ) ₈ -, -(CH ₂ )- [C(CH ₃ )CF ₃ ] ₂ -(CH ₂ ) ₉ -, -(CH ₂ ) ₂ -[C(CH ₃ )CF ₃ ] ₂ -(CH ₂ )-, -(CH ₂ ) ₃ -[C(CH ₃ )CF ₃ ] ₂ - (CH ₂ )-, -(CH ₂ )4-[C(CH ₃ )CF3]2-(CH ₂ )-, -(CH ₂ )5-[C(CH ₃ )CF3]2-(CH ₂ )-, -(CH ₂ )6- [C(CH ₃ )CF3]2-(CH ₂ )-, -(CH ₂ )7-[C(CH ₃ )CF3]2-(CH ₂ )-, -(CH ₂ )8-[C(CH ₃ )CF3]2- (CH ₂ )-, -(CH ₂ ) ₉ -[C(CH ₃ )CF ₃ ] ₂ -(CH ₂ )-, -(CH ₂ ) ₂ -[C(CH ₃ )CF ₃ ] ₂ -(CH ₂ ) ₂ -, -(CH ₂ ) ₃ - [C(CH ₃ )CF ₃ ] ₂ -(CH ₂ ) ₃ -, -(CH ₂ ) ₄ -[C(CH ₃ )CF ₃ ] ₂ -(CH ₂ ) ₄ -, -(CH ₂ ) ₅ -[C(CH ₃ )CF ₃ ] ₂ - (CH ₂ ) ₅ -, -(CH ₂ ) ₂ -[C(CH ₃ )CF ₃ ] ₂ -(CH ₂ ) ₃ -, -(CH ₂ ) ₂ -[C(CH ₃ )CF ₃ ] ₂ -(CH ₂ ) ₄ -, - (CH ₂ ) ₂ -[C(CH ₃ )CF3]2-(CH ₂ )5-, -(CH ₂ ) ₂ -[C(CH ₃ )CF3]2-(CH ₂ )6-, -(CH ₂ ) ₂ - [C(CH ₃ )CF3]2-(CH ₂ )7-, -(CH ₂ ) ₂ -[C(CH ₃ )CF3]2-(CH ₂ )8-, -(CH ₂ )3-[C(CH ₃ )CF3]2- (CH ₂ ) ₂ -, -(CH ₂ )3-[C(CH ₃ )CF3]2-(CH ₂ )4-, -(CH ₂ )3-[C(CH ₃ )CF3]2-(CH ₂ )5-, - (CH ₂ ) ₃ -[C(CH ₃ )CF ₃ ] ₂ -(CH ₂ ) ₆ -, -(CH ₂ ) ₃ -[C(CH ₃ )CF ₃ ] ₂ -(CH ₂ ) ₇ -, -(CH ₂ ) ₄ - [C(CH ₃ )CF3]2-(CH ₂ ) ₂ -, -(CH ₂ )4-[C(CH ₃ )CF3]2-(CH ₂ )3-, -(CH ₂ )4-[C(CH ₃ )CF3]2- (CH ₂ )5-, -(CH ₂ )4-[C(CH ₃ )CF3]2-(CH ₂ )6-, -(CH ₂ )5-[C(CH ₃ )CF3]2-(CH ₂ ) ₂ -, - (CH ₂ ) ₅ -[C(CH ₃ )CF ₃ ] ₂ -(CH ₂ ) ₃ -, -(CH ₂ ) ₅ -[C(CH ₃ )CF ₃ ] ₂ -(CH ₂ ) ₄ -, -(CH ₂ ) ₆ - [C(CH ₃ )CF3]2-(CH ₂ ) ₂ -, -(CH ₂ )6-[C(CH ₃ )CF3]2-(CH ₂ )3-, -(CH ₂ )6-[C(CH ₃ )CF3]2- (CH ₂ )4-,

-[C(CH ₃ )CF ₃ ] ₃ -(CH ₂ )-, -(CH ₂ )-[C(CH ₃ )CF ₃ ] ₃ -, -(CH ₂ )-[C(CH ₃ )CF ₃ ] ₃ -(CH ₂ )-, - (CH ₂ )-[C(CH ₃ )CF ₃ ] ₃ -(CH ₂ ) ₂ -, -(CH ₂ )-[C(CH ₃ )CF ₃ ] ₃ -(CH ₂ ) ₃ -, -(CH ₂ )- [C(CH ₃ )CF3]3-(CH ₂ )4-, -(CH ₂ )-[C(CH ₃ )CF3]3-(CH ₂ )5-, -(CH ₂ )-[C(CH ₃ )CF3]3- (CH ₂ ) ₆ -, -(CH ₂ )-[C(CH ₃ )CF ₃ ] ₃ -(CH ₂ ) ₇ -, -(CH ₂ )-[C(CH ₃ )CF ₃ ] ₃ -(CH ₂ ) ₈ -, -(CH ₂ ) ₂ - [C(CH ₃ )CF3]3-(CH ₂ )-, -(CH ₂ )3-[C(CH ₃ )CF3]3-(CH ₂ )-, -(CH ₂ )4-[C(CH ₃ )CF3]3- (CH ₂ )-, -(CH ₂ )5-[C(CH ₃ )CF3]3-(CH ₂ )-, -(CH ₂ )6-[C(CH ₃ )CF3]3-(CH ₂ )-, -(CH ₂ )7- [C(CH ₃ )CF3]3-(CH ₂ )-, -(CH ₂ )8-[C(CH ₃ )CF3]3-(CH ₂ )-, -(CH ₂ ) ₂ -[C(CH ₃ )CF3]3- (CH ₂ ) ₂ -, -(CH ₂ ) ₃ -[C(CH ₃ )CF ₃ ] ₃ -(CH ₂ ) ₃ -, -(CH ₂ ) ₄ -[C(CH ₃ )CF ₃ ] ₃ -(CH ₂ ) ₄ -, - (CH ₂ ) ₂ -[C(CH ₃ )CF3]3-(CH ₂ )3-, -(CH ₂ ) ₂ -[C(CH ₃ )CF3]3-(CH ₂ )4-, -(CH ₂ ) ₂ - [C(CH ₃ )CF3]3-(CH ₂ )5-, -(CH ₂ ) ₂ -[C(CH ₃ )CF3]3-(CH ₂ )6-, -(CH ₂ ) ₂ -[C(CH ₃ )CF3]3- (CH ₂ ) ₇ -, -(CH ₂ ) ₃ -[C(CH ₃ )CF ₃ ] ₃ -(CH ₂ ) ₂ -, -(CH ₂ ) ₃ -[C(CH ₃ )CF ₃ ] ₃ -(CH ₂ ) ₄ -, - (CH ₂ )3-[C(CH ₃ )CF3]3-(CH ₂ )5-, -(CH ₂ )3-[C(CH ₃ )CF3]3-(CH ₂ )6-, -(CH ₂ )4- [C(CH ₃ )CF3]3-(CH ₂ ) ₂ -, -(CH ₂ )4-[C(CH ₃ )CF3]3-(CH ₂ )3-, -(CH ₂ )4-[C(CH ₃ )CF3]3- (CH ₂ )5-, -(CH ₂ )5-[C(CH ₃ )CF3]3-(CH ₂ ) ₂ -, -(CH ₂ )5-[C(CH ₃ )CF3]3-(CH ₂ )3-, - (CH ₂ ) ₅ -[C(CH ₃ )CF ₃ ] ₃ -(CH ₂ ) ₄ -, -(CH ₂ ) ₆ -[C(CH ₃ )CF ₃ ] ₃ -(CH ₂ ) ₂ -, -(CH ₂ ) ₆ - [C(CH ₃ )CF3]3-(CH ₂ )3-,

-[C(CH ₃ )CF ₃ ] ₄ -(CH ₂ )-, -(CH ₂ )-[C(CH ₃ )CF ₃ ] ₄ -, -(CH ₂ )-[C(CH ₃ )CF ₃ ] ₄ -(CH ₂ )-, - (CH ₂ )-[C(CH ₃ )CF ₃ ] ₄ -(CH ₂ ) ₂ -, -(CH ₂ )-[C(CH ₃ )CF ₃ ] ₄ -(CH ₂ ) ₃ -, -(CH ₂ )- [C(CH ₃ )CF3]4-(CH ₂ )4-, -(CH ₂ )-[C(CH ₃ )CF3]4-(CH ₂ )5-, -(CH ₂ )-[C(CH ₃ )CF3]4- (CH ₂ )6-, -(CH ₂ )-[C(CH ₃ )CF3]4-(CH ₂ )7-, -(CH ₂ )-[C(CH ₃ )CF3]4-(CH ₂ )8-, -(CH ₂ )- [C(CH ₃ )CF ₃ ] ₄ -(CH ₂ ) ₉ -, -(CH ₂ )-[C(CH ₃ )CF ₃ ] ₄ -(CH ₂ ) ₁₀ -, -(CH ₂ ) ₂ -[C(CH ₃ )CF ₃ ] ₄ - (CH ₂ )-, -(CH ₂ ) ₃ -[C(CH ₃ )CF ₃ ] ₄ -(CH ₂ )-, -(CH ₂ ) ₄ -[C(CH ₃ )CF ₃ ] ₄ -(CH ₂ )-, -(CH ₂ ) ₅ - [C(CH ₃ )CF ₃ ] ₄ -(CH ₂ )-, -(CH ₂ ) ₆ -[C(CH ₃ )CF ₃ ] ₄ -(CH ₂ )-, -(CH ₂ ) ₇ -[C(CH ₃ )CF ₃ ] ₄ - (CH ₂ )-, -(CH ₂ ) ₂ -[C(CH ₃ )CF3]4-(CH ₂ ) ₂ -, -(CH ₂ )3-[C(CH ₃ )CF3]4-(CH ₂ )3-, - (CH ₂ )4-[C(CH ₃ )CF3]4-(CH ₂ )4-, -(CH ₂ )5-[C(CH ₃ )CF3]4-(CH ₂ )5-, -(CH ₂ ) ₂ - [C(CH ₃ )CF3]4-(CH ₂ )3-, -(CH ₂ ) ₂ -[C(CH ₃ )CF3]4-(CH ₂ )4-, -(CH ₂ ) ₂ -[C(CH ₃ )CF3]4- (CH ₂ ) ₅ -, -(CH ₂ ) ₂ -[C(CH ₃ )CF ₃ ] ₄ -(CH ₂ ) ₆ -, -(CH ₂ ) ₃ -[C(CH ₃ )CF ₃ ] ₄ -(CH ₂ ) ₂ -, - (CH ₂ )3-[C(CH ₃ )CF3]4-(CH ₂ )4-, -(CH ₂ )4-[C(CH ₃ )CF3]4-(CH ₂ ) ₂ -, -(CH ₂ )4- [C(CH ₃ )CF3]4-(CH ₂ )3-, -(CH ₂ )5-[C(CH ₃ )CF3]4-(CH ₂ ) ₂ -, -(CH ₂ )5-[C(CH ₃ )CF3]4- (CH ₂ ) ₃ -, -(CH ₂ ) ₆ -[C(CH ₃ )CF ₃ ] ₄ -(CH ₂ ) ₂ -,

-[C(CH ₃ )CF3]5-(CH ₂ )-, -(CH ₂ )-[C(CH ₃ )CF3]5-, -(CH ₂ )-[C(CH ₃ )CF3]5-(CH ₂ )-, - (CH ₂ )-[C(CH ₃ )CF3]5-(CH ₂ ) ₂ -, -(CH ₂ )-[C(CH ₃ )CF3]5-(CH ₂ )3-, -(CH ₂ )- [C(CH ₃ )CF ₃ ] ₅ -(CH ₂ ) ₄ -, -(CH ₂ )-[C(CH ₃ )CF ₃ ] ₅ -(CH ₂ ) ₅ -, -(CH ₂ )-[C(CH ₃ )CF ₃ ] ₅ - (CH ₂ ) ₆ -, -(CH ₂ ) ₂ -[C(CH ₃ )CF ₃ ] ₅ -(CH ₂ )-, -(CH ₂ ) ₃ -[C(CH ₃ )CF ₃ ] ₅ -(CH ₂ )-, -(CH ₂ ) ₄ - [C(CH ₃ )CF3]5-(CH ₂ )-, -(CH ₂ )5-[C(CH ₃ )CF3]5-(CH ₂ )-, -(CH ₂ )6-[C(CH ₃ )CF3]5- (CH ₂ )-, -(CH ₂ ) ₂ -[C(CH ₃ )CF ₃ ] ₅ -(CH ₂ ) ₂ -, -(CH ₂ ) ₃ -[C(CH ₃ )CF ₃ ] ₅ -(CH ₂ ) ₃ -, - (CH ₂ )4-[C(CH ₃ )CF3]5-(CH ₂ )4-, -(CH ₂ ) ₂ -[C(CH ₃ )CF3]5-(CH ₂ )3-, -(CH ₂ ) ₂ - [C(CH ₃ )CF3]5-(CH ₂ )4-, -(CH ₂ ) ₂ -[C(CH ₃ )CF3]5-(CH ₂ )5-, -(CH ₂ ) ₂ -[C(CH ₃ )CF3]5- (CH ₂ )6-, -(CH ₂ )3-[C(CH ₃ )CF3]5-(CH ₂ ) ₂ -, -(CH ₂ )3-[C(CH ₃ )CF3]5-(CH ₂ )4-, - (CH ₂ ) ₄ -[C(CH ₃ )CF ₃ ] ₅ -(CH ₂ ) ₂ -, -(CH ₂ ) ₄ -[C(CH ₃ )CF ₃ ] ₅ -(CH ₂ ) ₃ -, -(CH ₂ ) ₅ - [C(CH ₃ )CF3]5-(CH ₂ ) ₂ -,

-[CH(CH ₂ CF3)]-(CH ₂ )-, -(CH ₂ )-[CH(CH ₂ CF3)]-, -(CH ₂ )-[CH(CH ₂ CF3)]-(CH ₂ )-, -(CH ₂ )-[CH(CH ₂ CF ₃ )]-(CH ₂ ) ₂ -, -(CH ₂ )-[CH(CH ₂ CF ₃ )] -(CH ₂ ) ₃ -, -(CH ₂ )- [CH(CH ₂ CF3)]-(CH ₂ )4-, -(CH ₂ )-[CH(CH ₂ CF3)]-(CH ₂ )5-, -(CH ₂ )-[CH(CH ₂ CF3)]- (CH ₂ )6-, -(CH ₂ )-[CH(CH ₂ CF3)]-(CH ₂ )7-, -(CH ₂ )-[CH(CH ₂ CF3)]-(CH ₂ )8-, - (CH ₂ )-[CH(CH ₂ CF3)]-(CH ₂ )9-, -(CH ₂ )-[CH(CH ₂ CF3)]-(CH ₂ )10-, -(CH ₂ ) ₂ - [CH(CH ₂ CF ₃ )]-(CH ₂ )-, -(CH ₂ ) ₃ -[CH(CH ₂ CF ₃ )]-(CH ₂ )-, -(CH ₂ ) ₄ -[CH(CH ₂ CF ₃ )]- (CH ₂ )-, -(CH ₂ )5-[CH(CH ₂ CF3)]-(CH ₂ )-, -(CH ₂ )6-[CH(CH ₂ CF3)]-(CH ₂ )-, - (CH ₂ ) ₇ -[CH(CH ₂ CF ₃ )]-(CH ₂ )-, -(CH ₂ ) ₈ -[CH(CH ₂ CF ₃ )]-(CH ₂ )-, -(CH ₂ ) ₉ - [CH(CH ₂ CF ₃ )]-(CH ₂ )-, -(CH ₂ ) ₁₀ -[CH(CH ₂ CF ₃ )]-(CH ₂ )-, -(CH ₂ ) ₂ - [CH(CH ₂ CF3)]-(CH ₂ ) ₂ -, -(CH ₂ )3-[CH(CH ₂ CF3)]-(CH ₂ )3-, -(CH ₂ )4- [CH(CH ₂ CF3)]-(CH ₂ )4-, -(CH ₂ )5-[CH(CH ₂ CF3)]-(CH ₂ )5-, -(CH ₂ ) ₂ - [CH(CH ₂ CF ₃ )]-(CH ₂ ) ₃ -, -(CH ₂ ) ₂ -[CH(CH ₂ CF ₃ )]-(CH ₂ ) ₄ -, -(CH ₂ ) ₂ - [CH(CH ₂ CF ₃ )]-(CH ₂ ) ₅ -, -(CH ₂ ) ₂ -[CH(CH ₂ CF ₃ )]-(CH ₂ ) ₆ -, -(CH ₂ ) ₂ - [CH(CH ₂ CF ₃ )]-(CH ₂ ) ₇ -, -(CH ₂ ) ₂ -[CH(CH ₂ CF ₃ )]-(CH ₂ ) ₈ -, -(CH ₂ ) ₂ - [CH(CH ₂ CF3)]-(CH ₂ )9-, -(CH ₂ )3-[CH(CH ₂ CF3)]-(CH ₂ ) ₂ -, -(CH ₂ )3- [CH(CH ₂ CF3)]-(CH ₂ )4-, -(CH ₂ )3-[CH(CH ₂ CF3)]-(CH ₂ )5-, -(CH ₂ )3- [CH(CH ₂ CF3)]-(CH ₂ )6-, -(CH ₂ )3-[CH(CH ₂ CF3)]-(CH ₂ )7-, -(CH ₂ )3- [CH(CH ₂ CF ₃ )]-(CH ₂ ) ₈ -, -(CH ₂ ) ₄ -[CH(CH ₂ CF ₃ )]-(CH ₂ ) ₂ -, -(CH ₂ ) ₄ - [CH(CH ₂ CF3)]-(CH ₂ )3-, -(CH ₂ )4-[CH(CH ₂ CF3)]-(CH ₂ )5-, -(CH ₂ )4- [CH(CH ₂ CF3)]-(CH ₂ )6-, -(CH ₂ )4-[CH(CH ₂ CF3)]-(CH ₂ )7-, -(CH ₂ )5- [CH(CH ₂ CF ₃ )]-(CH ₂ ) ₂ -, -(CH ₂ ) ₅ -[CH(CH ₂ CF ₃ )]-(CH ₂ ) ₃ -, -(CH ₂ ) ₅ - [CH(CH ₂ CF3)]-(CH ₂ )4-, -(CH ₂ )5-[CH(CH ₂ CF3)]-(CH ₂ )6-, -(CH ₂ )6- [CH(CH ₂ CF3)]-(CH ₂ ) ₂ -, -(CH ₂ )6-[CH(CH ₂ CF3)]-(CH ₂ )3-, -(CH ₂ )6- [CH(CH ₂ CF ₃ )]-(CH ₂ ) ₄ -, -(CH ₂ ) ₆ -[CH(CH ₂ CF ₃ )]-(CH ₂ ) ₅ -,

-[CH(CH ₂ CF ₃ )] ₂ -(CH ₂ )-, -(CH ₂ )-[CH(CH ₂ CF ₃ )] ₂ -, -(CH ₂ )-[CH(CH ₂ CF ₃ )] ₂ - (CH ₂ )-, -(CH ₂ )-[CH(CH ₂ CF3)]2-(CH ₂ ) ₂ -, -(CH ₂ )-[CH(CH ₂ CF3)]2-(CH ₂ )3-, - (CH ₂ )-[CH(CH ₂ CF ₃ )] ₂ -(CH ₂ ) ₄ -, -(CH ₂ )-[CH(CH ₂ CF ₃ )] ₂ -(CH ₂ ) ₅ -, -(CH ₂ )- [CH(CH ₂ CF3)]2-(CH ₂ )6-, -(CH ₂ )-[CH(CH ₂ CF3)]2-(CH ₂ )7-, -(CH ₂ )- [CH(CH ₂ CF3)]2-(CH ₂ )8-, -(CH ₂ )-[CH(CH ₂ CF3)]2-(CH ₂ )9-, -(CH ₂ ) ₂ - [CH(CH ₂ CF3)]2-(CH ₂ )-, -(CH ₂ )3-[CH(CH ₂ CF3)]2-(CH ₂ )-, -(CH ₂ )4- [CH(CH ₂ CF ₃ )] ₂ -(CH ₂ )-, -(CH ₂ ) ₅ -[CH(CH ₂ CF ₃ )] ₂ -(CH ₂ )-, -(CH ₂ ) ₆ - [CH(CH ₂ CF3)]2-(CH ₂ )-, -(CH ₂ )7-[CH(CH ₂ CF3)]2-(CH ₂ )-, -(CH ₂ )8- [CH(CH ₂ CF3)]2-(CH ₂ )-, -(CH ₂ )9-[CH(CH ₂ CF3)]2-(CH ₂ )-, -(CH ₂ ) ₂ - [CH(CH ₂ CF ₃ )] ₂ -(CH ₂ ) ₂ -, -(CH ₂ ) ₃ -[CH(CH ₂ CF ₃ )] ₂ -(CH ₂ ) ₃ -, -(CH ₂ ) ₄ - [CH(CH ₂ CF3)]2-(CH ₂ )4-, -(CH ₂ )5-[CH(CH ₂ CF3)]2-(CH ₂ )5-, -(CH ₂ ) ₂ - [CH(CH ₂ CF3)]2-(CH ₂ )3-, -(CH ₂ ) ₂ -[CH(CH ₂ CF3)]2-(CH ₂ )4-, -(CH ₂ ) ₂ - [CH(CH ₂ CF3)]2-(CH ₂ )5-, -(CH ₂ ) ₂ -[CH(CH ₂ CF3)]2-(CH ₂ )6-, -(CH ₂ ) ₂ - [CH(CH ₂ CF ₃ )] ₂ -(CH ₂ ) ₇ -, -(CH ₂ ) ₂ -[CH(CH ₂ CF ₃ )] ₂ -(CH ₂ ) ₈ -, -(CH ₂ ) ₃ - [CH(CH ₂ CF3)]2-(CH ₂ ) ₂ -, -(CH ₂ )3-[CH(CH ₂ CF3)]2-(CH ₂ )4-, -(CH ₂ )3- [CH(CH ₂ CF ₃ )] ₂ -(CH ₂ ) ₅ -, -(CH ₂ ) ₃ -[CH(CH ₂ CF ₃ )] ₂ -(CH ₂ ) ₆ -, -(CH ₂ ) ₃ - [CH(CH ₂ CF ₃ )] ₂ -(CH ₂ ) ₇ -, -(CH ₂ ) ₄ -[CH(CH ₂ CF ₃ )] ₂ -(CH ₂ ) ₂ -, -(CH ₂ ) ₄ - [CH(CH ₂ CF3)]2-(CH ₂ )3-, -(CH ₂ )4-[CH(CH ₂ CF3)]2-(CH ₂ )5-, -(CH ₂ )4- [CH(CH ₂ CF3)]2-(CH ₂ )6-, -(CH ₂ )5-[CH(CH ₂ CF3)]2-(CH ₂ ) ₂ -, -(CH ₂ )5- [CH(CH ₂ CF ₃ )] ₂ -(CH ₂ ) ₃ -, -(CH ₂ ) ₅ -[CH(CH ₂ CF ₃ )] ₂ -(CH ₂ ) ₄ -, -(CH ₂ ) ₆ - [CH(CH ₂ CF ₃ )] ₂ -(CH ₂ ) ₂ -, -(CH ₂ ) ₆ -[CH(CH ₂ CF ₃ )] ₂ -(CH ₂ ) ₃ -, -(CH ₂ ) ₆ - [CH(CH ₂ CF3)]2-(CH ₂ )4-,

-[CH(CH ₂ CF3)]3-(CH ₂ )-, -(CH ₂ )-[CH(CH ₂ CF3)]3-, -(CH ₂ )-[CH(CH ₂ CF3)]3- (CH ₂ )-, -(CH ₂ )-[CH(CH ₂ CF3)]3-(CH ₂ ) ₂ -, -(CH ₂ )-[CH(CH ₂ CF3)]3-(CH ₂ )3-, - (CH ₂ )-[CH(CH ₂ CF ₃ )] ₃ -(CH ₂ ) ₄ -, -(CH ₂ )-[CH(CH ₂ CF ₃ )] ₃ -(CH ₂ ) ₅ -, -(CH ₂ )- [CH(CH ₂ CF3)]3-(CH ₂ )6-, -(CH ₂ )-[CH(CH ₂ CF3)]3-(CH ₂ )7-, -(CH ₂ )- [CH(CH ₂ CF3)]3-(CH ₂ )8-, -(CH ₂ ) ₂ -[CH(CH ₂ CF3)]3-(CH ₂ )-, -(CH ₂ )3- [CH(CH ₂ CF ₃ )] ₃ -(CH ₂ )-, -(CH ₂ ) ₄ -[CH(CH ₂ CF ₃ )] ₃ -(CH ₂ )-, -(CH ₂ ) ₅ - [CH(CH ₂ CF3)]3-(CH ₂ )-, -(CH ₂ )6-[CH(CH ₂ CF3)]3-(CH ₂ )-, -(CH ₂ )7- [CH(CH ₂ CF3)]3-(CH ₂ )-, -(CH ₂ )8-[CH(CH ₂ CF3)]3-(CH ₂ )-, -(CH ₂ ) ₂ - [CH(CH ₂ CF ₃ )] ₃ -(CH ₂ ) ₂ -, -(CH ₂ ) ₃ -[CH(CH ₂ CF ₃ )] ₃ -(CH ₂ ) ₃ -, -(CH ₂ ) ₄ - [CH(CH ₂ CF ₃ )] ₃ -(CH ₂ ) ₄ -, -(CH ₂ ) ₂ -[CH(CH ₂ CF ₃ )] ₃ -(CH ₂ ) ₃ -, -(CH ₂ ) ₂ - [CH(CH ₂ CF3)]3-(CH ₂ )4-, -(CH ₂ ) ₂ -[CH(CH ₂ CF3)]3-(CH ₂ )5-, -(CH ₂ ) ₂ - [CH(CH ₂ CF ₃ )] ₃ -(CH ₂ ) ₆ -, -(CH ₂ ) ₂ -[CH(CH ₂ CF ₃ )] ₃ -(CH ₂ ) ₇ -, -(CH ₂ ) ₃ - [CH(CH ₂ CF3)]3-(CH ₂ ) ₂ -, -(CH ₂ )3-[CH(CH ₂ CF3)]3-(CH ₂ )4-, -(CH ₂ )3- [CH(CH ₂ CF3)]3-(CH ₂ )5-, -(CH ₂ )3-[CH(CH ₂ CF3)]3-(CH ₂ )6-, -(CH ₂ )4- [CH(CH ₂ CF3)]3-(CH ₂ ) ₂ -, -(CH ₂ )4-[CH(CH ₂ CF3)]3-(CH ₂ )3-, -(CH ₂ )4- [CH(CH ₂ CF ₃ )] ₃ -(CH ₂ ) ₅ -, -(CH ₂ ) ₅ -[CH(CH ₂ CF ₃ )] ₃ -(CH ₂ ) ₂ -, -(CH ₂ ) ₅ - [CH(CH ₂ CF3)]3-(CH ₂ )3-, -(CH ₂ )5-[CH(CH ₂ CF3)]3-(CH ₂ )4-, -(CH ₂ )6- [CH(CH ₂ CF3)]3-(CH ₂ ) ₂ -, -(CH ₂ )6-[CH(CH ₂ CF3)]3-(CH ₂ )3-,

-[CH(CH ₂ CF ₃ )] ₄ -(CH ₂ )-, -(CH ₂ )-[CH(CH ₂ CF ₃ )] ₄ -, -(CH ₂ )-[CH(CH ₂ CF ₃ )] ₄ - (CH ₂ )-, -(CH ₂ )-[CH(CH ₂ CF3)]4-(CH ₂ ) ₂ -, -(CH ₂ )-[CH(CH ₂ CF3)]4-(CH ₂ )3-, - (CH ₂ )-[CH(CH ₂ CF3)]4-(CH ₂ )4-, -(CH ₂ )-[CH(CH ₂ CF3)]4-(CH ₂ )5-, -(CH ₂ )- [CH(CH ₂ CF3)]4-(CH ₂ )6-, -(CH ₂ )-[CH(CH ₂ CF3)]4-(CH ₂ )7-, -(CH ₂ )- [CH(CH ₂ CF ₃ )] ₄ -(CH ₂ ) ₈ -, -(CH ₂ )-[CH(CH ₂ CF ₃ )] ₄ -(CH ₂ ) ₉ -, -(CH ₂ )- [CH(CH ₂ CF3)]4-(CH ₂ )10-, -(CH ₂ ) ₂ -[CH(CH ₂ CF3)]4-(CH ₂ )-, -(CH ₂ )3- [CH(CH ₂ CF ₃ )] ₄ -(CH ₂ )-, -(CH ₂ ) ₄ -[CH(CH ₂ CF ₃ )] ₄ -(CH ₂ )-, -(CH ₂ ) ₅ - [CH(CH ₂ CF ₃ )] ₄ -(CH ₂ )-, -(CH ₂ ) ₆ -[CH(CH ₂ CF ₃ )] ₄ -(CH ₂ )-, -(CH ₂ ) ₇ - [CH(CH ₂ CF3)]4-(CH ₂ )-, -(CH ₂ ) ₂ -[CH(CH ₂ CF3)]4-(CH ₂ ) ₂ -, -(CH ₂ )3- [CH(CH ₂ CF3)]4-(CH ₂ )3-, -(CH ₂ )4-[CH(CH ₂ CF3)]4-(CH ₂ )4-, -(CH ₂ )5- [CH(CH ₂ CF ₃ )] ₄ -(CH ₂ ) ₅ -, -(CH ₂ ) ₂ -[CH(CH ₂ CF ₃ )] ₄ -(CH ₂ ) ₃ -, -(CH ₂ ) ₂ - [CH(CH ₂ CF ₃ )] ₄ -(CH ₂ ) ₄ -, -(CH ₂ ) ₂ -[CH(CH ₂ CF ₃ )] ₄ -(CH ₂ ) ₅ -, -(CH ₂ ) ₂ - [CH(CH ₂ CF ₃ )] ₄ -(CH ₂ ) ₆ -, -(CH ₂ ) ₃ -[CH(CH ₂ CF ₃ )] ₄ -(CH ₂ ) ₂ -, -(CH ₂ ) ₃ - [CH(CH ₂ CF3)]4-(CH ₂ )4-, -(CH ₂ )4-[CH(CH ₂ CF3)]4-(CH ₂ ) ₂ -, -(CH ₂ )4- [CH(CH ₂ CF3)]4-(CH ₂ )3-, -(CH ₂ )5-[CH(CH ₂ CF3)]4-(CH ₂ ) ₂ -, -(CH ₂ )5- [CH(CH ₂ CF3)]4-(CH ₂ )3-, -(CH ₂ )6-[CH(CH ₂ CF3)]4-(CH ₂ ) ₂ -,

-[CH(CH ₂ CF ₃ )] ₅ -(CH ₂ )-, -(CH ₂ )-[CH(CH ₂ CF ₃ ) ₅ -, -(CH ₂ )-[CH(CH ₂ CF ₃ )] ₅ - (CH ₂ )-, -(CH ₂ )-[CH(CH ₂ CF3)]5-(CH ₂ ) ₂ -, -(CH ₂ )-[CH(CH ₂ CF3)]5-(CH ₂ )3-, - (CH ₂ )-[CH(CH ₂ CF3)]5-(CH ₂ )4-, -(CH ₂ )-[CH(CH ₂ CF3)]5-(CH ₂ )5-, -(CH ₂ )- [CH(CH ₂ CF ₃ )] ₅ -(CH ₂ ) ₆ -, -(CH ₂ ) ₂ -[CH(CH ₂ CF ₃ )] ₅ -(CH ₂ )-, -(CH ₂ ) ₃ - [CH(CH ₂ CF3)]5-(CH ₂ )-, -(CH ₂ )4-[CH(CH ₂ CF3)]5-(CH ₂ )-, -(CH ₂ )5- [CH(CH ₂ CF3)]5-(CH ₂ )-, -(CH ₂ )6-[CH(CH ₂ CF3)]5-(CH ₂ )-, -(CH ₂ ) ₂ - [CH(CH ₂ CF ₃ )] ₅ -(CH ₂ ) ₂ -, -(CH ₂ ) ₃ -[CH(CH ₂ CF ₃ )] ₅ -(CH ₂ ) ₃ -, -(CH ₂ ) ₄ - [CH(CH ₂ CF ₃ )] ₅ -(CH ₂ ) ₄ -, -(CH ₂ ) ₂ -[CH(CH ₂ CF ₃ )] ₅ -(CH ₂ ) ₃ -, -(CH ₂ ) ₂ - [CH(CH ₂ CF3)]5-(CH ₂ )4-, -(CH ₂ ) ₂ -[CH(CH ₂ CF3)]5-(CH ₂ )5-, -(CH ₂ ) ₂ - [CH(CH ₂ CF ₃ )] ₅ -(CH ₂ ) ₆ -, -(CH ₂ ) ₃ -[CH(CH ₂ CF ₃ )] ₅ -(CH ₂ ) ₂ -, -(CH ₂ ) ₃ - [CH(CH ₂ CF3)]5-(CH ₂ )4-, -(CH ₂ )4-[CH(CH ₂ CF3)]5-(CH ₂ ) ₂ -, -(CH ₂ )4- [CH(CH ₂ CF3)]5-(CH ₂ )3-, -(CH ₂ )5-[CH(CH ₂ CF3)]5-(CH ₂ ) ₂ -,

-[C(CH ₃ )(CH ₂ CF3)]-(CH ₂ )-, -(CH ₂ )-[C(CH ₃ )(CH ₂ CF3)]-, -(CH ₂ )- [C(CH ₃ )(CH ₂ CF ₃ )]-(CH ₂ )-, -(CH ₂ )-[C(CH ₃ )(CH ₂ CF ₃ )]-(CH ₂ ) ₂ -, -(CH ₂ )- [C(CH ₃ )(CH ₂ CF3)]-(CH ₂ )3-, -(CH ₂ )-[C(CH ₃ )(CH ₂ CF3)]-(CH ₂ )4-, -(CH ₂ )- [C(CH ₃ )(CH ₂ CF3)]-(CH ₂ )5-, -(CH ₂ )-[C(CH ₃ )(CH ₂ CF3)]-(CH ₂ )6-, -(CH ₂ )- [C(CH ₃ )(CH ₂ CF ₃ )]-(CH ₂ ) ₇ -, -(CH ₂ )-[C(CH ₃ )(CH ₂ CF ₃ )]-(CH ₂ ) ₈ -, -(CH ₂ )- [C(CH ₃ )(CH ₂ CF3)]-(CH ₂ )9-, -(CH ₂ )-[C(CH ₃ )(CH ₂ CF3)]-(CH ₂ )10-, -(CH ₂ ) ₂ - [C(CH ₃ )(CH ₂ CF3)]-(CH ₂ )-, -(CH ₂ )3-[C(CH ₃ )(CH ₂ CF3)]-(CH ₂ )-, -(CH ₂ )4- [C(CH ₃ )(CH ₂ CF3)]-(CH ₂ )-, -(CH ₂ )5-[C(CH ₃ )(CH ₂ CF3)]-(CH ₂ )-, -(CH ₂ )6- [C(CH ₃ )(CH ₂ CF ₃ )]-(CH ₂ )-, -(CH ₂ ) ₇ -[C(CH ₃ )(CH ₂ CF ₃ )]-(CH ₂ )-, -(CH ₂ ) ₈ - [C(CH ₃ )(CH ₂ CF3)]-(CH ₂ )-, -(CH ₂ )9-[C(CH ₃ )(CH ₂ CF3)]-(CH ₂ )-, -(CH ₂ )10- [C(CH ₃ )(CH ₂ CF ₃ )]-(CH ₂ )-, -(CH ₂ ) ₂ -[C(CH ₃ )(CH ₂ CF ₃ )]-(CH ₂ ) ₂ -, -(CH ₂ ) ₃ - [C(CH ₃ )(CH ₂ CF ₃ )]-(CH ₂ ) ₃ -, -(CH ₂ ) ₄ -[C(CH ₃ )(CH ₂ CF ₃ )]-(CH ₂ ) ₄ -, -(CH ₂ ) ₅ - [C(CH ₃ )(CH ₂ CF3)]-(CH ₂ )5-, -(CH ₂ ) ₂ -[C(CH ₃ )(CH ₂ CF3)]-(CH ₂ )3-, -(CH ₂ ) ₂ - [C(CH ₃ )(CH ₂ CF3)]-(CH ₂ )4-, -(CH ₂ ) ₂ -[C(CH ₃ )(CH ₂ CF3)]-(CH ₂ )5-, -(CH ₂ ) ₂ - [C(CH ₃ )(CH ₂ CF ₃ )]-(CH ₂ ) ₆ -, -(CH ₂ ) ₂ -[C(CH ₃ )(CH ₂ CF ₃ )]-(CH ₂ ) ₇ -, -(CH ₂ ) ₂ - [C(CH ₃ )(CH ₂ CF ₃ )]-(CH ₂ ) ₈ -, -(CH ₂ ) ₂ -[C(CH ₃ )(CH ₂ CF ₃ )]-(CH ₂ ) ₉ -, -(CH ₂ ) ₃ - [C(CH ₃ )(CH ₂ CF ₃ )]-(CH ₂ ) ₂ -, -(CH ₂ ) ₃ -[C(CH ₃ )(CH ₂ CF ₃ )]-(CH ₂ ) ₄ -, -(CH ₂ ) ₃ - [C(CH ₃ )(CH ₂ CF3)]-(CH ₂ )5-, -(CH ₂ )3-[C(CH ₃ )(CH ₂ CF3)]-(CH ₂ )6-, -(CH ₂ )3- [C(CH ₃ )(CH ₂ CF3)]-(CH ₂ )7-, -(CH ₂ )3-[C(CH ₃ )(CH ₂ CF3)]-(CH ₂ )8-, -(CH ₂ )4- [C(CH ₃ )(CH ₂ CF3)]-(CH ₂ ) ₂ -, -(CH ₂ )4-[C(CH ₃ )(CH ₂ CF3)]-(CH ₂ )3-, -(CH ₂ )4- [C(CH ₃ )(CH ₂ CF ₃ )]-(CH ₂ ) ₅ -, -(CH ₂ ) ₄ -[C(CH ₃ )(CH ₂ CF ₃ )]-(CH ₂ ) ₆ -, -(CH ₂ ) ₄ - [C(CH ₃ )(CH ₂ CF3)]-(CH ₂ )7-, -(CH ₂ )5-[C(CH ₃ )(CH ₂ CF3)]-(CH ₂ ) ₂ -, -(CH ₂ )5- [C(CH ₃ )(CH ₂ CF3)]-(CH ₂ )3-, -(CH ₂ )5-[C(CH ₃ )(CH ₂ CF3)]-(CH ₂ )4-, -(CH ₂ )5- [C(CH ₃ )(CH ₂ CF ₃ )]-(CH ₂ ) ₆ -, -(CH ₂ ) ₆ -[C(CH ₃ )(CH ₂ CF ₃ )]-(CH ₂ ) ₂ -, -(CH ₂ ) ₆ - [C(CH ₃ )(CH ₂ CF3)]-(CH ₂ )3-, -(CH ₂ )6-[C(CH ₃ )(CH ₂ CF3)]-(CH ₂ )4-, -(CH ₂ )6- [C(CH ₃ )(CH ₂ CF3)]-(CH ₂ )5-,

-[C(CH ₃ )(CH ₂ CF ₃ )] ₂ -(CH ₂ )-, -(CH ₂ )-[C(CH ₃ )(CH ₂ CF ₃ )] ₂ -, -(CH ₂ )- [C(CH ₃ )(CH ₂ CF ₃ )] ₂ -(CH ₂ )-, -(CH ₂ )-[C(CH ₃ )(CH ₂ CF ₃ )] ₂ -(CH ₂ ) ₂ -, -(CH ₂ )- [C(CH ₃ )(CH ₂ CF3)]2-(CH ₂ )3-, -(CH ₂ )-[C(CH ₃ )(CH ₂ CF3)]2-(CH ₂ )4-, -(CH ₂ )- [C(CH ₃ )(CH ₂ CF ₃ )] ₂ -(CH ₂ ) ₅ -, -(CH ₂ )-[C(CH ₃ )(CH ₂ CF ₃ )] ₂ -(CH ₂ ) ₆ -, -(CH ₂ )- [C(CH ₃ )(CH ₂ CF3)]2-(CH ₂ )7-, -(CH ₂ )-[C(CH ₃ )(CH ₂ CF3)]2-(CH ₂ )8-, -(CH ₂ )- [C(CH ₃ )(CH ₂ CF3)]2-(CH ₂ )9-, -(CH ₂ ) ₂ -[C(CH ₃ )(CH ₂ CF3)]2-(CH ₂ )-, -(CH ₂ )3- [C(CH ₃ )(CH ₂ CF3)]2-(CH ₂ )-, -(CH ₂ )4-[C(CH ₃ )(CH ₂ CF3)]2-(CH ₂ )-, -(CH ₂ )5- [C(CH ₃ )(CH ₂ CF ₃ )] ₂ -(CH ₂ )-, -(CH ₂ ) ₆ -[C(CH ₃ )(CH ₂ CF ₃ )] ₂ -(CH ₂ )-, -(CH ₂ ) ₇ - [C(CH ₃ )(CH ₂ CF3)]2-(CH ₂ )-, -(CH ₂ )8-[C(CH ₃ )(CH ₂ CF3)]2-(CH ₂ )-, -(CH ₂ )9- [C(CH ₃ )(CH ₂ CF3)]2-(CH ₂ )-, -(CH ₂ ) ₂ -[C(CH ₃ )(CH ₂ CF3)]2-(CH ₂ ) ₂ -, -(CH ₂ )3- [C(CH ₃ )(CH ₂ CF ₃ )] ₂ -(CH ₂ ) ₃ -, -(CH ₂ ) ₄ -[C(CH ₃ )(CH ₂ CF ₃ )] ₂ -(CH ₂ ) ₄ -, -(CH ₂ ) ₅ - [C(CH ₃ )(CH ₂ CF3)]2-(CH ₂ )5-, -(CH ₂ ) ₂ -[C(CH ₃ )(CH ₂ CF3)]2-(CH ₂ )3-, -(CH ₂ ) ₂ - [C(CH ₃ )(CH ₂ CF3)]2-(CH ₂ )4-, -(CH ₂ ) ₂ -[C(CH ₃ )(CH ₂ CF3)]2-(CH ₂ )5-, -(CH ₂ ) ₂ - [C(CH ₃ )(CH ₂ CF3)]2-(CH ₂ )6-, -(CH ₂ ) ₂ -[C(CH ₃ )(CH ₂ CF3)]2-(CH ₂ )7-, -(CH ₂ ) ₂ - [C(CH ₃ )(CH ₂ CF ₃ )] ₂ -(CH ₂ ) ₈ -, -(CH ₂ ) ₃ -[C(CH ₃ )(CH ₂ CF ₃ )] ₂ -(CH ₂ ) ₂ -, -(CH ₂ ) ₃ - [C(CH ₃ )(CH ₂ CF3)]2-(CH ₂ )4-, -(CH ₂ )3-[C(CH ₃ )(CH ₂ CF3)]2-(CH ₂ )5-, -(CH ₂ )3- [C(CH ₃ )(CH ₂ CF ₃ )] ₂ -(CH ₂ ) ₆ -, -(CH ₂ ) ₃ -[C(CH ₃ )(CH ₂ CF ₃ )] ₂ -(CH ₂ ) ₇ -, -(CH ₂ ) ₄ - [C(CH ₃ )(CH ₂ CF ₃ )] ₂ -(CH ₂ ) ₂ -, -(CH ₂ ) ₄ -[C(CH ₃ )(CH ₂ CF ₃ )] ₂ -(CH ₂ ) ₃ -, -(CH ₂ ) ₄ - [C(CH ₃ )(CH ₂ CF3)]2-(CH ₂ )5-, -(CH ₂ )4-[C(CH ₃ )(CH ₂ CF3)]2-(CH ₂ )6-, -(CH ₂ )5- [C(CH ₃ )(CH ₂ CF3)]2-(CH ₂ ) ₂ -, -(CH ₂ )5-[C(CH ₃ )(CH ₂ CF3)]2-(CH ₂ )3-, -(CH ₂ )5- [C(CH ₃ )(CH ₂ CF ₃ )] ₂ -(CH ₂ ) ₄ -, -(CH ₂ ) ₆ -[C(CH ₃ )(CH ₂ CF ₃ )] ₂ -(CH ₂ ) ₂ -, -(CH ₂ ) ₆ - [C(CH ₃ )(CH ₂ CF ₃ )] ₂ -(CH ₂ ) ₃ -, -(CH ₂ ) ₆ -[C(CH ₃ )(CH ₂ CF ₃ )] ₂ -(CH ₂ ) ₄ -, -[C(CH ₃ )(CH ₂ CF ₃ )] ₃ -(CH ₂ )-, -(CH ₂ )-[C(CH ₃ )(CH ₂ CF ₃ )] ₃ -, -(CH ₂ )- [C(CH ₃ )(CH ₂ CF3)]3-(CH ₂ )-, -(CH ₂ )-[C(CH ₃ )(CH ₂ CF3)]3-(CH ₂ ) ₂ -, -(CH ₂ )- [C(CH ₃ )(CH ₂ CF3)]3-(CH ₂ )3-, -(CH ₂ )-[C(CH ₃ )(CH ₂ CF3)]3-(CH ₂ )4-, -(CH ₂ )- [C(CH ₃ )(CH ₂ CF3)]3-(CH ₂ )5-, -(CH ₂ )-[C(CH ₃ )(CH ₂ CF3)]3-(CH ₂ )6-, -(CH ₂ )- [C(CH ₃ )(CH ₂ CF ₃ )] ₃ -(CH ₂ ) ₇ -, -(CH ₂ )-[C(CH ₃ )(CH ₂ CF ₃ )] ₃ -(CH ₂ ) ₈ -, -(CH ₂ ) ₂ - [C(CH ₃ )(CH ₂ CF3)]3-(CH ₂ )-, -(CH ₂ )3-[C(CH ₃ )(CH ₂ CF3)]3-(CH ₂ )-, -(CH ₂ )4- [C(CH ₃ )(CH ₂ CF3)]3-(CH ₂ )-, -(CH ₂ )5-[C(CH ₃ )(CH ₂ CF3)]3-(CH ₂ )-, -(CH ₂ )6- [C(CH ₃ )(CH ₂ CF ₃ )] ₃ -(CH ₂ )-, -(CH ₂ ) ₇ -[C(CH ₃ )(CH ₂ CF ₃ )] ₃ -(CH ₂ )-, -(CH ₂ ) ₈ - [C(CH ₃ )(CH ₂ CF3)]3-(CH ₂ )-, -(CH ₂ ) ₂ -[C(CH ₃ )(CH ₂ CF3)]3-(CH ₂ ) ₂ -, -(CH ₂ )3- [C(CH ₃ )(CH ₂ CF3)]3-(CH ₂ )3-, -(CH ₂ )4-[C(CH ₃ )(CH ₂ CF3)]3-(CH ₂ )4-, -(CH ₂ ) ₂ - [C(CH ₃ )(CH ₂ CF ₃ )] ₃ -(CH ₂ ) ₃ -, -(CH ₂ ) ₂ -[C(CH ₃ )(CH ₂ CF ₃ )] ₃ -(CH ₂ ) ₄ -, -(CH ₂ ) ₂ - [C(CH ₃ )(CH ₂ CF ₃ )] ₃ -(CH ₂ ) ₅ -, -(CH ₂ ) ₂ -[C(CH ₃ )(CH ₂ CF ₃ )] ₃ -(CH ₂ ) ₆ -, -(CH ₂ ) ₂ - [C(CH ₃ )(CH ₂ CF3)]3-(CH ₂ )7-, -(CH ₂ )3-[C(CH ₃ )(CH ₂ CF3)]3-(CH ₂ ) ₂ -, -(CH ₂ )3- [C(CH ₃ )(CH ₂ CF ₃ )] ₃ -(CH ₂ ) ₄ -, -(CH ₂ ) ₃ -[C(CH ₃ )(CH ₂ CF ₃ )] ₃ -(CH ₂ ) ₅ -, -(CH ₂ ) ₃ - [C(CH ₃ )(CH ₂ CF3)]3-(CH ₂ )6-, -(CH ₂ )4-[C(CH ₃ )(CH ₂ CF3)]3-(CH ₂ ) ₂ -, -(CH ₂ )4- [C(CH ₃ )(CH ₂ CF3)]3-(CH ₂ )3-, -(CH ₂ )4-[C(CH ₃ )(CH ₂ CF3)]3-(CH ₂ )5-, -(CH ₂ )5- [C(CH ₃ )(CH ₂ CF3)]3-(CH ₂ ) ₂ -, -(CH ₂ )5-[C(CH ₃ )(CH ₂ CF3)]3-(CH ₂ )3-, -(CH ₂ )5- [C(CH ₃ )(CH ₂ CF ₃ )] ₃ -(CH ₂ ) ₄ -, -(CH ₂ ) ₆ -[C(CH ₃ )(CH ₂ CF ₃ )] ₃ -(CH ₂ ) ₂ -, -(CH ₂ ) ₆ - [C(CH ₃ )(CH ₂ CF3)]3-(CH ₂ )3-,

-[C(CH ₃ )(CH ₂ CF3)]4-(CH ₂ )-, -(CH ₂ )-[C(CH ₃ )(CH ₂ CF3)]4-, -(CH ₂ )- [C(CH ₃ )(CH ₂ CF ₃ )] ₄ -(CH ₂ )-, -(CH ₂ )-[C(CH ₃ )(CH ₂ CF ₃ )] ₄ -(CH ₂ ) ₂ -, -(CH ₂ )- [C(CH ₃ )(CH ₂ CF3)]4-(CH ₂ )3-, -(CH ₂ )-[C(CH ₃ )(CH ₂ CF3)]4-(CH ₂ )4-, -(CH ₂ )- [C(CH ₃ )(CH ₂ CF3)]4-(CH ₂ )5-, -(CH ₂ )-[C(CH ₃ )(CH ₂ CF3)]4-(CH ₂ )6-, -(CH ₂ )- [C(CH ₃ )(CH ₂ CF3)]4-(CH ₂ )7-, -(CH ₂ )-[C(CH ₃ )(CH ₂ CF3)]4-(CH ₂ )8-, -(CH ₂ )- [C(CH ₃ )(CH ₂ CF ₃ )] ₄ -(CH ₂ ) ₉ -, -(CH ₂ )-[C(CH ₃ )(CH ₂ CF ₃ )] ₄ -(CH ₂ ) ₁₀ -, -(CH ₂ ) ₂ - [C(CH ₃ )(CH ₂ CF3)]4-(CH ₂ )-, -(CH ₂ )3-[C(CH ₃ )(CH ₂ CF3)]4-(CH ₂ )-, -(CH ₂ )4- [C(CH ₃ )(CH ₂ CF ₃ )] ₄ -(CH ₂ )-, -(CH ₂ ) ₅ -[C(CH ₃ )(CH ₂ CF ₃ )] ₄ -(CH ₂ )-, -(CH ₂ ) ₆ - [C(CH ₃ )(CH ₂ CF ₃ )] ₄ -(CH ₂ )-, -(CH ₂ ) ₇ -[C(CH ₃ )(CH ₂ CF ₃ )] ₄ -(CH ₂ )-, -(CH ₂ ) ₂ - [C(CH ₃ )(CH ₂ CF3)]4-(CH ₂ ) ₂ -, -(CH ₂ )3-[C(CH ₃ )(CH ₂ CF3)]4-(CH ₂ )3-, -(CH ₂ )4- [C(CH ₃ )(CH ₂ CF3)]4-(CH ₂ )4-, -(CH ₂ )5-[C(CH ₃ )(CH ₂ CF3)]4-(CH ₂ )5-, -(CH ₂ ) ₂ - [C(CH ₃ )(CH ₂ CF ₃ )] ₄ -(CH ₂ ) ₃ -, -(CH ₂ ) ₂ -[C(CH ₃ )(CH ₂ CF ₃ )] ₄ -(CH ₂ ) ₄ -, -(CH ₂ ) ₂ - [C(CH ₃ )(CH ₂ CF ₃ )] ₄ -(CH ₂ ) ₅ -, -(CH ₂ ) ₂ -[C(CH ₃ )(CH ₂ CF ₃ )] ₄ -(CH ₂ ) ₆ -, -(CH ₂ ) ₃ - [C(CH ₃ )(CH ₂ CF ₃ )] ₄ -(CH ₂ ) ₂ -, -(CH ₂ ) ₃ -[C(CH ₃ )(CH ₂ CF ₃ )] ₄ -(CH ₂ ) ₄ -, -(CH ₂ ) ₄ - [C(CH ₃ )(CH ₂ CF3)]4-(CH ₂ ) ₂ -, -(CH ₂ )4-[C(CH ₃ )(CH ₂ CF3)]4-(CH ₂ )3-, -(CH ₂ )5- [C(CH ₃ )(CH ₂ CF3)]4-(CH ₂ ) ₂ -, -(CH ₂ )5-[C(CH ₃ )(CH ₂ CF3)]4-(CH ₂ )3-, -(CH ₂ )6- [C(CH ₃ )(CH ₂ CF3)]4-(CH ₂ ) ₂ -,

-[C(CH ₃ )(CH ₂ CF ₃ )] ₅ -(CH ₂ )-, -(CH ₂ )-[C(CH ₃ )(CH ₂ CF ₃ )] ₅ -, -(CH ₂ )- [C(CH ₃ )(CH ₂ CF3)]5-(CH ₂ )-, -(CH ₂ )-[C(CH ₃ )(CH ₂ CF3)]5-(CH ₂ ) ₂ -, -(CH ₂ )- [C(CH ₃ )(CH ₂ CF3)]5-(CH ₂ )3-, -(CH ₂ )-[C(CH ₃ )(CH ₂ CF3)]5-(CH ₂ )4-, -(CH ₂ )- [C(CH ₃ )(CH ₂ CF ₃ )] ₅ -(CH ₂ ) ₅ -, -(CH ₂ )-[C(CH ₃ )(CH ₂ CF ₃ )] ₅ -(CH ₂ ) ₆ -, -(CH ₂ ) ₂ - [C(CH ₃ )(CH ₂ CF3)]5-(CH ₂ )-, -(CH ₂ )3-[C(CH ₃ )(CH ₂ CF3)]5-(CH ₂ )-, -(CH ₂ )4- [C(CH ₃ )(CH ₂ CF3)]5-(CH ₂ )-, -(CH ₂ )5-[C(CH ₃ )(CH ₂ CF3)]5-(CH ₂ )-, -(CH ₂ )6- [C(CH ₃ )(CH ₂ CF ₃ )] ₅ -(CH ₂ )-, -(CH ₂ ) ₂ -[C(CH ₃ )(CH ₂ CF ₃ )] ₅ -(CH ₂ ) ₂ -, -(CH ₂ ) ₃ - [C(CH ₃ )(CH ₂ CF ₃ )] ₅ -(CH ₂ ) ₃ -, -(CH ₂ ) ₄ -[C(CH ₃ )(CH ₂ CF ₃ )] ₅ -(CH ₂ ) ₄ -, -(CH ₂ ) ₂ - [C(CH ₃ )(CH ₂ CF3)]5-(CH ₂ )3-, -(CH ₂ ) ₂ -[C(CH ₃ )(CH ₂ CF3)]5-(CH ₂ )4-, -(CH ₂ ) ₂ - [C(CH ₃ )(CH ₂ CF ₃ )] ₅ -(CH ₂ ) ₅ -, -(CH ₂ ) ₂ -[C(CH ₃ )(CH ₂ CF ₃ )] ₅ -(CH ₂ ) ₆ -, -(CH ₂ ) ₃ - [C(CH ₃ )(CH ₂ CF3)]5-(CH ₂ ) ₂ -, -(CH ₂ )3-[C(CH ₃ )(CH ₂ CF3)]5-(CH ₂ )4-, -(CH ₂ )4- [C(CH ₃ )(CH ₂ CF3)]5-(CH ₂ ) ₂ -, -(CH ₂ )4-[C(CH ₃ )(CH ₂ CF3)]5-(CH ₂ )3-, -(CH ₂ )5- [C(CH ₃ )(CH ₂ CF3)]5-(CH ₂ ) ₂ -,

-(CH ₂ ) ₂ -(CF ₂ )-O-(CF ₂ )-(CH ₂ ) ₂ -, -(CH ₂ ) ₂ -(CF ₂ )-O-(CH ₂ )-O-(CF ₂ )-(CH ₂ ) ₂ - , -(CH ₂ ) ₂ -(CF2)-O-(CH ₂ ) ₂ -O-(CF2)-(CH ₂ ) ₂ ,

-(CH ₂ )-(CF2)-O-(CF2)-O-(CF2)-(CH ₂ )-, -(CH ₂ ) ₂ -(CF2)-O-(CF2)-O-(CF2)- (CH ₂ ) ₂ -, -(CH ₂ ) ₃ -(CF ₂ )-O-(CF ₂ )-O-(CF ₂ )-(CH ₂ ) ₃ -, -(CH ₂ ) ₄ -(CF ₂ )-O-(CF ₂ )-O- (CF2)-(CH ₂ )4-, -(CH ₂ )-(CF2)-O-(CF2)-O-(CF2)-(CH ₂ ) ₂ -, -(CH ₂ )-(CF2)-O-(CF2)- O-(CF2)-(CH ₂ )3-, -(CH ₂ )-(CF2)-O-(CF2)-O-(CF2)-(CH ₂ )4-, -(CH ₂ )-(CF2)-O- (CF2)-O-(CF2)-(CH ₂ )5-, -(CH ₂ )-(CF2)-O-(CF2)-O-(CF2)-(CH ₂ )6-, -(CH ₂ )-(CF2)- O-(CF ₂ )-O-(CF ₂ )-(CH ₂ ) ₇ -, -(CH ₂ ) ₂ -(CF ₂ )-O-(CF ₂ )-O-(CF ₂ )-(CH ₂ )-, -(CH ₂ ) ₃ - (CF2)-O-(CF2)-O-(CF2)-(CH ₂ )-, -(CH ₂ )4-(CF2)-O-(CF2)-O-(CF2)-(CH ₂ )- , -(CH ₂ ) ₅ -(CF ₂ )-O-(CF ₂ )-O-(CF ₂ )-(CH ₂ )-, -(CH ₂ ) ₆ -(CF ₂ )-O-(CF ₂ )-O-(CF ₂ )- (CH ₂ )-, -(CH ₂ ) ₇ -(CF ₂ )-O-(CF ₂ )-O-(CF ₂ )-(CH ₂ )-, -(CH ₂ ) ₂ -(CF ₂ )-O-(CF ₂ )-O- (CF2)-(CH ₂ )3-, -(CH ₂ ) ₂ -(CF2)-O-(CF2)-O-(CF2)-(CH ₂ )4-, -(CH ₂ ) ₂ -(CF2)-O- (CF2)-O-(CF2)-(CH ₂ )5-, -(CH ₂ ) ₂ -(CF2)-O-(CF2)-O-(CF2)-(CH ₂ )6-, -(CH ₂ )3- (CF ₂ )-O-(CF ₂ )-O-(CF ₂ )-(CH ₂ ) ₂ -, -(CH ₂ ) ₄ -(CF ₂ )-O-(CF ₂ )-O-(CF ₂ )-(CH ₂ ) ₂ - , -(CH ₂ ) ₅ -(CF ₂ )-O-(CF ₂ )-O-(CF ₂ )-(CH ₂ ) ₂ -, -(CH ₂ ) ₆ -(CF ₂ )-O-(CF ₂ )-O-(CF ₂ )- (CH ₂ ) ₂ -, -(CH ₂ ) ₃ -(CF ₂ )-O-(CF ₂ )-O-(CF ₂ )-(CH ₂ ) ₄ -, -(CH ₂ ) ₄ -(CF ₂ )-O-(CF ₂ )-O- (CF2)-(CH ₂ )3-, -(CH ₂ )3-(CF2)-O-(CF2)-O-(CF2)-(CH ₂ )5-, -(CH ₂ )5-(CF2)-O- (CF2)-O-(CF2)-(CH ₂ )3-,

-(CH ₂ )-(CF2)-O-(CF2) ₂ -O-(CF2)-(CH ₂ )-, -(CH ₂ ) ₂ -(CF2)-O-(CF2) ₂ -O-(CF2)- (CH ₂ ) ₂ -, -(CH ₂ ) ₃ -(CF ₂ )-O-(CF ₂ ) ₂ -O-(CF ₂ )-(CH ₂ ) ₃ -, -(CH ₂ ) ₄ -(CF ₂ )-O-(CF ₂ ) ₂ -O- (CF2)-(CH ₂ )4-, -(CH ₂ )-(CF2)-O-(CF2) ₂ -O-(CF2)-(CH ₂ ) ₂ -, -(CH ₂ )-(CF2)-O- (CF2) ₂ -O-(CF2)-(CH ₂ )3-, -(CH ₂ )-(CF2)-O-(CF2) ₂ -O-(CF2)-(CH ₂ )4-, -(CH ₂ )- (CF ₂ )-O-(CF ₂ ) ₂ -O-(CF ₂ )-(CH ₂ ) ₅ -, -(CH ₂ )-(CF ₂ )-O-(CF ₂ ) ₂ -O-(CF ₂ )-(CH ₂ ) ₆ - , -(CH ₂ )-(CF2)-O-(CF2) ₂ -O-(CF2)-(CH ₂ )7-, -(CH ₂ ) ₂ -(CF2)-O-(CF2) ₂ -O-(CF2)- (CH ₂ )-, -(CH ₂ )3-(CF2)-O-(CF2) ₂ -O-(CF2)-(CH ₂ )-, -(CH ₂ )4-(CF2)-O-(CF2) ₂ -O- (CF ₂ )-(CH ₂ )-, -(CH ₂ ) ₅ -(CF ₂ )-O-(CF ₂ ) ₂ -O-(CF ₂ )-(CH ₂ )-, -(CH ₂ ) ₆ -(CF ₂ )-O- (CF ₂ ) ₂ -O-(CF ₂ )-(CH ₂ )-, -(CH ₂ ) ₇ -(CF ₂ )-O-(CF ₂ ) ₂ -O-(CF ₂ )-(CH ₂ )-, -(CH ₂ ) ₂ - (CF2)-O-(CF2) ₂ -O-(CF2)-(CH ₂ )3-, -(CH ₂ ) ₂ -(CF2)-O-(CF2) ₂ -O-(CF2)-(CH ₂ )4- , -(CH ₂ ) ₂ -(CF ₂ )-O-(CF ₂ ) ₂ -O-(CF ₂ )-(CH ₂ ) ₅ -, -(CH ₂ ) ₂ -(CF ₂ )-O-(CF ₂ ) ₂ -O-(CF ₂ )- (CH ₂ )6-, -(CH ₂ )3-(CF2)-O-(CF2) ₂ -O-(CF2)-(CH ₂ ) ₂ -, -(CH ₂ )4-(CF2)-O-(CF2) ₂ -O- (CF2)-(CH ₂ ) ₂ -, -(CH ₂ )5-(CF2)-O-(CF2) ₂ -O-(CF2)-(CH ₂ ) ₂ -, -(CH ₂ )6-(CF2)-O- (CF2) ₂ -O-(CF2)-(CH ₂ ) ₂ -, -(CH ₂ )3-(CF2)-O-(CF2) ₂ -O-(CF2)-(CH ₂ )4-, -(CH ₂ )4- (CF ₂ )-O-(CF ₂ ) ₂ -O-(CF ₂ )-(CH ₂ ) ₃ -, -(CH ₂ ) ₃ -(CF ₂ )-O-(CF ₂ ) ₂ -O-(CF ₂ )-(CH ₂ ) ₅ - , -(CH ₂ )5-(CF2)-O-(CF2) ₂ -O-(CF2)-(CH ₂ )3-,

-(CH ₂ )-(CF2) ₂ -O-(CF2) ₂ -O-(CF2) ₂ -(CH ₂ )-, -(CH ₂ ) ₂ -(CF2) ₂ -O-(CF2) ₂ -O-(CF2) ₂ - (CH ₂ ) ₂ -, -(CH ₂ ) ₃ -(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -(CH ₂ ) ₃ -, -(CH ₂ ) ₄ -(CF ₂ ) ₂ -O-(CF ₂ ) ₂ - O-(CF2) ₂ -(CH ₂ )4-, -(CH ₂ )-(CF2) ₂ -O-(CF2) ₂ -O-(CF2) ₂ -(CH ₂ ) ₂ -, -(CH ₂ )-(CF2) ₂ - O-(CF2) ₂ -O-(CF2) ₂ -(CH ₂ )3-, -(CH ₂ )-(CF2) ₂ -O-(CF2) ₂ -O-(CF2) ₂ -(CH ₂ )3- , -(CH ₂ )-(CF2) ₂ -O-(CF2) ₂ -O-(CF2) ₂ -(CH ₂ )4-, -(CH ₂ )-(CF2) ₂ -O-(CF2) ₂ -O-(CF2) ₂ - (CH ₂ ) ₅ -, -(CH ₂ )-(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -(CH ₂ ) ₆ -, -(CH ₂ )-(CF ₂ ) ₂ -O-(CF ₂ ) ₂ - O-(CF2) ₂ -(CH ₂ )7-, -(CH ₂ ) ₂ -(CF2) ₂ -O-(CF2) ₂ -O-(CF2) ₂ -(CH ₂ )-, -(CH ₂ )3-(CF2) ₂ - O-(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -(CH ₂ )-, -(CH ₂ ) ₄ -(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -(CH ₂ )- , -(CH ₂ ) ₅ -(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -(CH ₂ )-, -(CH ₂ ) ₆ -(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -O- (CF2) ₂ -(CH ₂ )-, -(CH ₂ )7-(CF2) ₂ -O-(CF2) ₂ -O-(CF2) ₂ -(CH ₂ )-, -(CH ₂ ) ₂ -(CF2) ₂ -O- (CF2) ₂ -O-(CF2) ₂ -(CH ₂ )3-, -(CH ₂ ) ₂ -(CF2) ₂ -O-(CF2) ₂ -O-(CF2) ₂ -(CH ₂ )4-, -(CH ₂ ) ₂ - (CF ₂ ) ₂ -O-(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -(CH ₂ ) ₅ -, -(CH ₂ ) ₂ -(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -(CH ₂ ) ₆ - , -(CH ₂ ) ₃ -(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -(CH ₂ ) ₂ -, -(CH ₂ ) ₄ -(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -O- (CF ₂ ) ₂ -(CH ₂ ) ₂ -, -(CH ₂ ) ₅ -(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -(CH ₂ ) ₂ -, -(CH ₂ ) ₆ -(CF ₂ ) ₂ -O- (CF2) ₂ -O-(CF2) ₂ -(CH ₂ ) ₂ -, -(CH ₂ )3-(CF2) ₂ -O-(CF2) ₂ -O-(CF2) ₂ -(CH ₂ )4-, -(CH ₂ )4- (CF2) ₂ -O-(CF2) ₂ -O-(CF2) ₂ -(CH ₂ )3-, -(CH ₂ )3-(CF2) ₂ -O-(CF2) ₂ -O-(CF2) ₂ -(CH ₂ )5- , -(CH ₂ )5-(CF2) ₂ -O-(CF2) ₂ -O-(CF2) ₂ -(CH ₂ )3-,

-(CH ₂ )-(CF ₂ )-O-(CF ₂ )-O-(CF ₂ )-O-(CF ₂ )-(CH ₂ )-, -(CH ₂ ) ₂ -(CF ₂ )-O-(CF ₂ )-O- (CF2)-O-(CF2)-(CH ₂ ) ₂ -, -(CH ₂ )3-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH ₂ )3- , -(CH ₂ )4-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH ₂ )4-, -(CH ₂ )-(CF2)-O-(CF2)-O- (CF ₂ )-O-(CF ₂ )-(CH ₂ ) ₂ -, -(CH ₂ )-(CF ₂ )-O-(CF ₂ )-O-(CF ₂ )-O-(CF ₂ )-(CH ₂ ) ₃ - , -(CH ₂ )-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH ₂ )4-, -(CH ₂ )-(CF2)-O-(CF2)-O- (CF2)-O-(CF2)-(CH ₂ )5-, -(CH ₂ )-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH ₂ )6- , -(CH ₂ )-(CF ₂ )-O-(CF ₂ )-O-(CF ₂ )-O-(CF ₂ )-(CH ₂ ) ₇ -, -(CH ₂ ) ₂ -(CF ₂ )-O-(CF ₂ )-O- (CF ₂ )-O-(CF ₂ )-(CH ₂ )-, -(CH ₂ ) ₃ -(CF ₂ )-O-(CF ₂ )-O-(CF ₂ )-O-(CF ₂ )-(CH ₂ )- , -(CH ₂ )4-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH ₂ )-, -(CH ₂ )5-(CF2)-O-(CF2)-O- (CF ₂ )-O-(CF ₂ )-(CH ₂ )-, -(CH ₂ ) ₆ -(CF ₂ )-O-(CF ₂ )-O-(CF ₂ )-O-(CF ₂ )-(CH ₂ )- , -(CH ₂ )7-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH ₂ )-, -(CH ₂ ) ₂ -(CF2)-O-(CF2)-O- (CF2)-O-(CF2)-(CH ₂ )3-, -(CH ₂ ) ₂ -(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH ₂ )4- , -(CH ₂ ) ₂ -(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH ₂ )5-, -(CH ₂ ) ₂ -(CF2)-O-(CF2)-O- (CF ₂ )-O-(CF ₂ )-(CH ₂ ) ₆ -, -(CH ₂ ) ₃ -(CF ₂ )-O-(CF ₂ )-O-(CF ₂ )-O-(CF ₂ )-(CH ₂ ) ₂ - , -(CH ₂ )4-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH ₂ ) ₂ -, -(CH ₂ )5-(CF2)-O-(CF2)-O- (CF2)-O-(CF2)-(CH ₂ ) ₂ -, -(CH ₂ )6-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH ₂ ) ₂ - , -(CH ₂ ) ₃ -(CF ₂ )-O-(CF ₂ )-O-(CF ₂ )-O-(CF ₂ )-(CH ₂ ) ₄ -, -(CH ₂ ) ₄ -(CF ₂ )-O-(CF ₂ )-O- (CF2)-O-(CF2)-(CH ₂ )3-, -(CH ₂ )3-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH ₂ )5- , -(CH ₂ )5-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH ₂ )3-,

-(CH ₂ )-(CF2) ₂ -O-(CF2) ₂ -O-(CF2) ₂ -O-(CF2) ₂ -(CH ₂ )-, -(CH ₂ ) ₂ -(CF2) ₂ -O-(CF2) ₂ - O-(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -(CH ₂ ) ₂ -, -(CH ₂ ) ₃ -(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -O-(CF ₂ ) ₂ - (CH ₂ )3-, -(CH ₂ )4-(CF2) ₂ -O-(CF2) ₂ -O-(CF2) ₂ -O-(CF2) ₂ -(CH ₂ )4-, -(CH ₂ )-(CF2) ₂ - O-(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -(CH ₂ ) ₂ -, -(CH ₂ )-(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -O- (CF ₂ ) ₂ -(CH ₂ ) ₃ -, -(CH ₂ )-(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -(CH ₂ ) ₄ -, -(CH ₂ )- (CF2) ₂ -O-(CF2) ₂ -O-(CF2) ₂ -O-(CF2) ₂ -(CH ₂ )5-, -(CH ₂ )-(CF2) ₂ -O-(CF2) ₂ -O- (CF2) ₂ -O-(CF2) ₂ -(CH ₂ )6-, -(CH ₂ )-(CF2) ₂ -O-(CF2) ₂ -O-(CF2) ₂ -O-(CF2) ₂ -(CH ₂ )7- , -(CH ₂ ) ₂ -(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -(CH ₂ )-, -(CH ₂ ) ₃ -(CF ₂ ) ₂ -O- (CF ₂ ) ₂ -O-(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -(CH ₂ )-, -(CH ₂ ) ₄ -(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -O- (CF ₂ ) ₂ -(CH ₂ )-, -(CH ₂ ) ₅ -(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -(CH ₂ )-, -(CH ₂ ) ₆ - (CF2) ₂ -O-(CF2) ₂ -O-(CF2) ₂ -O-(CF2) ₂ -(CH ₂ )-, -(CH ₂ )7-(CF2) ₂ -O-(CF2) ₂ -O- (CF2) ₂ -O-(CF2) ₂ -(CH ₂ )-, -(CH ₂ ) ₂ -(CF2) ₂ -O-(CF2) ₂ -O-(CF2) ₂ -O-(CF2) ₂ -(CH ₂ )3- , -(CH ₂ ) ₂ -(CF2) ₂ -O-(CF2) ₂ -O-(CF2) ₂ -O-(CF2) ₂ -(CH ₂ )4-, -(CH ₂ ) ₂ -(CF2) ₂ -O- (CF ₂ ) ₂ -O-(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -(CH ₂ ) ₅ -, -(CH ₂ ) ₂ -(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -O- (CF2) ₂ -(CH ₂ )6-, -(CH ₂ )3-(CF2) ₂ -O-(CF2) ₂ -O-(CF2) ₂ -O-(CF2) ₂ -(CH ₂ ) ₂ -, -(CH ₂ )4- (CF2) ₂ -O-(CF2) ₂ -O-(CF2) ₂ -O-(CF2) ₂ -(CH ₂ ) ₂ -, -(CH ₂ )5-(CF2) ₂ -O-(CF2) ₂ -O- (CF ₂ ) ₂ -O-(CF ₂ ) ₂ -(CH ₂ ) ₂ -, -(CH ₂ ) ₆ -(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -(CH ₂ ) ₂ - , -(CH ₂ )3-(CF2) ₂ -O-(CF2) ₂ -O-(CF2) ₂ -O-(CF2) ₂ -(CH ₂ )4-, -(CH ₂ )4-(CF2) ₂ -O- (CF2) ₂ -O-(CF2) ₂ -O-(CF2) ₂ -(CH ₂ )3-, -(CH ₂ )3-(CF2) ₂ -O-(CF2) ₂ -O-(CF2) ₂ -O- (CF ₂ ) ₂ -(CH ₂ ) ₅ -, -(CH ₂ ) ₅ -(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -O-(CF ₂ ) ₂ -(CH ₂ ) ₃ -. Preferred examples for -R2- are -(CH ₂ )3-, -(CH ₂ )4-, -(CH ₂ )5-, -(CH ₂ )6-, - (CH ₂ ) ₇ -, -(CH ₂ ) ₈ -, -(CH ₂ ) ₉ -, -(CH ₂ ) ₁₀ -, -(CH ₂ ) ₁₁ -, -(CH ₂ ) ₂ -S-(CH ₂ ) ₂ -, -(CH ₂ ) ₂ - SO ₂ -(CH ₂ ) ₂ -, -(CH ₂ )-S-(CH ₂ ) ₂ -O-(CH ₂ )-, -(CH ₂ )-SO ₂ -(CH ₂ ) ₂ -O-(CH ₂ )-, - (CH ₂ )-SO ₂ -(CH ₂ ) ₂ -S-(CH ₂ )-, -(CH ₂ )-O-(CH ₂ ) ₂ -S-(CH ₂ ) ₂ -O-(CH ₂ )-, -(CH ₂ )-S- (CH ₂ ) ₂ -O-(CH ₂ ) ₂ -S-(CH ₂ )-, -(CH ₂ )-SO ₂ -(CH ₂ ) ₂ -O-(CH ₂ ) ₂ -SO ₂ -(CH ₂ )-, -(CH ₂ )- S-(CH ₂ ) ₂ -S-(CH ₂ ) ₂ -S-(CH ₂ )-, -(CH ₂ )-SO ₂ -(CH ₂ ) ₂ -SO ₂ -(CH ₂ ) ₂ -SO ₂ -(CH ₂ )-, - (CH ₂ )-O-(CH ₂ ) ₂ -SO ₂ -(CH ₂ ) ₂ -O-(CH ₂ )-, -(CH ₂ )12, -(CH ₂ )3-(CF2)-(CH ₂ )3-, - (CH ₂ )-(CF2)3-(CH ₂ )-, -(CH ₂ ) ₂ -(CF2)4-(CH ₂ ) ₂ -, -(CH ₂ )-[CH(CF3)]-(CH ₂ )-, - (CH ₂ )-[C(CH ₃ )CF ₃ ]-(CH ₂ )-, -(CH ₂ )-[CH(CH ₂ CF ₃ )]-(CH ₂ )-, -(CH ₂ )- [C(CH ₃ )(CH ₂ CF3)]-(CH ₂ )-, -(CH ₂ ) ₂ -(CF2)-O-(CF2)-O-(CF2)-(CH ₂ ) ₂ - and -(CH ₂ )-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH ₂ )- according to the invention. Compounds of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4- H), (I'), (I'-a), (I'-b), (I'-c), (I'-d), (I'-1), (I'-2), (I'-2-H), (I'-3), (I'-3-H), (I'-4), (I'-4- H) (I''), (I''-1), (I''-2), (I''-2-H), (I''-3), (I''-3-H), (I''-4) and (I''-4-H) with substituents as described before or preferably described before having a polymerizable group as described before or preferably described before or below are preferred in case the substituent -R ₂ - within the at least one linking element Y-R ₂ - corresponds to–(C(R) ₂ ) _o –, wherein R and o has a meaning as described or preferably described before.

Accordingly monomers of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I'), (I'-a), (I'-b), (I'-c), (I'-d), (I'-1), (I'-2), (I'-2-H), (I'-3), (I'-3-H), (I'-4), (I'-4-H) (I''), (I''-1), (I''-2), (I''-2-H), (I''-3), (I''-3-H), (I''-4) and (I''-4-H) for the preparation of an ophthalmic device or precursor article for an ophthalmic device as described before with substituents as described before or preferably described before having a polymerizable group as described before or preferably described before or below are preferred in case the substituent -R2- within the at least one linking element Y-R2- corresponds to–(C(R) ₂ ) _o –, wherein R and o has a meaning as described or preferably described before. Such ophthalmic devices and precursor articles prepared by using these monomers are especially preferred. Particularly preferred examples for -R2- are -(CH ₂ )3-, -(CH ₂ )4-, -(CH ₂ )5-, - (CH ₂ )6-, -(CH ₂ )7- according to the invention. Very particularly preferably, - R2- is -(CH ₂ )5- according to the invention. Therefore, the invention is furthermore directed to an ophthalmic device or precursor article for an ophthalmic device comprising polymerized compounds of formulae (I), (I-1), (I-2), (I-2-H), (I-3), (I-3-H), (I-4), (I-4-H), (I''), (I''-1), (I''-2), (I''-2-H), (I''-3), (I''-3-H), (I''-4) and (I''-4-H) as described before or preferably described before wherein -R2- is at each occurrence independently–(C(R) ₂ )o–, wherein R and o have a meaning as described or preferably described before.

The invention therefore relates to compounds of formulae (I), (I#), (I-1), (I- 2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I'), (I'-a), (I'-b), (I'-c), (I'-d), (I'-1), (I'-2), (I'-2-H), (I'-3), (I'-3-H), (I'-4), (I'-4-H) (I''), (I''-1), (I''-2), (I''-2-H), (I''-3), (I''-3-H), (I''-4) and (I''-4-H) as described before or preferably described before wherein -R2- is at each occurrence independently–(C(R) ₂ )o–, wherein R and o have a meaning as described or preferably described before. The substituent Y-R ₂ - within formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3- H), (I-4), (I-4-H), (I'), (I'-a), (I'-b), (I'-c), (I'-d), (I'-1), (I'-2), (I'-2-H), (I'-3), (I'-3- H), (I'-4), (I'-4-H) (I''), (I''-1), (I''-2), (I''-2-H), (I''-3), (I''-3-H), (I''-4) and (I''-4-H) is selected from the group consisting of O-R2-, -R2- where Y is a bond, SO ₂ - R ₂ - and S-R ₂ - _, wherein -R ₂ - has a meaning as described before or preferably or particularly preferably described before.

The substituent Y-R2- is preferably selected from the group consisting of O- R ₂ - and -R ₂ - where Y is a bond wherein -R ₂ - has a meaning as described before or preferably or particularly preferably described before. The substituent Y-R ₂ -R ₁ within formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I- 3-H), (I-4), (I-4-H), (I'), (I'-a), (I'-b), (I'-c), (I'-d), (I'-1), (I'-2), (I'-2-H), (I'-3), (I'- 3-H), (I'-4), (I'-4-H) (I''), (I''-1), (I''-2), (I''-2-H), (I''-3), (I''-3-H), (I''-4) and (I''-4- H) is selected from the group consisting of O-R ₂ -R ₁ , -R ₂ -R _1, SO ₂ -R ₂ -R ₁ and S-R2-R1, or preferably selected from the group consisting of O-R2-R1 and - R2-R1, wherein -R2- has a meaning as described before or preferably or particularly preferably described before and wherein R1 is trimethoxysilyl, dimethoxymethylsilyl or a polymerizable group according to formula (4),

,

wherein

X ₁₁ is selected from the group consisting of O, S, O-SO ₂ , SO ₂ -O, C(=O), OC(=O), C(=O)O, S(C=O) and (C=O)S,

R10, R11, R12 are at each occurrence independently of each other selected from the group consisting of H, F, a linear or branched, non- fluorinated, partially or completely fluorinated alkyl group having 1 to 20 C atoms or aryl with 6 to 14 C atoms and c is 0 or 1. In another preferred embodiment of the invention, c, 11, R ₁₀ , R ₁₁ and R ₁₂ within the compounds of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I- 4), (I-4-H), (I'), (I'-a), (I'-b), (I'-c), (I'-d), (I'-1), (I'-2), (I'-2-H), (I'-3), (I'-3-H), (I'- 4), (I'-4-H) (I''), (I''-1), (I''-2), (I''-2-H), (I''-3), (I''-3-H), (I''-4) and (I''-4-H) acting as monomers for the preparation of the ophthalmic device or precursor article of the ophthalmic device as described before or for the preparation of an oligomer, polymer or copolymer according to the invention or within the compounds according to the invention have the following preferred meaning:

Preferably, R11 and R12 are H. Preferably, c is 1.

Preferably, R ₁₀ is H, methyl, ethyl or phenyl. Particularly preferably, R ₁₀ is H or methyl.

Preferably, X11 is C(=O), OC(=O) or C(=O)O. Particularly preferably, X11 is C(=O)O. Preferred alkenyl groups of formula (4) as polymerizable groups R1 according to the invention are therefore represented by any one selected from the group consisting of formulae (4-1), (4-2), (4-3), (4-4), (4-5), (4-6), (4-7), (4-8), (4-9), (4-10), (4-11) and (4-12):

Particularly preferred alkenyl groups of formula (4) as polymerizable groups R ₁ according to the invention are represented by any one selected from the group consisting of formulae (4-1), (4-2), (4-3), (4-5), (4-6), (4-11) and (4- 12) as described before. The alkenyl group represented by formula (4-1) is called methacrylate. The alkenyl group represented by formula (4-2) is called acrylate. The preferred groups R ₁ are preferably combined with preferred groups of the linking element -R2- and/or the linking element Y-R2-. Combinations are excluded where two O atoms or one O atom and one S atom are directly bonded to each other as known for a skilled artisan in the field of organic chemistry. The substituent Y-R ₂ -R ₁ within formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I- 3-H), (I-4), (I-4-H), (I'), (I'-a), (I'-b), (I'-c), (I'-d), (I'-1), (I'-2), (I'-2-H), (I'-3), (I'- 3-H), (I'-4), (I'-4-H) (I''), (I''-1), (I''-2), (I''-2-H), (I''-3), (I''-3-H), (I''-4) and (I''-4- H) is therefore particularly preferably selected from the group consisting of O-R ₁ , O-(CH ₂ ) ₃ -R ₁ , O-(CH ₂ ) ₄ -R ₁ , O-(CH ₂ ) ₅ -R ₁ , O-(CH ₂ ) ₆ -R ₁ , O-(CH ₂ ) ₇ -R ₁ , - O-(CH ₂ ) ₈ -R ₁ , -O-(CH ₂ ) ₉ -R ₁ , -O-(CH ₂ ) ₁₀ -R ₁ , -O-(CH ₂ ) ₁₁ -R ₁ , -O-(CH ₂ ) ₁₂ -R _1, -O- (CH ₂ ) ₂ -S-(CH ₂ ) ₂ -R1, -O-(CH ₂ ) ₂ -SO ₂ -(CH ₂ ) ₂ -R1, O-(CH ₂ )-S-(CH ₂ ) ₂ -O-(CH ₂ )- R ₁ , O-(CH ₂ )-SO ₂ -(CH ₂ ) ₂ -O-(CH ₂ )-R ₁ , O-(CH ₂ )-SO ₂ -(CH ₂ ) ₂ -S-(CH ₂ )-R ₁ , O- (CH ₂ )-O-(CH ₂ ) ₂ -S-(CH ₂ ) ₂ -O-(CH ₂ )-R ₁ , O-(CH ₂ )-S-(CH ₂ ) ₂ -O-(CH ₂ ) ₂ -S-(CH ₂ )- R ₁ , O-(CH ₂ )-SO ₂ -(CH ₂ ) ₂ -O-(CH ₂ ) ₂ -SO ₂ -(CH ₂ )-R ₁ , O-(CH ₂ )-S-(CH ₂ ) ₂ -S- (CH ₂ ) ₂ -S-(CH ₂ )-R1, O-(CH ₂ )-SO ₂ -(CH ₂ ) ₂ -SO ₂ -(CH ₂ ) ₂ -SO ₂ -(CH ₂ )-R1, O- (CH ₂ )-O-(CH ₂ ) ₂ -SO ₂ -(CH ₂ ) ₂ -O-(CH ₂ )-R1, -O-(CH ₂ )3-(CF2)-(CH ₂ )3-R1, -O- (CH ₂ )-(CF2)3-(CH ₂ )-R1, -O-(CH ₂ ) ₂ -(CF2)4-(CH ₂ ) ₂ -R1, -O-(CH ₂ )-[CH(CF3)]- (CH ₂ )-R ₁ , -O-(CH ₂ )-[C(CH ₃ )CF ₃ ]-(CH ₂ )-R ₁ , -O-(CH ₂ )-[CH(CH ₂ CF ₃ )]-(CH ₂ )- R1, -O-(CH ₂ )-[C(CH ₃ )(CH ₂ CF3)]-(CH ₂ )-R1, -O-(CH ₂ ) ₂ -(CF2)-O-(CF2)-O- (CF2)-(CH ₂ ) ₂ -R1 and -O-(CH ₂ )-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH ₂ )-R1, wherein R ₁ is selected from the group consisting of an alkenyl of formula (4- 1), (4-2), (4-3), (4-4), (4-5), (4-6), (4-7), (4-8), (4-9), (4-10), (4-11), or (4-12); -(CH ₂ ) ₃ -R ₁ , -(CH ₂ ) ₄ -R ₁ , -(CH ₂ ) ₅ -R ₁ , -(CH ₂ ) ₆ -R ₁ , -(CH ₂ ) ₇ -R ₁ , -(CH ₂ ) ₈ -R ₁ , - (CH ₂ ) ₉ -R ₁ , -(CH ₂ ) ₁₀ -R ₁ , -(CH ₂ ) ₁₁ -R ₁ , -(CH ₂ ) ₁₂ -R _1, -(CH ₂ ) ₂ -S-(CH ₂ ) ₂ -R ₁ , - (CH ₂ ) ₂ -SO ₂ -(CH ₂ ) ₂ -R1, -(CH ₂ )-S-(CH ₂ ) ₂ -O-(CH ₂ )-R1, -(CH ₂ )-SO ₂ -(CH ₂ ) ₂ -O- (CH ₂ )-R ₁ , -(CH ₂ )-SO ₂ -(CH ₂ ) ₂ -S-(CH ₂ )-R ₁ , -(CH ₂ )-O-(CH ₂ ) ₂ -S-(CH ₂ ) ₂ -O- (CH ₂ )-R1, -(CH ₂ )-S-(CH ₂ ) ₂ -O-(CH ₂ ) ₂ -S-(CH ₂ )-R1, -(CH ₂ )-SO ₂ -(CH ₂ ) ₂ -O- (CH ₂ ) ₂ -SO ₂ -(CH ₂ )-R1, -(CH ₂ )-S-(CH ₂ ) ₂ -S-(CH ₂ ) ₂ -S-(CH ₂ )-R1, -(CH ₂ )-SO ₂ - (CH ₂ ) ₂ -SO ₂ -(CH ₂ ) ₂ -SO ₂ -(CH ₂ )-R1, -(CH ₂ )-O-(CH ₂ ) ₂ -SO ₂ -(CH ₂ ) ₂ -O-(CH ₂ )-R1, -(CH ₂ ) ₃ -(CF ₂ )-(CH ₂ ) ₃ -R ₁ , -(CH ₂ )-(CF ₂ ) ₃ -(CH ₂ )-R ₁ , -(CH ₂ ) ₂ -(CF ₂ ) ₄ -(CH ₂ ) ₂ -R ₁ , - (CH ₂ )-[CH(CF3)]-(CH ₂ )-R1, -(CH ₂ )-[C(CH ₃ )CF3]-(CH ₂ )-R1, -(CH ₂ )- [CH(CH ₂ CF3)]-(CH ₂ )-R1, -(CH ₂ )-[C(CH ₃ )(CH ₂ CF3)]-(CH ₂ )-R1, -(CH ₂ ) ₂ -(CF2)- O-(CF ₂ )-O-(CF ₂ )-(CH ₂ ) ₂ -R ₁ and -(CH ₂ )-(CF ₂ )-O-(CF ₂ )-O-(CF ₂ )-O-(CF ₂ )- (CH ₂ )-R1, -, where Y is a bond and wherein R1 is selected from the group consisting of an alkenyl of formula (4-1), (4-2), (4-3), (4-4), (4-5), (4-6), (4- 7), (4-8), (4-9), (4-10), (4-11), or (4-12); S-R1, S-(CH ₂ )3-R1, S-(CH ₂ )4-R1, S-(CH ₂ )5-R1, S-(CH ₂ )6-R1, S-(CH ₂ )7-R1, S- (CH ₂ ) ₈ -R ₁ , S-(CH ₂ ) ₉ -R ₁ , S-(CH ₂ ) ₁₀ -R ₁ , S-(CH ₂ ) ₁₁ -R ₁ , S-(CH ₂ ) ₁₂ -R _1, -S- (CH ₂ ) ₂ -S-(CH ₂ ) ₂ -R ₁ , -S-(CH ₂ ) ₂ -SO ₂ -(CH ₂ ) ₂ -R ₁ , S-(CH ₂ )-S-(CH ₂ ) ₂ -O-(CH ₂ )- R1, S-(CH ₂ )-SO ₂ -(CH ₂ ) ₂ -O-(CH ₂ )-R1, S-(CH ₂ )-SO ₂ -(CH ₂ ) ₂ -S-(CH ₂ )-R1, S- (CH ₂ )-O-(CH ₂ ) ₂ -S-(CH ₂ ) ₂ -O-(CH ₂ )-R1, S-(CH ₂ )-S-(CH ₂ ) ₂ -O-(CH ₂ ) ₂ -S-(CH ₂ )- R ₁ , S-(CH ₂ )-SO ₂ -(CH ₂ ) ₂ -O-(CH ₂ ) ₂ -SO ₂ -(CH ₂ )-R ₁ , S-(CH ₂ )-S-(CH ₂ ) ₂ -S- (CH ₂ ) ₂ -S-(CH ₂ )-R ₁ , S-(CH ₂ )-SO ₂ -(CH ₂ ) ₂ -SO ₂ -(CH ₂ ) ₂ -SO ₂ -(CH ₂ )-R ₁ , S- (CH ₂ )-O-(CH ₂ ) ₂ -SO ₂ -(CH ₂ ) ₂ -O-(CH ₂ )-R ₁ , S-(CH ₂ ) ₃ -(CF ₂ )-(CH ₂ ) ₃ -R ₁ , S-(CH ₂ )- (CF2)3-(CH ₂ )-R1, S-(CH ₂ ) ₂ -(CF2)4-(CH ₂ ) ₂ -R1, S-(CH ₂ )-[CH(CF3)]-(CH ₂ )-R1, S-(CH ₂ )-[C(CH ₃ )CF3]-(CH ₂ )-R1, S-(CH ₂ )-[CH(CH ₂ CF3)]-(CH ₂ )-R1, S-(CH ₂ )- [C(CH ₃ )(CH ₂ CF3)]-(CH ₂ )-R1, S-(CH ₂ ) ₂ -(CF2)-O-(CF2)-O-(CF2)-(CH ₂ ) ₂ -R1 and S-(CH ₂ )-(CF ₂ )-O-(CF ₂ )-O-(CF ₂ )-O-(CF ₂ )-(CH ₂ )-R ₁ , wherein R ₁ is selected from the group consisting of an alkenyl of formula (4-1), (4-2), (4-3), (4-4), (4-5), (4-6), (4-7), (4-8), (4-9), (4-10), (4-11), or (4-12); SO ₂ -(CH ₂ )3-R1, SO ₂ -(CH ₂ )4-R1, SO ₂ -(CH ₂ )5-R1, SO ₂ -(CH ₂ )6-R1, SO ₂ -(CH ₂ )7- R1, SO ₂ -(CH ₂ )8-R1, SO ₂ -(CH ₂ )9-R1, SO ₂ -(CH ₂ )10-R1, SO ₂ -(CH ₂ )11-R1, SO ₂ - (CH ₂ ) ₁₂ -R _1, SO ₂ -(CH ₂ ) ₂ -S-(CH ₂ ) ₂ -R ₁ , SO ₂ -(CH ₂ ) ₂ -SO ₂ -(CH ₂ ) ₂ -R ₁ , SO ₂ -(CH ₂ )- S-(CH ₂ ) ₂ -O-(CH ₂ )-R ₁ , SO ₂ -(CH ₂ )-SO ₂ -(CH ₂ ) ₂ -O-(CH ₂ )-R ₁ , SO ₂ -(CH ₂ )-SO ₂ - (CH ₂ ) ₂ -S-(CH ₂ )-R1, SO ₂ -(CH ₂ )-O-(CH ₂ ) ₂ -S-(CH ₂ ) ₂ -O-(CH ₂ )-R1, SO ₂ -(CH ₂ )- S-(CH ₂ ) ₂ -O-(CH ₂ ) ₂ -S-(CH ₂ )-R ₁ , SO ₂ -(CH ₂ )-SO ₂ -(CH ₂ ) ₂ -O-(CH ₂ ) ₂ -SO ₂ -(CH ₂ )- R1, SO ₂ -(CH ₂ )-S-(CH ₂ ) ₂ -S-(CH ₂ ) ₂ -S-(CH ₂ )-R1, SO ₂ -(CH ₂ )-SO ₂ -(CH ₂ ) ₂ -SO ₂ - (CH ₂ ) ₂ -SO ₂ -(CH ₂ )-R1, SO ₂ -(CH ₂ )-O-(CH ₂ ) ₂ -SO ₂ -(CH ₂ ) ₂ -O-(CH ₂ )-R1, SO ₂ - (CH ₂ )3-(CF2)-(CH ₂ )3-R1, SO ₂ -(CH ₂ )-(CF2)3-(CH ₂ )-R1, SO ₂ -(CH ₂ ) ₂ -(CF2)4- (CH ₂ ) ₂ -R ₁ , SO ₂ -(CH ₂ )-[CH(CF ₃ )]-(CH ₂ )-R ₁ , SO ₂ -(CH ₂ )-[C(CH ₃ )CF ₃ ]-(CH ₂ )- R1, SO ₂ -(CH ₂ )-[CH(CH ₂ CF3)]-(CH ₂ )-R1, SO ₂ -(CH ₂ )-[C(CH ₃ )(CH ₂ CF3)]- (CH ₂ )-R1, SO ₂ -(CH ₂ ) ₂ -(CF2)-O-(CF2)-O-(CF2)-(CH ₂ ) ₂ -R1 and SO ₂ -(CH ₂ )- (CF ₂ )-O-(CF ₂ )-O-(CF ₂ )-O-(CF ₂ )-(CH ₂ )-R ₁ , wherein R ₁ is selected from the group consisting of an alkenyl of formula (4-1), (4-2), (4-3), (4-4), (4-5), (4- 6), (4-7), (4-8), (4-9), (4-10), (4-11), or (4-12). Particularly preferably, the compounds of formulae (I), (I#), (I-1), (I-2), (I- 2H), (I-3), (I-3-H), (I-4), (I-4-H), (I'), (I'-1), (I'-2), (I'-2-H), (I'-3), (I'-3-H), (I'-4), (I'-4-H) (I''), (I''-1), (I''-2), (I''-2-H), (I''-3), (I''-3-H), (I''-4) and (I''-4-H) comprise a polymerizable group R ₁ which is represented by formulae (4-1), (4-2), (4- 5), (4-6), (4-11) and (4-12). Very particularly preferably, the compounds of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I'), (I'-1), (I'-2), (I'-2-H), (I'-3), (I'-3-H), (I'- 4), (I'-4-H) (I''), (I''-1), (I''-2), (I''-2-H), (I''-3), (I''-3-H), (I''-4) and (I''-4-H) comprise a polymerizable group R1 which is a methacryl or an acryl group represented by formula (4-1) and (4-2). The invention therefore relates further to an ophthalmic device or a precursor article for an ophthalmic device comprising polymerized compounds of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4- H), (I'), (I'-1), (I'-2), (I'-2-H), (I'-3), (I'-3-H), (I'-4), (I'-4-H) (I''), (I''-1), (I''-2), (I''- 2-H), (I''-3), (I''-3-H), (I''-4) and/or (I''-4-H) as described before or preferably described before wherein R1 is at each occurrence independently an acryl or methacryl group.

The invention therefore relates further to compounds of formulae (I), (I#), (I- 1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I'), (I'-1), (I'-2), (I'-2-H), (I'-3), (I'- 3-H), (I'-4), (I'-4-H) (I''), (I''-1), (I''-2), (I''-2-H), (I''-3), (I''-3-H), (I''-4) and/or (I''- 4-H) as described before or preferably described before wherein R1 is at each occurrence independently an acryl or methacryl group. Examples for compounds/monomers of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I'), (I'-a), (I'-b), (I'-c), (I'-d), (I'-1), (I'-2), (I'-2-H), (I'-3), (I'-3-H), (I'-4), (I'-4-H) (I''), (I''-1), (I''-2), (I''-2-H), (I''-3), (I''-3-H), (I''-4) and/or (I''-4-H) are the following compounds (A-001) to (A-180) as shown in tables 1 and 1-1. Table 1:

Preferred examples for compounds/monomers of formulae (I), (I#), (I-1), (I- 2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I'), (I'-a), (I'-b), (I'-c), (I'-d), (I'-1), (I'-2), (I'-2-H), (I'-3), (I'-3-H), (I'-4), (I'-4-H) (I''), (I''-1), (I''-2), (I''-2-H), (I''-3), (I''-3-H), (I''-4) and/or (I''-4-H) are the following compounds as shown in table 1-1. Table 1-1:

The compounds of the present application may be synthesized by methods well known to the skilled person. Preferably, all syntheses are carried out under an inert atmosphere using dried solvents.

An exemplary reaction sequence is shown in Scheme 1 for the compounds of formula (I#) where A is CH ₂ , m is 1, Y is O, -R ₂ - is -(CH ₂ ) _o -, m1 is 0, R ₆ and R7 are H and R1 is an alkenyl of formula (4-2) and R3, R4, R5, R8, R9, R' and n1 have a meaning as described or preferably described before.

In all schemes, Me is methyl.

Scheme 1:

The first type of reaction is the formation of a stable enol equivalent.

The second type of reaction is a Suzuki reaction.

The third type of reaction is a methoxy-deprotection reaction.

The fourth type of reaction is a Williamson ether synthesis reaction.

The fifth type of reaction is an esterification reaction. All these types of reaction and their reaction conditions are well known to a skilled person and can be easily optimized for the specific starting materials forming the compounds of formula (I). More details can be found in the experimental section. A representative synthesis according to Scheme 1 is described in Scheme 1-1.

Scheme 1-1:

. Another exemplary reaction sequence is shown in Scheme 2 for the compounds of formula (I#) where A is CH ₂ , m is 1, Y is a bond, -R2- is - (CH ₂ )o-, m1 is 0, R6 and R7 are H and R1 is an alkenyl of formula (4-2) and R3, R4, R5, R8, R9, R' and n1 have a meaning as described or preferably described before.

. The first type of reaction is the formation of a stable enol equivalent.

The second type of reaction is Suzuki reaction.

The third type of reaction is a methoxy-deprotection reaction.

The fourth type of reaction is triflation reaction.

The fifth type of reaction is a cross-coupling reaction.

The sixth type of reaction is an acid-catalyzed deprotection reaction. The seventh type of reaction is an esterification reaction. All these types of reaction and their reaction conditions are well known to a skilled person and can be easily optimized for the specific starting materials forming the compounds of formula (I). More details can be found in the experimental section. A representative synthesis according to Scheme 1 is described in Scheme 2-1. Scheme 2-1: Scheme 2-1 continued:

.

Another exemplary reaction sequence is shown in Scheme 3 for the compounds of formula (I#) where A is CH ₂ , m is 2, Y is O, -R2- is -(CH ₂ )o-, m1 is 0, R ₆ and R ₇ are H and R ₁ is an alkenyl of formula (4-2) and R ₃ , R ₄ , R ₅ , R ₈ , R ₉ , R' and n1 have a meaning as described or preferably described before. Scheme 3:

. The first type of reaction is a Wittig reaction.

The second type of reaction is a hypervalent iodine-mediated ring- expansion reaction. The third type of reaction is the formation of a stable enol equivalent. The fourth type of reaction is a Suzuki reaction.

The fifth type of reaction is a methoxy-deprotection reaction. The sixth type of reaction is an esterification reaction.

All these types of reaction and their reaction conditions are well known to a skilled person and can be easily optimized for the specific starting materials forming the compounds of formula (I). More details can be found in the experimental section. A representative synthesis according to Scheme 3 is described in Scheme 3-1. Scheme 3-1:

. Another exemplary reaction sequence is shown in Scheme 4 for the compounds of formula (I#) where A is CH ₂ , m is 2, Y is a bond, -R ₂ - is - (CH ₂ )o-, m1 is 0, R6 and R7 are H and R1 is an alkenyl of formula (4-2) and R3, R4, R5, R8, R9, R' and n1 have a meaning as described or preferably described before. Scheme 4:

. The first type of reaction is a Wittig reaction. The second type of reaction is a hypervalent iodine-mediated ring- expansion reaction. The third type of reaction is the formation of a stable enol equivalent. The fourth type of reaction is a Suzuki reaction.

The fifth type of reaction is a methoxy-deprotection reaction. The sixth type of reaction is a triflation reaction. The seventh type of reaction is a cross- coupling reaction. The eight type of reaction is an acid-catalyzed deprotection reaction. The ninth type of reaction is an esterification reaction. All these types of reaction and their reaction conditions are well known to a skilled person and can be easily optimized for the specific starting materials forming the compounds of formula (I). More details can be found in the experimental section. A representative synthesis according to Scheme 4 is described in Scheme 4-1. Scheme 4-1:

. Another exemplary reaction sequence is shown in Scheme 5-1 for the compounds of formula (I#) where A is CH ₂ , m is 2, Y is O, -R2- is -(CH ₂ )5-, m1 is 1, n is 0, R6 and R7 are H and R9 is an alkenyl of formula (4-11) or (4- 12) and R3, R4, R5, R8, R9, R' and n1 have a meaning as described or preferably described before.

Scheme 5-1:

Another exemplary reaction sequence is shown in Scheme 6 for the compounds of formula (I#) where A is CH ₂ , m is 2, Y is O, -R2- is -(CH ₂ )o-, m1 is 0, n is 1, R6 and R7 are H, R9 is H or R' and R1 is a methyl- diethoxysilyl group and R3, R4, R5, R8, R' and n1 have a meaning as described or preferably described before. Scheme 6:

. The first type of reaction is a Wittig reaction. The second type of reaction is a hypervalent iodine-mediated ring-expansion reaction. The third type of reaction is the formation of a stable enol equivalent. The fourth type of reaction is a Suzuki reaction. The fifth type of reaction is a methoxy- deprotection reaction. The sixth type of reaction is a Mitsunobu reaction. The seventh type is a hydrosylilation reaction. A representative synthesis according to Scheme 6 is described in Scheme 6-1.

Scheme 6-1:

As described before, the compounds/monomers of formula (I), (I#), (I-1), (I- 2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I'), (I'-a), (I'-b), (I'-c), (I'-d), (I'-1), (I'-2), (I'-2-H), (I'-3), (I'-3-H), (I'-4), (I'-4-H) (I''), (I''-1), (I''-2), (I''-2-H), (I''-3), (I''-3-H), (I''-4) and (I''-4-H) as described before or preferably described before contain a polymerizable group and are predestinated as monomers for an oligomerization or a polymerization. The invention is therefore further directed to an oligomer, polymer or copolymer comprising at least one polymerized compound of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I'), (I'-a), (I'-b), (I'-c), (I'-d), (I'-1), (I'-2), (I'-2-H), (I'-3), (I'-3-H), (I'-4), (I'-4-H) (I''), (I''-1), (I''-2), (I''-2-H), (I''- 3), (I''-3-H), (I''-4) or (I''-4-H) as described before or preferably described before where oligomers, polymers and copolymers of 2-(4- vinylphenyl)indene and 2-[4-(2-propen-1-yl)phenyl-1H-indene are excluded. The term "polymer" generally means a molecule of high relative molecular mass, the structure of which essentially comprises the multiple repetition of units derived, actually or conceptually, from molecules of low relative molecular mass (PAC, 1996, 68, 2291). The term“polymer” includes homopolymers and copolymers if not mentioned otherwise within the description. The term "oligomer" generally means a molecule of

intermediate relative molecular mass, the structure of which essentially comprises a small plurality of units derived, actually or conceptually, from molecules of lower relative molecular mass (PAC, 1996, 68, 2291). In a preferred sense according to the present invention a polymer means a compound having ³ 30 repeating units, and an oligomer means a

compound with > 1 and < 30 repeating units. Above and below, in formulae showing a polymer, an oligomer, a

compound of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I'), (I'-a), (I'-b), (I'-c), (I'-d), (I'-1), (I'-2), (I'-2-H), (I'-3), (I'-3-H), (I'-4), (I'-4-H) (I''), (I''-1), (I''-2), (I''-2-H), (I''-3), (I''-3-H), (I''-4) or (I''-4-H) or a monomeric unit or a polymer formed from a compound of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I'), (I'-a), (I'-b), (I'-c), (I'-d), (I'-1), (I'-2), (I'- 2-H), (I'-3), (I'-3-H), (I'-4), (I'-4-H) (I''), (I''-1), (I''-2), (I''-2-H), (I''-3), (I''-3-H), (I''-4) or (I''-4-H), an asterisk ("*") denotes a linkage to the adjacent repeating unit in the polymer chain or oligomer chain or to a terminal end group. Suitable terminal end groups are known to the skilled artisan and depend on the polymerization method used. The terms "repeating unit" and "monomeric unit" mean the constitutional repeating unit (CRU), which is the smallest constitutional unit the repetition of which constitutes a regular macromolecule, a regular oligomer molecule, a regular block or a regular chain (PAC, 1996, 68, 2291). Unless stated otherwise, the molecular weight is given as the number average molecular weight Mn or weight average molecular weight MW, which is determined by gel permeation chromatography (GPC) against polystyrene standards in eluent solvents such as tetrahydrofuran, trichloromethane (TCM, chloroform), chlorobenzene or 1,2,4-trichloro- benzene. Unless stated otherwise, tetrahydrofuran is used as solvent. The degree of polymerization (n) means the number average degree of polymerization given as n = Mn/MU, wherein MU is the molecular weight of the single repeating unit as described in J. M. G. Cowie, Polymers:

Chemistry & Physics of Modern Materials, Blackie, Glasgow, 1991. In the polymers including copolymers according to the present invention, the total number of repeating units n is preferably ³ 30, very preferably ^ 100, most preferably ³ 200, and preferably up to 5000, very preferably up to 3000, most preferably up to 2000, including any combination of the aforementioned lower and upper limits of n. The polymers of the present invention include homopolymers, statistical copolymers, random copolymers, alternating copolymers and block copolymers, and combinations of the aforementioned. Throughout the description and claims of this specification, the words “comprise” and“contain” and variations of the words, for example “comprising” and“comprises”, mean“including but not limited to”, and are not intended to (and do not) exclude other components Preferably the polymerizable group R1 forms the regioregular, alternated, regiorandom, statistical, block or random homopolymer or copolymer backbone or is part of the polymer backbone where R ₁ has a meaning as described or preferably described before.

Preferably, such oligomer, polymer or copolymer according to the invention comprises a constitutional unit M ⁰ based on formulae (I), (I') or (I'')

,

, where the polymerizable group R ₁ on each occurrence is polymerized and forms the regioregular, alternated, regiorandom, statistical, block or random oligomer or polymer backbone or is part of the copolymer backbone. The invention is furthermore directed to an ophthalmic device or a precursor article for an ophthalmic device as described before or preferably described below comprising an oligomer, polymer or copolymer comprising a constitutional unit M ⁰ based on formulae (I), (I') or (I'') as described before or preferably described before where R1 on each occurrence is polymerized and forms the regioregular, alternated, regiorandom, statistical, block or random oligomer or polymer backbone or is part of the copolymer backbone. Preferably, such polymerized groups R ₁ are of formulae (1-p), (2-p), (3-p) or (4-p)

, , , , where the asterisk“*” within formulae (1-p) to (4-p) denotes a linkage to the adjacent repeating unit in the polymer chain or oligomer chain or to a terminal end group, the asterisk“**” within formulae (1-p) to (4-p) denotes the linkage to the remainder of formula (I) as described before or preferably described before and R10, R11, R12, X11 and c has a meaning as described before or preferably described before. The invention is furthermore directed to an ophthalmic device or a precursor article for an ophthalmic device as described before or preferably described below where said polymerized group R ₁ is of formulae (1-p), (2- p), (3-p) or (4-p) as described before. The invention is furthermore directed to an oligomer, polymer or copolymer as described before or preferably described below where said polymerized group R1 is of formulae (1-p), (2-p), (3-p) or (4-p) as described before. Particularly preferably, such oligomer, polymer or copolymer according to the invention comprises a constitutional unit M ⁰ of formulae (M ⁰ -I'), (M ⁰ -I''), (M ⁰ -I'-1), (M ⁰ -I''-1), (M ⁰ -I'-2-H), (M ⁰ -I''-2-H), (M ⁰ -I'-3-H), (M ⁰ -I''-3-H), (M ⁰ -I'-4- H) or (M ⁰ -I''-4-H),

, wherein -R ₂ -, Y, R ₃ , R ₄ , R ₅ , R ₆ , R ₇ , R ₈ , A, m, R', n1, X ₁₁ , R ₁₀ , R ₁₁ , R ₁₂ and c have a meaning as described before or preferably described before or below for the compounds of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3- H), (I-4), (I-4-H), (I'), (I'-a), (I'-b), (I'-c), (I'-d), (I'-1), (I'-2), (I'-2-H), (I'-3), (I'-3- H), (I'-4), (I'-4-H) (I''), (I''-1), (I''-2), (I''-2-H), (I''-3), (I''-3-H), (I''-4) and (I''-4-H) and R9 is H or R' for compounds of formulae (M ⁰ -I'), (M ⁰ -I'-1), (M ⁰ -I'-2-H), (M ⁰ -I'-3-H) or (M ⁰ -I'-4-H). Combinations are excluded where two O atoms or an O atom and a S atom are directly linked to each other as known for a skilled artisan in the field of organic chemistry. The invention is furthermore directed to an ophthalmic device or a precursor article for an ophthalmic device as described before or preferably described below wherein the constitutional unit M ⁰ is of formulae (M ⁰ -I'-a), (M ⁰ -I'-b), (M ⁰ -I'-c), (M ⁰ -I'-d) or (M ⁰ -I'') as described before and where the asterisk“*” denotes at each occurrence a linkage to the adjacent repeating unit in the polymer chain or oligomer chain or to a terminal end group. Preferably, such oligomer, polymer or copolymer according to the invention comprises a constitutional unit M ⁰ of formulae (M ⁰ -I'), (M ⁰ -I''), (M ⁰ -I'-1), (M ⁰ - I''-1), (M ⁰ -I'-2-H), (M ⁰ -I''-2-H), (M ⁰ -I'-3-H), (M ⁰ -I''-3-H), (M ⁰ -I'-4-H) or (M ⁰ -I''-4- H), as described before, wherein

-R ₂ - is selected from -(CH ₂ ) ₃ -, -(CH ₂ ) ₄ -, -(CH ₂ ) ₅ -, -(CH ₂ ) ₆ -, -(CH ₂ ) ₇ -, -(CH ₂ ) ₈ -, -(CH ₂ )9-, -(CH ₂ )10-, -(CH ₂ )11-, -(CH ₂ ) ₂ -S-(CH ₂ ) ₂ -, -(CH ₂ ) ₂ -SO ₂ -(CH ₂ ) ₂ -, - (CH ₂ )-S-(CH ₂ ) ₂ -O-(CH ₂ )-, -(CH ₂ )-SO ₂ -(CH ₂ ) ₂ -O-(CH ₂ )-, -(CH ₂ )-SO ₂ -(CH ₂ ) ₂ - S-(CH ₂ )-, -(CH ₂ )-O-(CH ₂ ) ₂ -S-(CH ₂ ) ₂ -O-(CH ₂ )-, -(CH ₂ )-S-(CH ₂ ) ₂ -O-(CH ₂ ) ₂ -S- (CH ₂ )-, -(CH ₂ )-SO ₂ -(CH ₂ ) ₂ -O-(CH ₂ ) ₂ -SO ₂ -(CH ₂ )-, -(CH ₂ )-S-(CH ₂ ) ₂ -S-(CH ₂ ) ₂ - S-(CH ₂ )-, -(CH ₂ )-SO ₂ -(CH ₂ ) ₂ -SO ₂ -(CH ₂ ) ₂ -SO ₂ -(CH ₂ )-, -(CH ₂ )-O-(CH ₂ ) ₂ -SO ₂ - (CH ₂ ) ₂ -O-(CH ₂ )-, -(CH ₂ ) _12, -(CH ₂ ) ₃ -(CF ₂ )-(CH ₂ ) ₃ -, -(CH ₂ )-(CF ₂ ) ₃ -(CH ₂ )-, - (CH ₂ ) ₂ -(CF2)4-(CH ₂ ) ₂ -, -(CH ₂ )-[CH(CF3)]-(CH ₂ )-, -(CH ₂ )-[C(CH ₃ )CF3]-(CH ₂ )-, -(CH ₂ )-[CH(CH ₂ CF3)]-(CH ₂ )-, -(CH ₂ )-[C(CH ₃ )(CH ₂ CF3)]-(CH ₂ )-, -(CH ₂ ) ₂ - (CF ₂ )-O-(CF ₂ )-O-(CF ₂ )-(CH ₂ ) ₂ - and -(CH ₂ )-(CF ₂ )-O-(CF ₂ )-O-(CF ₂ )-O-(CF ₂ )- (CH ₂ )- or has a meaning as preferably described before;

Y is O, S, SO ₂ , or a bond or has a meaning as preferably described before; R3, R4 and R8 are H, F, a straight-chain alkyl group with 1 to 4 C atoms or a straight-chain alkoxy group with 1 to 4 C atoms or has a meaning as preferably described before;

R ₅ is H, F, CN, SO ₂ CF ₃ , CF ₃ , CF ₂ CF ₃ , or CH ₂ CF ₃ or has a meaning as preferably described before;

R6 and R7 are H, F, a linear or branched alkyl group having 1 to 4 C atoms or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms or has a meaning as preferably described before; A is CH ₂ or CHR ₀ and R ₀ has a meaning as described before or preferably described before or A is preferably CH ₂ ;

m is 0, 1, 2 or 3 or has a meaning as preferably described before;

R' is selected from the group consisting of F, a linear or branched partially or fully fluorinated alkyl group having 1 to 10 C atoms, a linear or branched alkyl group having 1 to 10 C atoms, a linear or branched alkoxy group having 1 to 10 C atoms, a linear or branched partially or fully fluorinated alkoxy group having 1 to 10 C atoms and a linear or branched thioalkyl group having 1 to 10 C atoms or has a meaning as preferably described before;

n ₁ is 0, 1, 2, 3 or 4 or has a meaning as preferably described before;

X ₁₁ is selected from the group consisting of O, S, O-SO ₂ , SO ₂ -O, C(=O), OC(=O), C(=O)O, S(C=O) and (C=O)S, or has a meaning as preferably described before;

R11 and R12 are H;

R10 is H, methyl, ethyl or phenyl, or has a meaning as preferably described before; and

c is 1.

Preferably, such oligomer, polymer or copolymer according is comprised in the ophthalmic device or precursor article for an ophthalmic device according to the invention. Particularly preferably, such oligomer, polymer or copolymer comprises a constitutional unit M ⁰ of formulae (M ⁰ -I'), (M ⁰ -I''), (M ⁰ -I'-1), (M ⁰ -I''-1), (M ⁰ -I'-2- H), (M ⁰ -I''-2-H), (M ⁰ -I'-3-H), (M ⁰ -I''-3-H), (M ⁰ -I'-4-H) or (M ⁰ -I''-4-H), as described before, wherein

-R ₂ - is selected from -(CH ₂ ) ₃ -, -(CH ₂ ) ₄ -, -(CH ₂ ) ₅ -, -(CH ₂ ) ₆ -, -(CH ₂ ) ₇ -, -(CH ₂ ) ₈ -, -(CH ₂ ) ₉ -, -(CH ₂ ) ₁₀ -, -(CH ₂ ) ₁₁ -, -(CH ₂ ) ₂ -S-(CH ₂ ) ₂ -, -(CH ₂ ) ₂ -SO ₂ -(CH ₂ ) ₂ -, - (CH ₂ )-S-(CH ₂ ) ₂ -O-(CH ₂ )-, -(CH ₂ )-SO ₂ -(CH ₂ ) ₂ -O-(CH ₂ )-, -(CH ₂ )-SO ₂ -(CH ₂ ) ₂ - S-(CH ₂ )-, -(CH ₂ )-O-(CH ₂ ) ₂ -S-(CH ₂ ) ₂ -O-(CH ₂ )-, -(CH ₂ )-S-(CH ₂ ) ₂ -O-(CH ₂ ) ₂ -S- (CH ₂ )-, -(CH ₂ )-SO ₂ -(CH ₂ ) ₂ -O-(CH ₂ ) ₂ -SO ₂ -(CH ₂ )-, -(CH ₂ )-S-(CH ₂ ) ₂ -S-(CH ₂ ) ₂ - S-(CH ₂ )-, -(CH ₂ )-SO ₂ -(CH ₂ ) ₂ -SO ₂ -(CH ₂ ) ₂ -SO ₂ -(CH ₂ )-, -(CH ₂ )-O-(CH ₂ ) ₂ -SO ₂ - (CH ₂ ) ₂ -O-(CH ₂ )-, -(CH ₂ ) _12, -(CH ₂ ) ₃ -(CF ₂ )-(CH ₂ ) ₃ -, -(CH ₂ )-(CF ₂ ) ₃ -(CH ₂ )-, - (CH ₂ ) ₂ -(CF2)4-(CH ₂ ) ₂ -, -(CH ₂ )-[CH(CF3)]-(CH ₂ )-, -(CH ₂ )-[C(CH ₃ )CF3]-(CH ₂ )-, -(CH ₂ )-[CH(CH ₂ CF3)]-(CH ₂ )-, -(CH ₂ )-[C(CH ₃ )(CH ₂ CF3)]-(CH ₂ )-, -(CH ₂ ) ₂ - (CF2)-O-(CF2)-O-(CF2)-(CH ₂ ) ₂ - and -(CH ₂ )-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)- (CH ₂ )- or has a meaning as preferably described before;

Y is O, S, SO ₂ , or a bond or has a meaning as preferably described before; R3, R4 and R8 are H;

R ₅ is H, F or CF ₃ or has a meaning as preferably described before;

R6 and R7 are H;

A is CH ₂ ;

m is 0, 1, 2 or 3 or has a meaning as preferably described before;

R' is selected from the group consisting of F, a linear or branched partially or fully fluorinated alkyl group having 1 to 10 C atoms, a linear or branched alkyl group having 1 to 10 C atoms, a linear or branched alkoxy group having 1 to 10 C atoms, a linear or branched partially or fully fluorinated alkoxy group having 1 to 10 C atoms and a linear or branched thioalkyl group having 1 to 10 C atoms or has a meaning as preferably described before;

n1 is 0, 1, 2, 3 or 4 or has a meaning as preferably described before;

X11 is selected from the group consisting of O, S, O-SO ₂ , SO ₂ -O, C(=O), OC(=O), C(=O)O, S(C=O) and (C=O)S, or has a meaning as preferably described before;

R11 and R12 are H;

R10 is H, methyl, ethyl or phenyl, or has a meaning as preferably described before;

c is 1, and the position of the phenyl group is at the C atom of the isolated double bond which is adjacent to C(R ₆ )(R ₇ ).

Particularly preferably, such oligomer, polymer or copolymer is comprised in the ophthalmic device or precursor article for an ophthalmic device according to the invention. Particularly preferably, such oligomer or polymer comprises a constitutional unit M ⁰ of formulae (M ⁰ -I'), (M ⁰ -I''), (M ⁰ -I'-1), (M ⁰ -I''-1), (M ⁰ -I'-2-H), (M ⁰ -I''-2- H), (M ⁰ -I'-3-H), (M ⁰ -I''-3-H), (M ⁰ -I'-4-H) or (M ⁰ -I''-4-H), as described before, wherein

-R ₂ - is selected from -(CH ₂ ) ₃ -, -(CH ₂ ) ₄ -, -(CH ₂ ) ₅ -, -(CH ₂ ) ₆ -, -(CH ₂ ) ₇ -, -(CH ₂ ) ₈ -, -(CH ₂ )9-, -(CH ₂ )10-, -(CH ₂ )11-, -(CH ₂ ) ₂ -S-(CH ₂ ) ₂ -, -(CH ₂ ) ₂ -SO ₂ -(CH ₂ ) ₂ -, - (CH ₂ )-S-(CH ₂ ) ₂ -O-(CH ₂ )-, -(CH ₂ )-SO ₂ -(CH ₂ ) ₂ -O-(CH ₂ )-, -(CH ₂ )-SO ₂ -(CH ₂ ) ₂ - S-(CH ₂ )-, -(CH ₂ )-O-(CH ₂ ) ₂ -S-(CH ₂ ) ₂ -O-(CH ₂ )-, -(CH ₂ )-S-(CH ₂ ) ₂ -O-(CH ₂ ) ₂ -S- (CH ₂ )-, -(CH ₂ )-SO ₂ -(CH ₂ ) ₂ -O-(CH ₂ ) ₂ -SO ₂ -(CH ₂ )-, -(CH ₂ )-S-(CH ₂ ) ₂ -S-(CH ₂ ) ₂ - S-(CH ₂ )-, -(CH ₂ )-SO ₂ -(CH ₂ ) ₂ -SO ₂ -(CH ₂ ) ₂ -SO ₂ -(CH ₂ )-, -(CH ₂ )-O-(CH ₂ ) ₂ -SO ₂ - (CH ₂ ) ₂ -O-(CH ₂ )-, -(CH ₂ ) _12, -(CH ₂ ) ₃ -(CF ₂ )-(CH ₂ ) ₃ -, -(CH ₂ )-(CF ₂ ) ₃ -(CH ₂ )-, - (CH ₂ ) ₂ -(CF ₂ ) ₄ -(CH ₂ ) ₂ -, -(CH ₂ )-[CH(CF ₃ )]-(CH ₂ )-, -(CH ₂ )-[C(CH ₃ )CF ₃ ]-(CH ₂ )-, -(CH ₂ )-[CH(CH ₂ CF3)]-(CH ₂ )-, -(CH ₂ )-[C(CH ₃ )(CH ₂ CF3)]-(CH ₂ )-, -(CH ₂ ) ₂ - (CF ₂ )-O-(CF ₂ )-O-(CF ₂ )-(CH ₂ ) ₂ - and -(CH ₂ )-(CF ₂ )-O-(CF ₂ )-O-(CF ₂ )-O-(CF ₂ )- (CH ₂ )- or has a meaning as preferably described before;

Y is O, S, SO ₂ , or a bond or has a meaning as preferably described before; R3, R4 and R8 are H;

R ₅ is H, F or CF ₃ or has a meaning as preferably described before;

R6 and R7 are H;

A is CH ₂ ;

m is 0, 1, 2 or 3 or has a meaning as preferably described before;

R' is selected from the group consisting of F, a linear or branched partially or fully fluorinated alkyl group having 1 to 10 C atoms, a linear or branched alkyl group having 1 to 10 C atoms, a linear or branched alkoxy group having 1 to 10 C atoms, a linear or branched partially or fully fluorinated alkoxy group having 1 to 10 C atoms and a linear or branched thioalkyl group having 1 to 10 C atoms or has a meaning as preferably described before;

n1 is 0, 1, 2, 3 or 4 or has a meaning as preferably described before;

the position of the phenyl group is at the C atom of the isolated double bond which is adjacent to C(R ₆ )(R ₇ ); and within formulae (M ⁰ -I'), (M ⁰ -I''), (M ⁰ -I'-1), (M ⁰ -I''-1), (M ⁰ -I'-2-H), (M ⁰ -I''-2-H), (M ⁰ -I'-3-H), (M ⁰ -I''-3-H), (M ⁰ -I'-4-H) and (M ⁰ -I''-4-H) is derived from any one of the preferred alkenyl groups of formulae (4-1), (4-2), (4-3), (4-4), (4-5), (4-6), (4-7), (4-8), (4-9), (4-10), (4-11) and (4-12) or any preferred embodiment thereof.

Particularly preferably, such oligomer, polymer or copolymer is comprised in the ophthalmic device or precursor article for an ophthalmic device according to the invention. The copolymer may be an oligomer or polymer comprising one or more polymerized compounds of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I'), (I'-a), (I'-b), (I'-c), (I'-d), (I'-1), (I'-2), (I'-2-H), (I'-3), (I'-3-H), (I'-4), (I'-4-H) (I''), (I''-1), (I''-2), (I''-2-H), (I''-3), (I''-3-H), (I''-4) or (I''-4-H) as described before or preferably described before or one or more

constitutional units M ⁰ of formulae (M ⁰ -I'), (M ⁰ -I'-a), (M ⁰ -I'-b), (M ⁰ -I'-c), (M ⁰ -I'- d), (M ⁰ -I''), (M ⁰ -I'-1), (M ⁰ -I''-1), (M ⁰ -I'-2-H), (M ⁰ -I''-2-H), (M ⁰ -I'-3-H), (M ⁰ -I''-3- H), (M ⁰ -I'-4-H) and/or (M ⁰ -I''-4-H) as described before or preferably described before or one or more constitutional units (M ⁰ -001) to (M ⁰ -180) as described below, which may be the same or different from one another, and one or more constitutional units M ² , which may be the same or different from one another. Said one or more constitutional units M ² are chemically different from the units M ⁰ . Preferably, said one or more constitutional units M ² are derived by polymerization of one or more monomers selected from the group consisting of styrene, ethoxyethyl methacrylate (EOEMA), methyl methacrylate (MMA), methyl acrylates, n-alkyl acrylates (the n-alkyl group comprising 2-20 C-atoms), n-alkyl methacrylates (the n-alkyl group comprising 2-20 C-atoms), ethoxyethoxy ethylacrylate (EEEA), 2- hydroxyethyl methacrylate (HEMA), tetrahydrofuryl methacrylate (THFMA), glycidylmethacrylate (GMA), 16-hydroxyhexadecyl acrylate, 16- hydroxyhexadecyl methacrylate, 18-hydroxyoctadecyl acrylate, 18- hydroxyoctadecyl methacrylate, 2-phenoxyethyl acrylate (EGPEA), heptafluorobutyl acrylate, heptafluorobutyl methacrylate, hexafluorobutyl acrylate, hexafluorobutyl methacrylate, hexafluoroisopropyl acrylate, hexafluoroisopropyle methacrylate, petanfluoropropyl acrylate,

pentafluoropropyl methacrylate, tetrafluoropropyl methacrylate, trifluoroethyl acrylate, and trifluoroethyl methacrylate. The invention therefore relates further to an ophthalmic device or a precursor article for the ophthalmic device as described or preferably described before comprising beside of the at least one polymerized compound of formulae (I), (I') or (I'') or the constitutional unit M ⁰ of formulae (M ⁰ -I'), (M ⁰ -I'-a), (M ⁰ -I'-b), (M ⁰ -I'-c), (M ⁰ -I'-d), (M ⁰ -I''), (M ⁰ -I'-1), (M ⁰ -I''-1), (M ⁰ - I'-2-H), (M ⁰ -I''-2-H), (M ⁰ -I'-3-H), (M ⁰ -I''-3-H), (M ⁰ -I'-4-H) and/or (M ⁰ -I''-4-H) as described before or preferably described before or one or more

constitutional units (M ⁰ -001) to (M ⁰ -180) as described below at least one further polymerized monomer selected from the group consisting of styrene, ethoxyethyl methacrylate (EOEMA), methyl methacrylate (MMA), methyl acrylate, n-alkyl acrylates (the n-alkyl group comprising 2-20 C-atoms), n- alkyl methacrylates (the n-alkyl group comprising 2-20 C-atoms),

ethoxyethoxy ethylacrylate (EEEA), 2-hydroxyethyl methacrylate (HEMA), tetrahydrofuryl methacrylate (THFMA), glycidylmethacrylate (GMA), 16- hydroxyhexadecyl acrylate, 16-hydroxyhexadecyl methacrylate, 18- hydroxyoctadecyl acrylate, 18-hydroxyoctadecyl methacrylate, 2- phenoxyethyl acrylate (EGPEA), Bisphenol A diacrylate-1 EO/Phenol (BPADA), 2-[3'-2'H-benzotriazol- 2'-yl)-4'-hydroxyphenyl]ethyl methacrylate (BTPEM) or ehtyleneglycoldimethacrylate.

Particularly preferably, the at least one further polymerized monomer is selected from methyl methacrylate, 2-hydroxyethyl methacrylate, 2- phenoxyethyl acrylate, ethoxyethoxy ethylacrylate, 8-methylnonyl methacrylate, n-butyl methacrylate, 2-ethyl hexylmethacrylate or a mixture thereof. Particularly preferably, such copolymer is comprised in the ophthalmic device or precursor article for an ophthalmic device according to the invention. Alternatively the oligomer or polymer, preferably the polymer, according to the invention is a homopolymer, i.e. an oligomer or polymer, preferably a polymer, comprising one or more constitutional units M ⁰ of formula (M ⁰ -I'), (M ⁰ -I'-a), (M ⁰ -I'-b), (M ⁰ -I'-c), (M ⁰ -I'-d), (M ⁰ -I''), (M ⁰ -I'-1), (M ⁰ -I''-1), (M ⁰ -I'-2-H), (M ⁰ -I''-2-H), (M ⁰ -I'-3-H), (M ⁰ -I''-3-H), (M ⁰ -I'-4-H) or (M ⁰ -I''-4-H) as described before or preferably described before or (M ⁰ -001) to (M ⁰ -180) as described below and wherein all constitutional units M ⁰ are the same. Exemplary homopolymeric compounds based on compounds of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I'), (I'-a), (I'-b), (I'-c), (I'-d), (I'-1), (I'-2), (I'-2-H), (I'-3), (I'-3-H), (I'-4), (I'-4-H) (I''), (I''-1), (I''-2), (I''-2- H), (I''-3), (I''-3-H), (I''-4) and/or (I''-4-H) are the following compounds (P- 001) to (P-180) as shown in table 2. Table 2: